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Squamous cell carcinoma of the head and neck region (HNSCC) is an aggressive malignancy with 
generally poor prognosis and high mortality. The Special AT-rich binding protein 1 (SATB1) is a genome 
organizer protein that participates in regulating gene expression by acting as a trans-acting element as 
well as by recruiting chromatin remodeling complexes and enzymes. SATB1 is often overexpressed in 
cancer, and its possible role in tumour progression has been explored in several types of cancers and 
also suggested in HNSCC. However, its influence on molecular and cellular processes in HNSCC has 
not been examined, and, using primary cell lines, provided the basis of this thesis.  
This is a comprehensive study of molecular and cellular processes being affected upon siRNA-mediated 
SATB1 knockdown in vitro and in vivo. 15 HNSCC primary cell lines were obtained from the University of 
Turku and screened for SATB1 mRNA levels. The comparison of SATB1 mRNA levels with location, 
lymph node metastasis, disease staging (TNM) or SATB2 mRNA levels revealed no association. Hence, 
for deeper analysis 7 primary cell lines were selected based on growth inhibitory effects upon transient 
SATB1 knockdown, rather than their initial SATB1 mRNA levels. Growth inhibition upon SATB1 depletion 
was shown in monolayer (viable cell quantitation and colony forming ability) as well as non-adherent 
(spheroid assay) culture conditions. In some cell lines, cell death induced by apoptosis or retardation of 
cell cycle progression was observed as well. Parallel to this, using the FLAVINO assay, colony forming 
abilities of tumour cells from patient biopsies obtained from the University Hospital of Leipzig (Department 
of Otorhinolaryngology, Head and Neck Surgery) were tested post SATB1 knockdown. For molecular 
analysis, effects of SATB1 knockdown on transcription rates of selected oncogenes were analyzed. 
Among EMT markers, N-cadherin and beta catenin levels were found reduced upon SATB1 knockdown. 
The transcription of HER3 and its ligands Heregulin α & β was attenuated in all the seven primary cell 
lines, irrespectively of the growth inhibitory effects of SATB1 knockdown. These results demonstrated 
the role of SATB1 in the process of EMT and in autocrine signalling. Effects of HER3 inhibition on 
transcription rates of SATB1 were tested as well. HER3 inhibition was achieved by Patritumab, a novel 
monoclonal antibody against HER3. While SATB1 transcription rates remained unchanged upon HER3 
inhibition, growth inhibition assays (2D and 3D) revealed that the combined use of HER1 and HER3 
inhibitory antibodies provides better tumour cell inhibition over the single treatment. Finally, antitumor 
effects of SATB1 knockdown were monitored in vivo in two xenograft models (UT-SCC-14 and UT-SCC-
42B). Treatment of tumor xenograft-bearing mice with siRNAs formulated in polymeric nanoparticles 
revealed reduced tumour growth, based on the knockdown of SATB1 as demonstrated on the protein 
level.  
Taken together, in this work SATB1 knockdown is demonstrated to mediate growth inhibition, induction 
of apoptosis, cell cycle retardation, negative impact on EMT and autocrine signaling and in vivo anti-







2.1 Cancer and its Classification 
 
Hyperplasia is uncontrolled proliferation of cells in the body. Abnormally increased rate of proliferation is 
characterised by overgrowth of unhealthy cells, exhaustion of the nutrition supply of the neighbouring 
cells and beyond certain size also damage the tissue architecture and penetration of the nearby tissue. 
These cells form a tumour. Tumour is broadly classified into two forms. It begins with the benign form, 
where abnormally dividing cells form a mass of cells encapsulated by a protective covering called basal 
membrane. Uncontrolled proliferation in absence of DNA repair mechanism leads to accumulation of 
mutations which generates more aggressive cells with increasing invasive and migratory potential. Once 
the basal membrane of the benign tumour is ruptured, the cells migrate to the neighbouring tissues, enter 
the circulatory system and spread throughout the body. Migration and formation of distant colonies or 
tumours is referred to as Metastasis of Cancer [1]. 
Cancer is classified into 5 broad categories depending on the type of tissue of origin. Sarcoma is the 
cancer that originates in connective tissues like muscles, bones, cartilages, adipose tissues and other 
tissues like tendons, ligaments and blood vessels. Leukaemia is the cancer that begins in blood forming 
tissue, bone marrow. Lymphoma and Myeloma are the cancers of the immune cells. Cancerous tumour 
originated in Brain or Spinal cord is referred as the cancer of the central nervous system. Lastly, the 
Carcinomas are a broad category that covers cancer developed in epithelial or squamous cells. 
Cancerous tumour originating from epithelial cells which are glandular in nature (secretion) is further 
classified as adenocarcinoma. Squamous cells are found in the inner lining of the nasopharynx and upper 
aero-digestive track, oesophagus, colorectal region, lungs, urinary bladder, urethra, skin, lips, vagina, 
cervix, penis, anus and renal pelvis. Cancer originating in this region is broadly referred as carcinoma. 
[2] 
 
2.2 Head and Neck Squamous Cell Carcinoma 
 
The beginning part of the aero-digestive track is commonly known as the head and neck region. It is the 





formed by epithelial tissues consisting of different layers, starting with basal membrane then epithelial 
layer and lastly the squamous cell layer.  
Figure 1 on page 3 illustrates different parts of the Head and Neck region which has squamous cells 
lining the cavity. Tumours originating in squamous tissue are different (aetiology, molecular biology, 
treatment regimen and response) from tumours originating in epithelial, lymphatic system or nervous 
tissues in this region. Head and Neck cancer is a universal set covering cancer of all the tissues in this 
region. Squamous cell carcinoma of the Head and Neck region (HNSCC) is a subset of this universal set. 
[3, 4]   
Beginning from the superior part, carcinoma developed in the nasal cavity or Nasopharynx is called 
Nasopharyngeal carcinomas. Cancer developed in larynx, hypopharynx and oropharynx is known as 
pharyngeal carcinomas (Laryngeal, hypo-pharyngeal or oropharyngeal). Carcinoma of the tonsil is also 
included in the group of Oropharyngeal carcinomas (OPSCC) owing to its location. Carcinoma of the 
supra layer of the tongue which is an epithelial layer is included in Squamous cell carcinoma of the buccal 
or oral cavity. Carcinomas originating on the floor of the mouth, lips, hard palate and side walls of the 
cavity are also classified as oral cavity carcinomas. All these types are collectively referred to as the Head 
and Neck Squamous Cell Carcinoma (HNSCC). A commonly occurring carcinoma in the buccal cavity is 
the cancer of salivary gland which is not classified in HNSCC due to its glandular nature 
Figure 1 Region of the head and neck where HNSCC is commonly diagnosed except for Salivary gland which will be 
classified as adenocarcinoma owing to its glandular nature. (Image credit: For the National Cancer Institute(C) (2012) 





(adenocarcinoma) [3, 4]. However, cancer of the ductal epithelial cells of the salivary glands are classified 
as squamous carcinoma.  
HNSCC, although collectively referred to as a disease originating from the same tissue type, is 
heterogeneous with respect to several aspects like site of origin, location, molecular biology, clinical 
staging and responsiveness to the treatment. Because of the heterogeneity, the treatment response and 
prognosis of the disease, it is more complex than expected [5, 6]. When a tumour is formed in the 
squamous layer of the head and neck region, it is characterized by a peculiar horizontal growth up to 
certain size (≤ 2.5 cm diameter). The cancer proliferates horizontally rather than penetrating vertically. 
Moreover, beyond lateral growth, some cases present with several tumour nodes growing individually 
and behave like an independent tumour node. This is referred to as a multi-foci growth; different tumours 
grow independently without any common point of origin. Difference in sensitivity to radiation therapy was 
also observed among such tumour nodes. A broad term was proposed by Slaughter D. P. in 1953 and it 
is still in use to describe this phenomenon: Field cancerization [7]. Tumours originated from squamous 
cells tend to form patches which mostly consist of keratinized cells resulting in a distinguishable white 
spot (Oral Leucoplakia) [6]. Accompanied by keratinization is the process of fibrosis and atrophy of the 
surrounding cells and tissue resulting in a reddish spot (Erythroplakia) [6]. Often such distinct patches 
are not visible macroscopically, which are still termed as ‘Fields’. Such patches are proven to be 
dysplastic during histopathological examination or when they develop a distinct lesion as a recurrent 
tumour. The possibility of a single focal origin of such different fields is ruled out owing to their different 
response to the treatment and growth rate. Different chronic exposure towards carcinogens and 
continuous process of differentiation results in such variegated fields of squamous cell carcinoma. This 
characteristic of HNSCCs make it even more difficult to control and treat.  
Tumour-Node-Metastasis (TNM) classification is a worldwide accepted classification used in cancer to 
get a picture of the intensity of the diseased condition and prognostic classification in the context of 
recommended treatment. T-primary tumour, N-disease positive lymph nodes and M- distant metastasis 
are presented as a formula, and particular combinations are aggregated to define staging of the disease. 
In recent 8th edition of the TNM classification for HNSCC, revised classification has exclusive staging and 
TNM classification for different location and p16INK4a-positivity as surrogate for HPV positive OPSCC and 
negative HNSCC. The classification helps in describing the size and extension of the tumour and growth 
characteristics (early, T1-T2 without infiltrating other tissue, T3 infiltrating other tissue or being >4 cm in 
one dimension, or infiltrating other organs, being resectable by surgical operation T4a, or not T4b), 
number of lymph nodes infiltrated by tumour cells: N0, none, N1 [<3 cm], N2a [3-6 cm], or N3a [>6 cm], 





higher N category N1→N2a or N3b in all other cases, direction of the growth (N2b bilateral, N2c 
contralateral) of infiltrated lymph node as well as absence (M0) or presence of distant metastasis (M1). 
The UICC staging aggregates the TNM categories in a single prognostic figure, UICC I T1N0M0 with 
>90%, UICC II T2N0M0 >80%, UICC III T1-T3 N0-N1 M0 >50%, and UICC IV all others <50% 5-years 
overall survival. Differentiation of operable (up to T4a) and in-operable tumours (T4b) in UICC stage IVA 
and IVB, respectively, is omitted. [6, 8, 9] 
 
2.2.1 Aetiology of HNSCC 
 
Malignancy of the Head and neck region is the sixth deadliest cancer in the world. 90% of these 
malignancies are from Squamous cell carcinomas [8]. There are several proven causes of HNSCCs [10].  
• Viral Infection 
• Smoking Tobacco 
• Alcohol consumption 
• Persistent Irritation  
• Age 
• Genetic predisposition 
• Immunosuppression 
 
2.2.1.1 Viral Infection  
 
Human Papilloma Virus (HPV) infection has been a proven cause of carcinoma of the Squamous cells of 
the Cervix/Penis [11]. However, the fact that HPV infection also results in cancerous condition in 
Squamous tissues of the head and neck region was accepted much later. From several types of HPVs, 
High risk viruses (type 16, 18, 31, 33, and 35) are the major cause of HNSCCs [12–14]. Among them, 
most frequently occurring infection is by either type 16 or type 18, both contains viral protein E6 and E7 
which has oncogenic potential [12, 15]. Low risk HPVs are responsible for causing genetic warts and 
lesions on the skin layer. They do not transform into malignant condition and are curable up to some 
extent [12]. Low risk HPV are not capable of episomal integration of the viral genome into the host 
genome and hence does not create cancerous condition; for example, HPV type 6 and 11 [12]. Apart 
from HPV, Epstein Barr Virus (EBV) [16] infection is also found to be associated with HNSCCs, especially 





Viral proteins of EBV facilitate expression of oncogenes which may accelerate the course of development 




There are numerous studies proving that smoking tobacco not only can cause lung cancer but also 
Carcinoma of the squamous layer of head and neck region [3, 10].  
 
2.2.1.3 Alcohol  
 
Chronic exposure of alcohol increases chances of not only liver cirrhosis but also HNSCCs. Increasing 
use of alcohol in younger age is a serious concern since it can lead to HNSCCs in younger adults. Often 
combined use of smoking tobacco and alcohol increases the risk of HNSCCs [3, 10, 18].  
 
2.2.1.4 Persistent irritation/Carcinogens  
 
Substances which have the potential to damage the nuclear content of the cell or interact with the DNA 
are classified as potential carcinogens. When a tissue of our body is chronically exposed to such chemical 
substances, the chances of developing a cancerous condition are increased. Apart from tobacco and 
alcohol, areca nut is also one of such agents containing carcinogens which is commonly used in south 
east Asia and India [8, 10]. Areca nut is consumed orally with tobacco which increases the risk of 
oncogenic transformation in the squamous cell layer of the oral cavity [8]. Other chemicals, classified as 
carcinogens upon contact with the mucosal layer cause chemical irritation which damages the squamous 
layer, triggering proliferation. With unduly increased rate of proliferation, chances of genetic alterations 
leading to cancerous conditions are higher. Reports of Orthodontic appliances [19] and covers of ball-
point pens [20] creating cancerous tumours have been reported. Not only chemical irritation, but also 
frequent injuries, lack of nutrition and others are able to increase the risk of developing an oncogenic 






2.2.1.5 Age  
 
Although several studies show no correlation of poor prognosis or expression of certain oncogenes with 
age, reports on differences in the severity of the diseases in different age groups are published. The 
diseases are more aggressive and recurrent in younger patients when compared with older patients. The 
aetiology of younger patients is mainly HPV infection along with smoking and/or alcohol. However, in 
most of the older patients, aetiology is chronic exposure to smoking and/or alcohol.  Moreover, 
chromosomal instability of both HPV negative patients of young and old age group is same but attenuated 
immunity in older patients is the leading reason for the development of primary lesions leading to a 
malignant situation.  
Surveys have also revealed differences in the proportion of sex in young and old patients. Older patients 
are 60-70% males while in younger population, it is reduced to 50 to 60%. Besides, in a subgroup of 
patients with no tobacco or alcohol use, female patients account for almost 70% of the cases [21]. These 
differences may reflect increased sexual activity with multiple partners and careless attitude for minor 
health problems at younger age. The reason for reports of aggressive and recurrent tumours in younger 
patients is lack of awareness and inconsiderate approach for visiting doctors during early onset. Initial 
and less aggressive lesions (supposedly benign in nature) are ignored, while later aggressive tumours or 
malignant transformation is difficult to control or treat. Such reasons question the contribution of factors 
like age and sex in terms of prognosis, recurrence and overall survival after surgical excision, chemo- or 
radiation therapy. [10] 
 
2.2.1.6 Genetic predisposition  
 
There are instances where the patient has never been exposed knowingly to any carcinogen but develops 
cancerous tumour. Primary reason in such cases is genetic predisposition. These individuals are more 
prone to get a cancerous condition than others. Mutations in somatic genes which control cellular 
processes like cell proliferation, apoptosis, survival etc can increase the chances of generating cancerous 
lesions. Increased EGFR copy number was more common in non-smoker patients of HNSCCs than in 
the smoking group of patients [22]. Mutation in genes like p53 or p16INK4a can increase the susceptibility 
of the individual to develop hyperplastic tumour [23, 24]. Single nucleotide polymorphism (SNPs) in the 





Apart from such mutations, individuals with well-defined inherited syndromes like Fanconi’s anaemia, 
Epidermolysis bullosa, Xeroderma pigmentosum and blooms syndrome have increased risk of HNSCCs 
[26]. People with unexplained family history of cancer are also at higher risk because of a possible 
inherited susceptibility to carcinogens. [10]  
 
2.2.1.7 Immunosuppression  
 
Reduced immunity may increase the chances of developing a cancerous lesion, and eventually 
metastatic condition. A study showed that the deficiency or disruption of specific cytotoxic mechanisms 
of the T cells resulted in increased susceptibility to spontaneous or chemically induced carcinogenesis in 
experimental animals [27, 28]. Another study has shown that HIV positive patients are at higher risk than 
individuals with normal immune system [27, 28]. HIV infection also increases the chances of HPV 
infection which can later create HNSCCs [29, 30]. Individuals undergoing solid organ transplant have to 
consume drugs that reduce the IL2 secretion, for supressing the cytotoxic mechanism of the T cells which 
again increases chances of developing cancerous tumours [31]. A study showed that people who 
underwent liver transplant because of liver cirrhosis (triggered by excess alcohol consumption) have 
higher chances of developing HNSCCs. [32]. 
 
2.3 Molecular Mechanisms behind oncogenic transformation in HNSCC 
 
A steady rise in the proportion and number of incidences of HPV positive HNSCC tumours and the 
unravelling of the differences in molecular mechanisms has helped in distinguishing between the broad 
categories of HPV positive and negative HNSCCs. After several studies, it has been established that 
HPV positive tumours vary from HPV negative tumours with regard to genetic profile, chromosomal 
instability, prognosis, treatment response, overall and disease-free survival [5, 6, 14]. The fact that the 
treatment modalities of both groups are similar needs to be revised. The molecular landscape of HPV 







2.3.1 HPV positive HNSCC 
 
HPV infection is known to be the primary reason for cervical cancers in females all over the world. Not 
only cervical cancer, but carcinoma of the squamous layer of the anogenital areas, in both males and 
females, are caused by HPV infection. HNSCCs are the latest addition in this list. In HNSCCs, it is mostly 
localized in the oropharyngeal region [33–35]. To understand the mechanism of how HPV causes initially 
benign lesions in the squamous layer, its molecular biology needs to be discussed. 
HPV is a non-enveloped virus containing double stranded circular DNA of ~8 kb. The genome is divided 
into three groups of genes: Early genes, late genes and long control region (LCR). Sequence of LCR 
helps in the classification of HPVs. Based on its sequence, there are more than 150 types of HPVs [35]. 
Figure 2 on page 9 shows the genome of HPV type 16. E1, E2, E4, E5, E6 and E7 are the early genes. 
L1 and L2 are the late genes. LCR is the non-coding region which controls replication and transcription 
of the viral genome. [12] 
First contact of the virus occurs with the Heparan Sulphate Proteoglycans (HSPGs) of the basal epithelial 
cell layer deep below the squamous layer. Usually the basal layer is not easily accessible because of the 
covering squamous layer but micro wounds or cuts makes them accessible for viral attachment.  
Very smartly, the virus chooses to invade dividing basal epithelial cells. Dividing epithelial cells have 
active DNA polymerase which helps in integration as well as replication of the viral genome. Early proteins 
like E1 and E2 help in the integration of the viral genome, followed by replication and transcription of the 
viral polycistronic mRNA. Approximately 50-100 copies of the viral genome are detected per infected cell.  





Once the viral genome is integrated and replicated within the genome, proteins E5, E6 and E7 are 
translated. E5 is a transmembrane protein which integrates into the cytoplasmic membrane and interacts 
with Epidermal Growth Factor Receptor (EGFR) triggering the signal for growth and proliferation. The E6 
protein facilitates amplification of the viral genome in dividing cells along with ubiquitin E3A mediated 
degradation of p53 tumour suppressor protein. E6 also degrades the PDZ domain containing protein 
which can transcribe tumour suppressor proteins. E6 protein of the high-risk viruses additionally activates 
telomerase activity which increases the replicative potential of the cells whereas this function of the E6 
protein is not reported in low risk HPVs. The E7 protein accomplishes degradation of Retinoblastoma 
protein (pRB), also by ubiquitination. Degradation of pRB tumour suppressor proteins activates E2F 
transcription factor which transcribes genes required for cell division, further pushing the cells to enter 
active cell cycle. E7 further inhibits cell cycle inhibitors p27 and p21 which further allows cell proliferation. 
Because of the complete hijacking of the cell cycle control, the cell divides despite chromosomal damage 
which leads to chromosomal instability and eventually oncogenesis. Chromosomal damage also sends 
an apoptotic signal, but in absence of p53, this signal is not translated into any physiological response. 
E6 and E7 proteins are also responsible for the upregulation of p16INK4a protein which inhibits the cell 
cycle arrest process by inhibiting the Cyclin Dependent Kinase inhibitor.  
L1 and L2 proteins are translated generating small virions which pack its replicated genome. The E4 
protein present in the cytoplasm interacts with the cytokeratin network to destabilize it, facilitating virus 
release and increase of the size of the infected area. This also explains why most of the HPV positive 
tumours are basaloid in appearance while their HPV negative counterparts have a keratinized population 
of tumour cells. The E8 protein fuses with E2 protein and acts as a repressor of transcription and 
replication during viral life cycle (see review [12]). 
Abundant amounts of p16INK4a protein is an established surrogate marker for an HPV infection in 
histopathological examination. PCR based detection of E6 and E7 along with p16INK4a 
immunohistochemistry are collectively used for proving the HPV status of the tumour [36, 37].  
Basically, HPV infection drives unlimited proliferation of the basal epithelial cells. It does not directly cause 
oncogenic transformation. But because of the integration of the viral genome and absence of repair 
mechanism of the damaged nuclear content, several mutations are introduced as the cells continue to 







2.3.2 HPV negative HNSCC 
 
As described above, carcinogenesis in HNSCCs can occur due to factors like chronic exposure to 
carcinogens, genetic susceptibility, suppressed immune function, persistent irritation or long-term 
damage to the mucosal layer. In such cases, Chromosomal instability is higher than in HPV positive 
tumours. Due to chronic exposure to carcinogens, genetic alterations or reduced immune functions, cells 
with damaged DNA continue to proliferate, accumulating errors in their nuclear content. The accumulation 
of such mutations eventually leads to oncogenic transformation. Loss of chromosomal arm, increasing 
copy numbers of a given gene, loss or gain of functional mutations, epigenetic changes causing 
euchromatin or heterochromatin status, transposition of genes etc causes upregulation of cell 
proliferating, growth promoting and differentiation related genes with simultaneous downregulation of cell 
cycle inhibitors, senescence inducing pathways and pro-apoptotic proteins.  
Epigenetic silencing is combined with the loss of a chromosomal arm leading to loss of both the alleles 
of a gene, a phenomenon termed as loss of heterozygosity [5]. Increase in copy numbers of a given gene, 
overexpression and gain of function mutation (inability to turn off the signal) of a central protein or other 
proteins of the signal transduction pathway can act together to create a highly aggressive tumour entity.  
A study published in the year 2015 by the Cancer Genome Atlas gave a detailed review on most 
frequently occurring genetic alteration in HNSCCs. Among several genes, TP53, Retinoblastoma, TGF 
alpha and beta, EGFR and its downstream signal transducer proteins, proteins of Wnt pathways and 
some other genes were found to be mutated in most of the 279 tumour samples analysed. This report 
also showed a comparison of HPV positive and negative tumours and affirmed the fact that HPV positive 
tumours do have chromosome instability but lesser than HPV negative tumours. [38] 
Frequently occurring mutations in HNSCCs are explained below.  
 
2.3.2.1 Cell cycle deregulation  
 
The most frequently mutated gene was reported to be TP53 which encodes the p53 gene of the p53 
family. This gene is expressed at low levels in a healthy cell. When a cell suffers from DNA damage 
(single stranded DNA, mismatch base pair or double stranded break), p53 is upregulated. This protein 
helps the cell in three ways. First and most important is to block the cell cycle even in presence of 





kinase Cdk2 which will arrest the cell at S phase. Later, p53 also activates GADD45 and 14-3-3σ which 
causes cell cycle arrest at M phase by inhibiting Cyclin B1 nuclear localization. The second mode of 
action is facilitating DNA repair by halting cell cycle progression. DNA repair induces transcription of 
genes which phosphorylates p53, preventing its degradation thereby causing cell cycle arrest. The third 
mode of action is inducing apoptosis by acting as a transcription factor of apoptosis inducing genes like 
Bax, Noxa, PUMA, Fas etc. It can also interact with Bcl2 and Bcl-XL to facilitate mitochondrial outer 
membrane permeabilization.  
Thus, p53 is a protein that solely controls three very important processes: Cell cycle arrest, DNA repair 
and inducing apoptosis as the last resort upon DNA damage. All these three processes are ‘Anti-cancer’ 
processes. [39] 
It is not surprising that the clonal selection in cancerous lesions facilitates p53 loss by missense mutation 
and/or allelic loss (chromosome 17p13) [40]. This protein is found to be mutated in ~84% of HNSCCs 
tumours [5, 41].  
Apart from p53, Cyclin D1 is a frequently mutated gene that contributes to cell cycle progression from G1 
to S phase. Cyclin D1 together with Cyclin Dependent kinase 4 and 6 phosphorylates pRb 
(retinoblastoma) protein which releases E2F transcriptional factor which mediates transcription of genes 
required for DNA replication and progression from G1 to S phase of cell cycle. The Cyclin D1 gene on 
chromosome 11q13 is not only overexpressed but also amplification of the copy number is reported [42]. 
p16INK4a whose action is contradictory to Cyclin D1, suffers loss of heterozygosity. p16INK4a disrupts the 
cyclin D-CDK4 or CDK6 complex, thereby preventing phosphorylation of pRb and arresting the 
progression of cell cycle from G1 to S phase by preventing nuclear localization of E2F. [5]  
TERT (Telomerase reverse transcriptase) enables telomerase elongation which in turn increases the 
replicative potential of the cell. Increased TERT activity is often found in HNSCCs tumour samples [43]. 
Collective action of Cyclin D1, TERT, absence of interference by p53 and absence of inhibition by p16INK4a 
and pRb orchestrates a strong push for the cell to proliferate. In the absence of mutations in either of 
these proteins, other proteins generating similar cellular effects are mutated [5, 6, 38, 44].  
 
2.3.2.2 Growth Signal Reception  
 
Receptor Tyrosine kinases is a family of surface membrane receptors comprising of several proteins that 





in this family, however, the focus will be on Epidermal growth factor receptor (EGFR) and Vascular 
endothelial growth factor receptor (VEGFR).  
EGFR has been the target of choice in several cancer entities after recent advances in the knowledge of 
EGFR and its role in cancer progression. HER receptor family consists of 4 different members, namely 
HER1 (EGFR), HER2, HER3 and HER4. These receptors can form homo- or heterodimers. Since several 
combinations are possible, these receptors have a pleotropic mode of action for transducing their signal 
down to the nucleus. Further addition to the complexity of these pathways is the ability of the receptor to 
bind multiple ligands.  
Three different commonly occurring mutations are reported in the EGFR gene which help in cancer 
progression: Overexpression [45, 46] or copy number amplification [47], mutation that disables the protein 
to turn off the signal once turned on [48] and lastly mutations that make it resistant to therapeutics 
targeting its tyrosine kinase domain [49]. A report says only 1% of Caucasian population and 7% of Asian 
population harboured EGFR point mutations [50, 51]. EGFRvIII mutant variant was reported in 42% of 
the HNSCC tumours analysed in a study at University of Pittsburgh, USA [49]. Even after reports on the 
prevalence of EGFRvIII mutations in HNSCCs, another report counters this by stating that this mutation 
is irrelevant with targeted therapy (Cetuximab and Gefitinib) and radiotherapy [52]. Reports on EGFR 
overexpression and mutations are less convincing because several such studies were based on 
immunohistochemical staining and gene sequencing which lacked a control (normal mucosa) for 
comparison [5].  
However, a series of publications proved enhanced radio- and chemo- sensitization upon inhibiting HER1 
[53, 54] and HER3 [55] activation by respective antibodies (biological therapy, e.g.: Cetuximab (HER1)). 
Despite debatable results published for HER receptors (HER1-HER3), inhibiting these receptors have 
shown better clinical outcome for HNSCC patients [56, 57]. This could be explained by the ability of HER 
receptors to form heterodimers as well dimerization with receptors other than HER family. Fusion of 
receptors (EGFR with MET or FGFR) have also been reported. Extracellular domain of EGFR with 
intracellular domain of MET is an example of such fusion. This explains improved ability to harbour limited 
amount of growth signal in tumour microenvironment [38]. 
Vascular endothelial growth factor receptor is another protein of the receptor tyrosine kinase family, 
although, in this case, only the ligand VEGF is overexpressed by cancer cells, which acts on the 
endothelial linings of the blood capillaries in vicinity. Results showed an increase in expression levels of 





The process of differentiation is regulated by Transforming growth factor beta (TGF-β) which has 
pleiotropic functions. The pathway is silenced to promote tumour cell proliferation [59, 60]. However, this 
pathway is again switched on to promote differentiation and hence metastasis [61]. TGF-β is often 
downregulated or suffers loss of heterozygosity (chromosome 18q, TGFBII, SMAD2 and SMAD4) [62]. 
SMAD4 which is downstream of TGF-β signalling is often lost in HNSCCs which makes the TGF-β 
pathway ineffective, helping in tumour progression. SMAD4 forms SMAD complex with SMAD2 and 
SMAD3 which causes transcription of genes that inhibit proliferation, promote apoptosis and decrease 
transcription of survival proteins [5].  Loss of TGF-β is found to be associated with increased expression 
of NF-kB (nuclear factor Kappa B). TGF-β acts as a growth inhibitory signal while NF-kB increases 
transcription of survival proteins that prevents cell death by apoptosis [60]. Transforming growth factor 
suppresses cell proliferation to stimulate differentiation. However, the process of differentiation in cancer 
cells is also mediated by several other means.  
 
2.3.2.3 Signal Transduction  
 
Receptors receive signals from the external microenvironment and transduce them to the nucleus for 
necessary gene expression to implement cellular changes. Downstream to above mentioned receptors 
are signal transducers or secondary messengers present in the cytoplasm or attached to the cytosolic 
side of the plasma membrane. A large variety of proteins and pathways come into the spotlight, like the 
ERK pathway, Phospho-inositol 3 kinase pathway, Ras-MAPK pathway, Wnt pathway etc. These 
pathways are often deregulated (overly stimulated) in HNSCCs tumours. [6, 38]  
Receptor tyrosine Kinases (RTKs) begin their action by phosphorylating the tyrosine residues in their 
cytoplasmic domain which leads to activation of a chain of regulatory proteins among which PTEN 
(Phosphatase and Tensin homologue) and PI3K (Phosphatidyl Inositol 3 Kinase) are important to this 
discussion. Phospotidyl-inositol 1,4- bisphosphate (PIP2) is phosphorylated by PI3K to form Phosphatidyl 
inositol 1,4,5-triphosphate (PIP3). PIP3 gives away a phosphate group to phosphorylate AKT via 3-
phosphoinosited-dependent kinase-1 (PDK1). AKT acts via multiple pathways to stimulate cell 
proliferation, inhibit apoptosis and increase cell survival. PTEN is an inhibitory protein in this pathway. 
PTEN dephosphorylates PIP3 to PIP2. By achieving this, AKT is not activated and hence cell proliferation 
is stopped. PTEN suffers from inactivating mutations in 10% of HNSCC tumours [5]. This implicates that 
the AKT pathway once turned on, is not turned off because of non-functional PTEN. PI3K is often found 





contains changes that forces prolonged activation even in absence of activating signals, causing 
hyperactivation of the downstream pathways which are mediated through a serial activation of AKT and 
mTOR. Overexpression and activating mutation in PI3K shifts the axis more towards hyperactivation of 
AKT pathways [38, 63].  
Beta Catenin is constantly translated in the cytoplasm of a cell. However, this protein is sequestered by 
a complex of proteins (Axin, APC and GSK3ß). This complex phosphorylates Beta catenin and causes 
proteasomal degradation of Beta catenin. In the presence of Wnt pathway activating signal, the protein 
complex binds to the plasma membrane, immobilizing the protein complex of Axin-APC-GSK3ß. Thus, 
the complex of Axin-APC-GSK3ß cannot phosphorylate Beta catenin. This prevents proteasomal 
degradation of beta catenin and it is transported into the nucleus for transcribing genes required for 
differentiation and cell proliferation (Cyclin D1) [6]. NOTCH receptors are another family of surface 
membrane receptor which sequester beta catenin and does not allow its nuclear translocation. Not only 
NOTCH or Axin/APC/GSK3ß sequester beta catenin but other membrane bound proteins like E-cadherin 
and FAT1 also help in preventing translocation of beta catenin in the nucleus. FAT1, located on 
chromosome 4q35.2 is often lost or mutated in HNSCCs [6, 64]. Another protein called AJUBA protein 
phosphorylates GSK3ß. Phosphorylated GSK3ß is capable of recruiting beta catenin to the protein 
complex of Axin/APC/GSK3ß and phosphorylate Beta catenin which is then degraded. Inactivating 
mutations in AJUBA are also reported in HNSCCs. Along with this, mutual loss/inactivating mutation of 
FAT1 and NOTCH 1 receptor have also been reported in HNSCCs, thus making Beta catenin pathways 
also an important facilitator of cancer advancement in HNSCCs. [6] 
Major chromosomal alterations are commonly found on arms 3p and 3q, 7p and 7q, 8q, 9p, 10q, 11q,17p 
and 18q in HPV negative HNSCC tumours. Because of such major changes in the genetic content of the 
cell, cell proliferation becomes uncontrollable. The Phenomenon of Field cancerization and patch 
cancerization further adds a layer of heterogeneity, making it more difficult to treat. [5, 6, 38] 
 
2.4 Treatment for HNSCC 
 
Cancer treatment is continuously advancing through the discovery of new therapeutic targets and 
improved clinical research databases which enables easy sharing of reports and new findings worldwide. 
Although present day treatment regimens have increased overall survival of patients as compared to the 





Conventional methods employ the use of physical (Radiation) and chemical agents (Chemotherapy). 
Nowadays, a novel therapy is included which is referred to as Biological therapy. In this case, the 
therapeutic agent used are of biological origin, that is a living organism (adenovirus or T cells), or a 
molecule produced by a living organism [65]. However, this class of novel drugs is also referred to as the 
Targeted cancer therapy where a particular receptor, signalling molecule etc are blocked or inhibited. 
Depending on their characteristics, origin or functions they can be classified into three broad categories: 
• Treatment using molecules of biological origin (cytokines, antibodies etc) 
• T Cell based therapies (engineered T lymphocytes (for e.g.: CAR-T cells)) 
• Immunotherapy (immune checkpoint inhibitors) 
The use of monoclonal antibody against growth factor receptors overexpressed on tumour cells is one 
good example of a targeted cancer therapy. In cell-based therapies, cells of the immune system are 
collected from the patient, propagated ex vivo and genetically engineered to express surface receptors 
which exclusively detects tumour associated surface antigen (TAA). Tumour infiltrating lymphocytes 
(TILs), Cytotoxic T lymphocytes (CTLs), transgenic T cell receptors (tgTCR) and Chimeric Antigen 
Receptor expressing T cells (CAR-T cells) are some of the examples of T cell-based therapies. Among 
these, last two, tgTCR and CAR-T cells, are genetically engineered form of T cell-based therapies. T cells 
are genetically transformed to express Chimeric Antigen Receptor (CAR) which is against TAA. 
Difference between tgTCR and CAR-T cells is that the former contains fusion of alpha and beta chain of 
the T cell receptor (TCR) fused with the receptor specific for TAA, while CAR-T is engineered to express 
fusion of zeta chain of TCR fused with antigen recognition domain derived from an antibody. These cells 
bind to the antigen expressed on tumour cells. Binding of the receptor to the antigen stimulates immune 
response and helps in directing the immune system against tumour cells. This system is also referred as 
the Adoptive Cell therapy. [66] Adenoviruses are also genetically modified and injected locally in the 
tumour area to express inhibitors/blockers that prevents suppression of the immune response against 
tumour cells [67]. This brings us to the third category of biological therapy which is Immunotherapy. 
Immunotherapy does not target the tumour cell directly, but inhibitors/monoclonal antibodies are used to 
prevent immunosuppression and to facilitate tumour cell clearance by the immune system. Systemic 
administration of the inhibitors/monoclonal antibodies is preferred over adenovirus transformation to 
avoid side effects.   
The decision of what kind of treatment course is best for the patient is determined by several factors, 
including 
• Staging of the diseases (TNM classification) 





• Age of the patient 
• Recurrent tumour 
• Location (Surgical removal possible or not) 
• Comorbidities before and during the treatment 
• HPV status 
• Weight and overall performance of the patient during first line of therapy 
• Previous systemic therapy, if any 
• Smoking/alcohol or tobacco chewing habits 
• Prognosis, if possible 
 
2.4.1 Surgical excision 
 
Surgical removal is possible when the cancerous lesions have not propagated extensively. Even after 
surgical removal, the patient is often subjected to chemotherapy. Subsequent chemotherapy ensures 
reduced risk of recurrent tumour at the same location or distant locations. Systemic drug administration 
also affects growth of cancer cells that have undergone metastasis and have not yet formed a clinically 
diagnosable colony or tumour. Systemic administration also helps in controlling cancer cell proliferation 
at locations which are difficult to dissect through surgery. If the tumour has several nodules/lesions, 
surgery is not a viable option under the objective of organ preservation. Radiation therapy combined with 
chemotherapy is employed. [68, 69] 
 
2.4.2 Radiation therapy 
 
Since radiation therapy alone is not a reliable cure for the disease, it is used in combination with 
chemotherapy. Highly differentiated tumours and metastasized tumours have a population of cells 
(identified as Cancer Stem Cells) that are resistant to radiation therapy. Moreover, cells in different stages 
of cell cycle, e.g.: G2/M, are more resistant to irradiation as compared to cells in G1 or S phase, which 
also creates heterogeneity in sensitivity towards radiation. Hence, improved regimens of treatment 
include chemotherapy during and after subjecting the patient to radiation therapy. Certain 
chemotherapeutic agents (discussed below) are capable of interfering with DNA synthesis and 
introducing DNA double strand breaks which increases sensitivity towards radiation and helps in 
obtaining better control over the disease. Oxygen supply of the tumour (vascularization) and haemoglobin 





decrease DNA repair abilities because of increased oxidative stress. Hence, patients with low 
haemoglobin may have cancerous lesions poorly responding to radiation therapy. Moreover, upregulation 
of DNA repair pathways, increased reactive oxidizing species (ROS) scavenging molecules like 
glutathione and other pathways to deal with oxidative stress can also contribute to resistance towards 




There are different groups of chemotherapeutic agents which are employed as a single agent or in 
combination to target multiple pathways of dividing tumour cells. Commonly employed chemotherapeutic 
agents in HNSCCs belongs to three main groups, based on their mechanism of action: 
• Platinum based compounds or compounds that introduce DNA break or halt the process of 
DNA polymerization 
• Compounds interfering with purine and pyrimidine base synthesis required for DNA 
polymerization during S phase of cell division 
• Cytoskeleton/microtubilli stabilizing compounds to arrest cell cycle 
 
2.4.3.1 Compounds that interact with DNA 
 
Platinum based compounds, namely Cisplatin, Carboplatin, Oxaliplatin, Ormaplatin and E-enloplatin are 
most widely used chemotherapeutic drugs for variety of cancer entities [72]. Among these, Cisplatin or 
Carboplatin are included in almost all treatment regimens of HNSCCs [73]. The mode of action of 
Cisplatin and Carboplatin is the same. After hydrolysation in the cytoplasm, they bind to the DNA (N7 of 
Guanine base) and create double strand breaks that halt DNA polymerization. Additionally, extensive 
DNA damage results in cell death by apoptosis. They also help in increasing oxidative stress by 
interacting with active sites of several enzymes that scavenge ROS. Carboplatin is preferred over 
cisplatin in cases with prior kidney problems. However, Carboplatin has a major side effect of 
myelosuppression [72, 73]. Ifosfamide is another compound which acts in a similar way to Cisplatin. Inter 
and intra strand cross links among DNA molecules are generated by Ifosfamide which leads to double 





Doxorubicin: There are two proposed mechanism of action for Doxorubicin. First is intercalation with DNA 
molecules and second by inhibiting DNA topoisomerase II enzyme. Upon its inhibition, it cannot relieve 
the torsional tension introduced by the helicase activity for DNA polymerization. Hence, increased tension 
causes double strand breaks and eventually induce apoptosis by excessive DNA damage. Other 
mechanism reported are generation of free radicals. Doxorubicin undergoes redox reactions in the 
cytoplasm generating free radicals which causes lipid peroxidation, damage to other cytoplasmic content 
and nuclear material. [75]  
 
2.4.3.2 Compounds that interfere with purine/pyrimidine base synthesis 
pathways (anti-metabolite drugs) 
 
This group of compounds is also referred as Anti-metabolite drugs since they hinder the metabolic 
pathway of purine or pyrimidine synthesis. 5-Fluro-uracil (5-Fu), Methotrexate, Pemetrexed are 
commonly used chemotherapeutic agents in HNSCCs [76–78]. These compounds block the active sites 
of the enzymes required for synthesis of purine or pyrimidine required for DNA synthesis and thus stalling 
the process of cell division. These compounds are often administered in combination with platinum-based 
compounds (Cisplatin or Carboplatin), but they are also used in single agent chemotherapy in 
combination with immunotherapy/radiation therapy. [71, 73] 
 
2.4.3.3 Taxanes or compounds that interact with the cytoskeleton/ 
microtubilli of the cells 
 
From the group of Taxanes, two compounds that are commonly employed as an anti-cancer drugs are 
Paclitaxel and Docetaxel. These two compounds interact with the same biomolecule (microtubule). 
However, their mechanisms of action are opposite. Paclitaxel promote microtubule assembly 
(polymerisation) and stabilizes the polymer. Depolymerization is inhibited, thereby hindering microtubule 
dynamics which is essential for the process of cell division (G2/M phase, nuclear division). Thus, causing 
cell cycle arrest and eventually cell death. [79, 80]. Docetaxel on the other hand inhibits microtubule 
polymerization [81]. Paclitaxel and Docetaxel are commonly used in HNSCC treatment. Vinblastine is a 





of action is like docetaxel. Vinblastine and other alkaloids of this group inhibit microtubule polymerisation. 
Not only it prevents microtubule polymerisation but it also causes spiral distortion in already formed 
microtubilli polymers [82]. Docetaxel is a second-generation molecule of the taxane group and is found 
to be more effective than Paclitaxel. Docetaxel is believed to have multiple mode of action by influencing 
the process of Angiogenesis, apoptosis and expression levels of certain oncogenes. However there is no 
evidence of direct effect of Docetaxel on these processes. [79]    
 
2.4.4 Biological therapy or Immunotherapy 
 
Biological therapy targets growth factor receptors which are a major class of surface receptors 
contributing to aggressive tumour growth. The Epithelial growth factor receptor family (EGFR) is one 
family being targeted since 1998 (Herceptin, for HER2). Herceptin was initially approved in late 90s for 
treatment for HER2 positive breast carcinoma. Later, it was approved for other cancer types. Cetuximab 
was approved by FDA in 2006 for the treatment of Head and neck cancer [56]. This class of therapeutic 
drugs consists not only of monoclonal antibody but also small molecules. Monoclonal antibodies mostly 
work by inhibiting the ligand binding site of the extracellular domain of the receptor. It targets EGFR by 
preventing ligand binding [56]. Panitumumab is another fully human monoclonal antibody which targets 
EGFR1 but fails to induce Antibody dependent Cell mediated cytotoxicity, unlike cetuximab [83]. 
Nimotuzumab, Zalutumumab, Sym 004 and ABBV-221 are some monoclonal antibodies which target 
members of the EGFR family [56]. Sym 004 is a mixture of two antibodies. One of them prevents ligand 
binding and another causes internalization of the receptor. In a trial with patients with Cetuximab resistant 
tumours, Sym 004 showed modest response upon its inclusion [84].  
Other than monoclonal antibodies, small molecules are used which inhibit the tyrosine kinase activity of 
the intracellular domain of the EGF receptors. These molecules include Erlotinib, Gefitinib, Dacomitinib 
and Afatinib [56]. Dacomitinib targets not only EGFR1 but also HER2 and HER4 [85]. Apart from above 
mentioned members of the biological therapy, other small molecules, monoclonal antibodies or 
oligonucleotides (modified and commonly known as ‘decoys’) are being tested. Target range in this 
strategy covers signal transducers present in the cytoplasm, e.g.: PI3K, STAT3 and mTOR. Although 
from the mechanism of action, these molecules sound very effective against tumour cells, they are always 
used as a combination therapy which includes platinum based compounds and/or Texans and/or anti-





Subset of biological therapy is immunotherapy. It targets immunosuppressive function of the tumour cells 
and its microenvironment. Hence, it is referred to as Immunotherapy. A single cell manages to form an 
aggressive tumour when it successfully evades immune surveillance. Thus, a suppressed immune 
system is also one of the major reasons for developing tumour and the immune system plays very 
important role in Cancer treatment.  
Program Death receptor 1 (PD1) is expressed on lymphocytes (T cells). The Ligand for this receptor, 
Program death receptor ligand -1 (PDL-1) is expressed on tumour cells. When lymphocytes infiltrate the 
tumour, PDL-1 binds to its receptor PD-1 on lymphocytes which triggers exhaustion of the immune cells, 
helping the tumour cells to escape from a cytotoxic reaction by immune cells. Monoclonal antibodies like 
Pembrolizumab and Nivolumab bind to PD-1 and block the binding site of PDL-1. [86]  
Like PD-1, CTLA-4 is another receptor expressed on regulatory T cells. Activation of this receptor is also 
associated with T cell suppression. A monoclonal antibody (Ipilimumab) blocking CTLA-4 is in clinical 
trials for HNSCC but already employed for treating melanoma [56]. Glucocorticoid-induced tumour 
necrosis factor (GITR) activation also promotes T cell activation and thus, improved immune response 
against tumour cells. A monoclonal antibody (INCAGNO1876) activating GITR is in phase I trial which 
includes patients of HNSCCs [56]. Tumour cells secret enzymes like Arginase-1 (Arg1) and Indoleamine 
2,3-dioxygenase (IDO) to modify the tumour microenvironment by depleting nutrients required for T cell 
proliferation. Another enzyme, Nitric oxide synthase (NOS2), produces Nitric oxide which inhibits T cell 
proliferation and is also secreted by tumour cells in its microenvironment. The collective activity of such 
enzymes makes T cell proliferation and survival difficult in tumour microenvironment. Small molecules 
inhibiting such enzymes (Arg1: INCB001158; IDO: Epacadostat; NOS2: L-NMMA) are in clinical trial and 
are promising agents used for immunotherapy in near future. [56]  
The Adoptive Cell therapy (ACT) has yet to make its way from bench to the bed in case of solid tumours. 
Among all, CAR-T cell therapy has shown promising results in case of acute and chronic B cell leukaemia. 
However, it has not been entirely successful in case of solid tumours. Pre-clinical studies are ongoing. 
3rd generation of CAR-T cells which are capable of not only recognizing TAA and elicit immune response 
but are also capable of propagation for sustained anti-tumour activity.  Reasons explained in a review for 
limited success of CAR-T cell therapy for solid tumours were 1) unfavourable tumour microenvironment 
with unsuitable pH, oxidative stress, lack of nutrients and hypoxia; 2) immune checkpoint inhibitors 
secreted by the tumour cells; 3) Regulatory T cells might suppress the activation of CAR-T cells. [87] 
However, CAR-T cell therapy has been tested in vitro as well as in vivo (tumour xenograft) in combination 





overexpressed on established HNSCC cell lines, was used as the TAA in this study. CAR-T cells were 
supplemented with adenoviral expression of Interlukin-12 and program cell death ligand-1 (PDL-1) which 
did not reduce the tumour volume or control the process of metastasis but increased overall survival from 
25 days to more than 100 days [67]. Oesophageal squamous cell carcinoma is another solid tumour in 
the class of squamous cell carcinoma for which CAR-T cell therapy was tested in vitro only [88]. However, 
in case of CAR-T cell therapy, majority of clinical trials focus on glioblastoma, neuroblastoma and 
Osteosarcoma [66].   
There are ongoing clinical trials of TILs for metastatic melanoma. Results of clinical trial employing CTLs 
for treating EBV positive Nasopharyngeal carcinoma are published with two complete response, one 
partial response and one instance of stable disease. [66] 
 
2.4.5 Treatment de-escalation for HPV positive tumours 
 
Therapies for HPV positive and HPV negative tumours are the same although their molecular biology 
divides them into separate groups. HPV positive cases show good prognosis and better overall survival 
rates.  Better outcomes of HPV positive patients, compared to HPV negative tumours, have led to revision 
of the current treatment strategies employed for treating HNSCC patients.  
Therapeutic drugs and radiation mentioned above have severe side effects and diminishes the quality of 
life of the patient. Among several commonly experienced side effects are fever, weakness, reduced 
immunity, anaemia, neurotoxicity, nephrotoxicity, hepatoxicity, nausea, loss of appetite, ototoxicity etc. 
Patients receiving radiation therapy, especially HNSCC patient, suffer from the additional side effect of 
stomatitis because of the location of the disease. This side effects results in difficulty in swallowing food 
and water and hence a pipe has to be used to administer food and water to the patient. Because of such 
high toxicity profile, treatment regimens of patient with good prognosis, preferentially HPV positive 
HNSCCs, were selected for reducing the intensity of the treatment with the aim to improve the quality of 
life along with achieving locoregional control of the disease and better progression free survival.  The 
idea of attenuating treatment regimens is referred to as ‘De-escalation’ of the treatment. It is currently 
being tested mostly in HPV positive patients worldwide in several independent trials. The results of these 
trials are awaited. Current updates on such trials are promising and may offer a treatment strategy better 






Four different approaches are being tested in treatment de-escalation trials. 
• Radiation combined with Cetuximab instead of Cisplatin 
• Induction chemotherapy followed by decrease radiation dose for good responders 
• Radiation therapy alone instead of chemoradiation therapy 
• Transoral surgery followed or not by postoperative radiotherapy 
In order to reduce the side effects caused by platinum-based compounds, Cetuximab (anti-HER1) is 
being tested for achieving locoregional control of the disease. In this regimen, radiation dose is also 
altered. High intensity radiation for short time is replaced by low intensity radiation for long time to reduce 
side effects due to radiation therapy.  Another approach is the use of chemotherapy as the first line of 
treatment followed by a decreased dose intensity of radiation therapy for progression free survival.  
Certain trials are testing radiation therapy as a sole therapy for treating HPV driven HNSCC patients. The 
patients selected in this trial are mostly low risk HPV positive HNSCC patients and do not have advanced 
disease (T0-1, N0-1). The goal is to achieve control over the disease with minimal therapy and hence 
reduced side effects. HPV driven HNSCCs have high proliferative rates since cell division is being pushed 
forward by the viral proteins to facilitate spread of the infection. Hence, rapidly dividing cells are better 
target for radiation therapy which causes heavy DNA damage beyond repair leading to cell death. 
Moreover, the presence of the viral protein causes immunogenic stimulation which supports clearance of 
the infected region. [90] 
Photon beam and proton beam therapy are also being tested. Using different radiations other than 
conventionally used X rays, these therapies provide us the ability to reduce the dose intensity. Proton 
beam therapy is more precisely targeted than Intensity modulated radiotherapy (IMRT) which reduces 
collateral damage to the surrounding tissues. A phenomenon called Bragg’s peak helps in understanding 
the advantage of proton beam therapy over IMRT or X rays. Proton beam deposits most of its energy at 
the end of the pathway (energy peak of deposition) and goes down drastically after the peak causing 
minimum damage for the tissues lying behind the tumour. Because of this phenomenon, the radiation 
therapy related tissue injury goes down, improving the quality of life of the patient. Because of the 
concentrated intensity of the energy at a desired location, dose intensity can be reduced, leading to 
reduced side effect and better quality of life of the patient post therapy. [91]   
Transoral Robotic surgery (TORS) along with advanced imaging techniques makes it possible to pin point 
the exact location and extent of the tumour in the tissue, enabling precise dissection of the tumour, leading 
to reduced tissue injury and organ preservation if possible. Robot operated surgeries are usually 





possible. Tumours with T1 or T2 grade are selected for this module and the results of the trial are awaited. 
[92, 93] 
 
2.5 Special AT rich sequence binding (SATB) protein family 
 
The Special AT rich sequence binding family of the proteins consist of two isoforms, SATB1 and SATB2. 
These two isoforms have 61% homology in their amino acid sequence [94]. To explain in detail their 
functions, a small revision on how our genomic material is packed inside the nucleus will be helpful.  
In a resting cell, or a cell that has not entered the prophase of the mitosis, nuclear material is not 
condensed and is organized in a very complex manner in three-dimensional space. The packaging is not 
only efficient but highly complex. The nuclear matrix or nuclear skeleton helps in organizing the genomic 
material. The nuclear matrix consists of all non-chromatin components of the nucleus. It is a dynamic 
network of structural proteins which help in maintaining the shape of the nucleus, organizing three-
dimensional arrangement of the DNA, DNA replication and repair, RNA transport, gene expression etc. 
Proteins that can interact with both nuclear matrix as well as DNA help in organizing the genomic material. 
Nuclear matrix proteins form a mesh-like structure which acts as an anchor for such DNA-protein 
interactions. These proteins are commonly referred to as the genome organizer proteins. Special DNA 
interacting domains of these proteins have affinity for specific DNA sequences. This affinity facilitates 
DNA-protein interactions which not only help in organizing chromatins but also control gene expression.  
DNA sequences which attach to the nuclear matrix proteins are known as the Matrix Attachment Regions 
(MARs) of the DNA. DNA sequences with preference for scaffold proteins are called Scaffold Attachment 
Regions (SARs). These DNA stretches are rich in Adenine (A) and Thymine (T) bases. Their size varies 
from 200 to 350 bp and are found at a varying distance of 5 to 300 kbp. Within MARs or SARs, there are 
stretches of sequences which are found to have a sequence bias for Guanine (G) and Cytosine (C) on 
either strand. This sequence bias generates opposite strands rich in As, Ts and Cs. These stretches are 
usually 20-40 base pair long. Because of its AT rich content, the double stranded DNA in this region tend 
to unwind under super-helical strain. This stretch of 20-40 base pairs rich in As and Ts is known as the 
Base Unpairing Regions (BURs). S/MARs may contain more than one BUR.  
The SATB1 protein was initially identified as a protein that binds to MARs with high sequence specificity. 
It was described as a tissue specific MAR-binding protein since it was found predominantly expressed in 





DNA in its minor groove. SATB1 interacts specifically with the BURs (the term ‘BURs’ was not used in 
this paper [95]). An ATC biased strand generates a special geometry of the sugar-phosphate backbone. 
SATB1 has high affinity for this altered sugar-phosphate backbone rather than the actual bases of the 
sequence. It does not interact directly with the bases, although base specificity is exhibited. [96, 97] 
To explain the functional properties of SATB1 or SATB2, it is inevitable to discuss their structure in brief. 
Figure 3 on page 26 schematic diagrams show the domains discovered in SATB1 and SATB2 proteins. 
Since SATB1 is the topic of this work, SATB2 is not covered in this discussion. SATB1 was discovered 
first and was found to be a protein that binds to the MARs upstream of the immunoglobulin H (IgH) cluster 
[95]. Major domains of this protein which helped in its characterization were the CUT domains and 
Homeodomain (HOX domain). These two domains help the protein to interact with the DNA and hence 
the protein functions as a transcriptional repressor or activator. The presence of Homeodomain identified 
the protein as a genome organizer important for development-related gene expression [98].  
Beginning from the N terminus of the protein, a nuclear localization signal (NLS) is found from 20 to 40 
amino acids which helps in translocating the protein inside the nucleus post translation. Along with the 
NLS, a Nuclear Matrix targeting sequence (NMTS) has been discovered which further explains the 
precise location inside the nucleus (interaction with the nuclear matrix). An important domain which was 
earlier identified as the PDZ domain is now found to resemble structurally to Ubiquitin and hence it is 
referred as the Ubiquitin Like Domain (ULD, 90-204 aa) [99]. As per the NCBI protein database, this 
domain is still referred as the PDZ domain [100]. The PDZ domain, now identified as ULD, was believed 
to be the domain that allowed interaction of SATB1 with other proteins. X-ray crystallography studies 
revealed that the Ubiquitin like domain’s primary function is to facilitate tetramerization of the protein. 
Tetramerization of the protein helps the tetramer complex to interact not only with a single chromatin but 
with two different chromatins [99]. This ability of the tetramer unit of the protein explains how it can 
juxtapose distant genes by generating chromatin loops of different sizes as well as interact with several 
proteins and the nuclear matrix. Further, an overlapping domain at the N terminus is characterized as 
CUT like Domain (CUTL) due to amino acid sequence similarity. After CUTL domain, there is NMTS 
which also harbours a Caspase 6 cleavage site [101]. After NMTS, two CUT domains are present and at 
last the most important domain that is the HOX domain or the Homeo domain, which enables interaction 
of the protein with DNA, is located from 644 to 701 amino acids. It was found that in absence of CUT1 
and CUT2 domains, the protein weakly interacts with DNA. DNA interaction is stronger in presence of all 
three domains necessary for DNA binding [102, 103]. The HOX domain also contains a nucleotide 
sequence specific binding domain which provides DNA sequence specificity to the protein. Although both 





sequence is identical [94]. Moreover, till date studies reveal contrasting function of both the proteins, both 
in normal physiology as well as cancerous condition.   
Post-translational modifications play an important role in regulating the function of a protein. In case of 
SATB1, there are several modifications reported. Phosphorylation at serine/threonine residues, 
acetylation and SUMOylation are some of the reported modifications which governs the activity and fate 
of the protein.  
Figure 3 Schematic diagram showing domains of SATB1 (A) and SATB2 (B) protein. Reference: NCBI, Protein 
database. 
Through E3 SUMO-protein ligase 1 (PIAS1), SUMOylation of the Lysine residue at 744 position facilitates 







SUMOylation of SATB1 causes cleavage by Caspase 6, degrading the protein to create a 65 kDa 
truncated protein known as ΔSATB1. Truncated SATB1 does not possess tetramer interface or ULD 
which facilitates tetramerization of the protein. Tetramerization of the protein is very crucial for its DNA 
binding activity. Hence, ΔSATB1 is unable to bind to the DNA and so it is eventually degraded. Protein 
Kinase C mediated phosphorylation of threonine at position 188 prevents interaction of PIAS1 and 
SATB1, inhibiting SUMOylation of the protein, thereby preventing its degradation. [104, 105]   
Repressor/activator activity of SATB1 is governed by its phosphorylation state. Phosphorylation of serine 
at position 185 determines whether the protein will interact with co-repressor or co-activators. 
Phosphorylated serine promotes the interaction of SATB1 with histone deacetylase (HDAC1) and 
C-terminal binding protein 1 (CtBP1). This complex epigenetically represses the target gene by 
deacetylating the histone proteins, converting the euchromatin to the heterochromatin state. The study 
reported that deacetylation of SATB1 disrupts its interaction with CtBP1. [106] 
In case of dephosphorylation of serine at position 185, SATB1 undergoes acetylation at Lysin residues 
136 and 175 by p300/CBP associated factor (PCAF). This abolishes the DNA binding ability of SATB1 
and prevents interaction with HDAC1 and CtBP1, thereby epigenetically repressing gene expression. 
Acetylation of the Lysine residue at position 136 diminishes tetramerization of the protein. SATB1 protein 
in its monomer form cannot bind to the DNA molecule efficiently. However, two mechanisms were 
discovered in this case. SATB1, upon acetylation by PCAF, loses its affinity for DNA thereby removing 
HDAC1 and CtBP1 gene silencing complexes and switching on the transcription of the target gene. 
Conversely, SATB1 when dephosphorylated can interact with p300 and CBP which acetylates histone 
proteins, thereby upregulating the expression of the gene epigenetically [105, 106]. This ability of SATB1 
to control gene expression (switch on and off) by interacting with DNA and different proteins makes it an 
interesting genome organizer.  
 
2.5.1 Role of SATB1 in the healthy individual 
 
2.5.1.1 SATB1 in controlling the process of differentiation in embryonic 
stem cells  
 
SATB1 and SATB2 proteins play opposing roles in controlling the expression of Nanog protein which is 





embryonic stem cells. Embryonic stem cells have two primary purposes, self-renewal and differentiation 
upon stimulation. Nanog is a transcriptional factor which controls the expression of genes necessary for 
maintaining the self-renewal state of the stem cells. Upon stimulation for differentiation, Nanog expression 
is reduced which facilitates the process of differentiation by exiting the self-renewal state. The absence 
of SATB1 upregulated Nanog expression which in turn resulted in maintaining the self-renewal state of 
the embryonic stem cells, and thus differentiation was not triggered. It was proven that SATB1 negatively 
regulates the expression of Nanog via KlF4 and Oct4. It was also found that the balance in the amount 
of SATB1 and SATB2 protein resulted in a delicate balance of homo and heterodimers of these proteins 
which controlled the process of self-renewal and differentiation. When the balance shifted towards 
SATB2, Nanog expression was increased and SATB1 expression was repressed. In short, SATB1, which 
facilitates the process of differentiation leading to lineage commitment by suppressing Nanog expression, 
is counteracted by SATB2 which drives embryonic stem cells towards self-renewal or pluripotent state. 
[107] 
A study partially contradicting these results was published by Kazuo Asanoma et al in the year 2012. 
Their data findings indicated SATB1 and SATB2 worked in concert to maintain the stem cell state and 
inhibit proliferation in trophoblast stem cells isolated from mice embryos. Knockdown of either of the 
proteins changed not only the gene expression of stem cell state-related genes but also changed the 
morphology of the trophoblast to trophoblast giant cells which exhibited polyploidy. Expression of stem 
cell state related genes was found to be directly correlated with SATB1 and SATB2 levels. Knockdown 
of either of the SATB proteins reduced expression of Eomes, Cdx2, Esrb and Id2. Expression levels of 
differentiation related genes like Prl3d1, Prl3b1, Gcm1 and Tpbpa increased in absence of SATB 
proteins. Induction of differentiation had a similar effect, that is, the expression of SATB1 and SATB2 
expression was downregulated. Thus, SATB proteins, expressed at same level, help in maintaining the 
stem cell state in trophoblast stem cells. [108] 
Although the model used for studying the functions of SATB proteins in this finding was different from 
what was used by Severse et al in 2009, an overview of these two works highlight how SATB1 proteins 








2.5.1.2 SATB1 in pre and post-natal brain development  
 
SATB family of proteins were found to be important for brain development of mice in both pre and 
post-natal condition. Studies with SATB1 null mice concluded two major inferences: 1) SATB1 is 
important for post-natal brain development and its plasticity. SATB1 achieves this by controlling the 
expression of Immediate Early Genes (IEGs) required for synaptic plasticity and in learning and memory 
development; 2) SATB2 is crucial for pre-natal brain development. 
SATB1 null mice exhibited normal cortical layer morphology in pre-natal mouse brain. In contrast to this, 
SATB2 null mice showed major deformities in brain development and resulted in immediate death after 
birth. This result indicated that SATB1 is dispensable during the embryonic development of the brain, 
while SATB2 is crucial during pre-natal stage.  
Post-Nataly, SATB2 expression disappears. It is after birth when SATB1 comes into the picture and is 
crucial for brain development throughout the life. SATB1 null mice exhibited a significantly reduced 
density of cortical excitatory pyramidal cells in 2-week-old mice as compared to the wild type.  
The development of new neuronal cells and novel synapsis is what is referred to as the neuronal plasticity. 
The majority of neuronal cells develop during the early phase of development. However, a minor fraction 
develops upon external stimuli which help in the process of learning and memory formation for the entire 
life. SATB1 null mice had reduced dendritic spine density which ultimately affects the process of learning 
and memory formation. Thus, SATB1, though not crucial during pre-natal brain development, is extremely 
important post-Nataly for maintaining the plasticity of the neurons in certain parts of the brain. 
Immediate Early Genes (IEGs) is a group of genes which are expressed upon external stimuli and play 
a critical role in neuronal plasticity. It was reported in this study that SATB1 binds to the genomic loci of 
IEGs. It not only binds to but also controls the expression levels of these genes. The expression of layer 
specific modulators of gene expression was unchanged in absence of SATB1. However, temporal and 
relative control of expression of IEGs was lost in SATB1 null mouse brains, indicating that SATB1 is 
crucial for their temporal and relative expression. SATB1 is not only a genome organizer but also acts as 
a transcriptional factor in co-ordination with several other trans-acting factors. Hence, in the absence of 
SATB1, necessary and sufficient factors required for timely expression of IEGs cannot juxtapose, 






2.5.1.3 SATB1 as a downstream regulator of p63 protein in skin growth and 
development  
 
The master regulator, as described by Fessing M. Y. et al in 2011, p63 protein is extremely important for 
programming the development of stratified epithelium. p63 is critical during embryonic development, 
epithelial stem cell development, skin growth, development and differentiation and in cancer progression. 
To facilitate the process of differentiation, p63 protein takes help of several genome organizer proteins, 
of which SATB1 is one of the important proteins. Initial results of ChIP assays were confirmed by promoter 
analysis studies to prove the direct involvement of p63 in regulating SATB1 expression. p63 protein binds 
directly to the promoter region (-1662 to -1738 bp upstream of the transcriptional start site of SATB1) of 
SATB1 and acts as a transcription factor for SATB1. SATB1 governs the expression of several genes of 
the EDC (epidermal differentiation complex) locus which is crucial for growth and differentiation of 
epidermal cells for skin formation. It also binds to Keratin Type I/II loci and keratin associated protein 
locus for expression of several genes for facilitating the process of skin development. Once SATB1 
expression is induced by p63, the former takes control of the entire regulatory network and controls the 
expression of ~2500 genes. SATB1 was found to be expressed at a very low level in p63-/- mouse 
epidermal tissues. Its absence resulted in deficiency of the expression of genes for the terminal 
differentiation process which was accompanied by morphological changes in the epidermis. Not only 
reduced expression, SATB1 deficiency also resulted in decompression of the EDC locus thus supporting 
the fact that SATB1 as a genomic organizer carries out the function of organizing chromatin loops and 
orchestrating the expression of differentiation related tissue specific genes simultaneously. [110] 
 
2.5.1.4 SATB1 functions in development and maintenance of the immune 
system 
 
SATB1 was originally detected as a protein with high affinity for MAR sites at the 3’ region of the IgH 
enhancer element [95]. It was discovered as a regulator important for the expression of immune system 
related proteins. A study published in the year 2000 described the importance of SATB1 in the 
development of normal functional T cells. SATB1 expression was found in all thymocyte subpopulations 
of triple negative, single positive, double positive and in T cells after activation [111]. Hence, ablation of 





development upon SATB1 knockout led to reduced numbers of mature T cells, especially a marked 
reduction in the number of functional CD4 and CD8 single positive peripheral T cells. This set of results 
indicate the importance of SATB1 in the process of development of functional CD4 and CD8 single 
positive T cells. IL-2Rα and IL-7Rα genes are normally expressed upon activation of T cells. They are 
transcriptionally silent at the developmental stage. Absence of SATB1 caused the untimely expression 
of IL-2Rα and IL-7Rα during the developmental phase, which indicates how SATB1 protein controls 
temporal and spatial gene expression during T cell development as well as normal functioning [111].  
SATB1 null mice also highlighted the importance of SATB1 in several other organs such as absorptive 
cells of the intestinal epithelium, osteoblasts and foetal neurons. Absence of SATB1 induced apoptosis 
in the absorptive cells of the intestinal epithelium, leading to failure in absorption of nutrition and water 
which led to death of the mice. [111] 
SATB1 expression is decreased after mature T cells enter circulation. Its expression resurfaces upon 
antigen stimulation to facilitate differentiation. On antigen encounter, naïve CD4+ T helper (TH) cells 
differentiate in TH1 and TH2. TH1 cells produce inflammatory cytokines like TNF-β and Interferon Gamma 
which mediate cellular immunity by attracting macrophages at the site of infection. TH2 cells produce 
cytokines which stimulate B cells to produce antibodies. STAT6 (signalling protein) and GATA3 
(transcriptional factor) along with SATB1 facilitate the expression of cytokines in TH2 cells. In resting 
stage, STAT6 and GATA3 are associated with cytokine locus of 200-kb but cannot initiate the process of 
transcription. Upon activation, SATB1 together with STAT6 and GATA3 organizes the chromatin loops 
into transcriptionally active structure and initiates the process of transcription of Interleukins (IL4, IL5, 
IL13). Organizing the chromatins into active loops delegate trans-acting proteins like c-Maf and Brg1 
along with RNA polymerase II which carries out the process. [112]  
SATB1 function in the immune system is not only restricted to T helper cells. Regulatory T cells (Treg) can 
differentiate into Effector T cells (Teff) upon activation. This process of differentiation is mediated by 
SATB1. SATB1 is silenced by Foxp3 directly by repressing SATB1 transcription as well as indirectly on 
the translational level by transcribing miRNA that binds to the 3’ untranslated region of SATB1 mRNA. 
SATB1 suppression is very important for regulating unwanted activation of Treg cells into Teff which is 
responsible for auto-immune disorders. Upon activation, Treg cells need help of the genome organizer 
protein SATB1 for regulating the expression of differentiation related genes to differentiate into Teff cells 
and carry out immune response. Thus, SATB1 is important not only for T cell development but also for 






2.5.1.5 Role of SATB1 in Hematopoietic stem cells (HSCs) 
 
Two independent studies describing roles of SATB1 in HSCs were published at a distance of a month in 
the year 2013. The first paper described the SATB1 relevance in maintaining the pluripotent or 
self-renewal state of HSCs [114], while the second paper described how temporal SATB1 expression 
drives HSCs differentiation towards lymphoid lineage [115].  
Britta Will et al emphasised on the role of SATB1 in maintaining the quiescent stage of the HSCs which 
is very important for lifelong supply of stem cells to ensure uninterrupted production of blood cells (both 
myeloid and lymphoid lineages). The study showed that lack of SATB1 triggered the expression of genes 
which forces the quiescent HSCs (in G0 phase) to enter the G1 phase of the cell cycle. Additionally, it 
was found that the expression of c-Myc and Numb, which facilitate the differentiation, increases in 
absence of SATB1 (SATB1-/- HSCs). SATB1 repressed expression of c-Myc and Numb genes via 
epigenetic regulation (H3K4me3 causes methylation of the promotors of c-Myc and Numb). Thus, SATB1 
inhibits unwanted cell division which, in its absence, is paralleled by a differentiation process resulting in 
the exhaustion of the HSC population. [114] 
Yusuke Satoh et al also published their work on the role of SATB1 in HSCs. Their work showed how 
SATB1 expression is important for commitment towards lymphoid lineage in HSCs. SATB1-/- HSCs had 
attenuated production of lymphocytes in vitro and in vivo. This result was consistent with their previous 
finding showing the importance of SATB1 in lymphocyte production, differentiation and normal 
functioning. Ectopic expression of SATB1 strongly induced differentiation towards lymphoid lineages. 
Commitment towards lymphoid lineage upon SATB1 expression was supported by the fact that genes 
related to lymphocyte production were upregulated (Rag1, IL7, Kit1 and Csf3r). Moreover, in the 
progenitor cell population, overexpression of SATB1 shifted the drift towards B lymphopoiesis and 
depletion of SATB1 impaired T lymphopoiesis in vivo. [115] 
 
2.5.1.6 SATB1 and its indirect involvement in Anti-tumour immunity 
 
For T cells, SATB1 is extremely important right from as early as progenitor cell stage of production until 
its terminal differentiation for effective immune functions. SATB1 directs progenitor cell differentiation 
towards the lymphoid lineage. Furthermore, SATB1 is inevitable for clonal selection in T cells. Once 





antigenic stimulation, SATB1 levels go up which facilitates differentiation and cytokine production 
important for mediating immune reaction. Its role is further extended in anti-tumour immunity. Escaping 
immune surveillance is described as one of the most important hallmarks of cancer and with increasing 
research focusing on immunotherapy for cancer, extensive amounts of data are being accumulated in 
this field. SATB1, again, is found to be inevitable for healthy functioning of the T cells in fighting tumour 
cells. SATB1 recruits NuRD complex to the CR-C and CR-B region of the Pdcd1 gene which encodes for 
Program Cell death receptor 1 (PD-1). NuRD complexes causes histone deacetylation, resulting in the 
epigenetic downregulation of the gene. This receptor is repressed on mature single positive T cells in the 
circulation. Upon activation, the SATB1 protein level increases further repressing Pdcd1 gene 
expression. Tumour microenvironment is rich in factors like Transforming Growth factor-β. TGF-β is an 
immunosuppressive cytokine produced by the tumour cells. T cell receptor (TCR) activation on T cells is 
triggered upon encountering tumour cells, however, the presence of TGF-β in the microenvironment 
suppresses SATB1 expression by Smad proteins. Smad proteins also localize at the CR-C region, turning 
on the epigenetic switch for the expression of program cell death receptor 1. PD-1 binds to its ligand 
Program cell death receptor ligand (PD-L) expressed by the majority of the tumour cells. Binding of PD-
1 with PD-L triggers exhaustion of the T cells in the tumour microenvironment, leading to apoptosis. Thus, 
SATB1, when expressed in Tumour reactive T cells, works against tumour cells. [116] 
 
2.5.1.7 The role of SATB1 in X chromosome inactivation 
 
Out of the two copies of the X chromosomes in female, one copy is transcriptionally silenced. Silencing 
of the X chromosome is carried out by Xist RNA (non-coding). This RNA, however, is not found in 
terminally differentiated cells in which the X chromosome is still in a transcriptionally silenced state. In 
the year 2009, Ruben Agrelo et al published their work showing the importance of SATB1 in the process 
of X chromosome inactivation via Xist. They reported that Xist and SATB1 function in a co-ordinating 
manner to achieve silencing of the X chromosome. SATB1 and SATB2 were both found to be expressed 
in a narrow window at the time of initiation of this process in embryonic stem cells. However, there primary 
model for the study was thymic lymphoma cells in which SATB1 depletion abrogated the process of X 
chromosome inactivation (XCI). [117] 
In 2012, Robert Nechanitzky et al reported that SATB1 and SATB2 were dispensable for XCI in mice 
fibroblastic cells isolated from a SATB1 null and SATB2 null mice embryo. They detected proper Barr 





To summarize the functions of SATB1, most of the physiological processes which are found to be 
influenced by SATB1 proteins require the tight regulation of expression of hundreds of genes 
simultaneously. This fact underlines its character of a genome organizer protein. Unfortunately, the ability 
of SATB1 to control expression of several genes, especially genes related to differentiation and 
proliferation, is also exploited by cancer cells.  
 
2.5.2 Role of SATB1 in Cancer progression 
 
Collective changes towards favouring proliferation and differentiation cause oncogenic transformation. 
Mutation in one or two genes cannot accomplish this process. A transformation like this requires large 
scale changes in the transcriptome of the cell. Sustaining growth signalling pathway activation, evading 
growth suppressing signals, avoid destruction by immune system, enabling replicative immortality,  
Figure 4 Molecular and cellular processes, affected upon altering SATB1 levels, studied in different cancer 
moieties. 
activating invasion and migration into surrounding tissues, sustaining DNA damage, dysregulating 
cellular energetics to meet extremely high energy demands and resisting cell death are defined hallmarks 
of cancer by Weinberg and Dickinson in the year 2011 [119]. The process may be initiated by a single 
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expression of several genes. This may rely on a genome organizer protein, capable of binding to several 
genomic loci, aberrantly expressed.  
Speculation on the relevance of SATB1 in the processes that requires simultaneous expression and 
suppression of several genes has been proven to be correct till date. Perhaps, it was this speculation of 
Han et al which lead to a pioneering discovery of the involvement of SATB1 in cancer progression in 
breast cancer. They used breast cancer cell lines and tumour specimens to demonstrate the importance 
of SATB1 in tumour progression. They showed how SATB1 controls expression of more than 1000 genes 
(up- and down- regulated) to achieve differentiation, to enable proliferation in adverse environment and 
help the growing tumour cells to achieve metastatic potential [120]. This study started a domino of studies 
to explore SATB1 relevance in cancer. Till date (October 2018), a broad search with keywords SATB1 
and Cancer on NCBI-PubMed shows a list of 206 publication. However, this might include publications 
disapproving SATB1 role in cancer progression, but the figure indicates how extensively this protein is 
studied in the context of cancer.  
From various studies compiled in a review article [121], the approach of the majority of the studies was 
to evaluate effects of SATB1 levels (knockdown, knockout or overexpression) on cellular processes 
crucial for cancer development. Very briefly, Figure 4 on page 34 compiles the pathophysiological 
processes evaluated in a variety of cancer moieties. Upon SATB1 ablation, cell cycle rate is reduced, 
apoptosis increased, expression and protein levels of EMT markers are decreased, invasive and 
migratory potential is attenuated, chemosensitivity is increased and some studies have also proven in 
vivo anti-tumour effects and reduction in metastatic nodules in lungs upon knockdown or knockout of 
SATB1. Both cellular processes and molecular markers associated with each process have been 
analysed. Apart from these studies, several other studies are published which have partially or completely 
analysed the transcriptome of the cell upon SATB1 depletion. Major molecular changes affected by 
SATB1 are discussed below.  
 
2.5.2.1 Cell cycle and Apoptosis 
 
Cell cycle progression and inhibition of apoptosis work collectively to bring about uncontrolled proliferation 
and survival of tumour cells. Cyclin D1 (CCND1) is a gene found to be regulated by SATB1 in colorectal 
carcinoma [122], glioma [123] and urinary bladder [124]. Myc is another protein which helps in cell cycle 





cancer [126] and liver cancer [127]. Proteins of the Epithelial growth factor receptor family are found 
upregulated in variety of cancer. SATB1-governed expression of EGFRs is proven in colorectal [128], 
glioma [123] and breast cancer [129]. Downstream to the surface receptors, expression of cytoplasmic 
signal transducers like ERK1/2 and AKT are also regulated by SATB1 [123, 128–130]. Furthermore, in 
colorectal carcinoma, the hyperactive Wnt pathway is mediated via SATB1 by facilitating beta-catenin to 
its target genes which ultimately results in increased proliferation, invasive potential and differentiation 
[128]. AREG (Amphiregulin) and NRG (Neuregulin) are ligands secreted by tumour cells as well as cancer 
associated fibroblasts [131–133]. Such ligands are upregulated by SATB1 in breast cancer and colorectal 
carcinoma [120, 128]. Transforming growth factors (TGF alpha and beta) are important signalling 
molecules expressed by tumour cells and associated fibroblasts. They inhibit activation of T cells upon 
encountering tumour cells. Moreover, they also inhibit anti-tumour activity by increasing expression of 
PD-1 ligand on T lymphocytes which upon binding with PDL1 on tumour cells triggers exhaustion of the 
T lymphocytes [116]. Timely regulation of differentiation associated cytokines like TGF-β is achieved by 
SATB1 [134, 135]. Overexpression of anti-apoptotic proteins like BCL2 and BIRC5 is also caused by 
SATB1 [123, 136–138].  
 
2.5.2.2 Invasion  
 
To invade the tissue, the tumour cells need to produce enzymes that degrade the rigid extracellular matrix 
to facilitate movement of the cells. Among several such factors, matrix metalloprotease (MMPs) enzymes 
are a family of proteins which can degrade the extracellular matrix to enable invasion of the tumour cells. 
Out of several members of this family, MMP2, MMP3 and MMP9 are found to be upregulated by SATB1 
expression in breast cancer [120], colorectal carcinoma [122], glioma [139], Osteosarcoma [136] and 




Epithelial to mesenchymal transition (EMT) renders a unique property of mesenchymal tissues to the 
tumour cells, a property which is active only during embryonic development and injured tissues [141]. It 
is shut down in healthy adult cells. This machinery is reactivated in tumour cells because of its urge to 





major cause of death in cancer patients, known as metastasis. Mesenchymal cells have the capabilities 
to invade, migrate and inhibit apoptosis. After an extensive set of studies, a finite number of markers have 
been discovered whose presence or relative levels mark this transition (EMT). Among others, 
E-cadherins, N-cadherins, Beta catenin, Vimentin, TWIST (Twist basic helix-loop-helix transcription 
factor), SNAIL (Snail family of transcriptional repressor) 1 & 2, ZEB (Zinc finger E box binding 
homeobox)1 & 2 and Fibronectin [142] are most relevant and commonly upregulated in most cancer 
types.  
TWIST, SNAIL and ZEB are transcription factors which help in switching on genes that render stemness 
to the cancer cells. They also control the expression of genes that play role in cell-cell adhesion. These 
transcription factors are active during embryogenesis, in mesenchymal cells. Vimentin and actin of the 
smooth muscles are proteins in the category of cytoskeleton which help in maintaining cell shape, 
migration and dynamics of the cytoskeleton. E- and N-cadherins are calcium dependent adherent 
proteins expressed on the surface of the cells. They have opposite function and hence during the event 
of EMT, their expression levels are inversely correlated. E-cadherin promotes cell-cell adhesion and cell 
anchorage in the tissue. N-cadherin and fibronectin help in the attachment of the cells with surrounding 
stromal cells and extracellular matrix, providing anchorage to the cell for migration. Studies have reported 
that the ratio of E- and N- cadherin gives information about migratory potential of the cell. Thus, 
upregulation in N-cadherin expression against stable expression of E-Cadherin can also help in the 
process of migration [143]. In fact, several transcriptional factors, like Beta catenin, ZEB1 and SNAIL2 
repress expression of E-cadherin and promote dissociation of the cancer cell from its surrounding tissues 
and facilitate migration. [142]  
In case of breast cancer [120], urinary bladder [144], glioma [123] and colorectal cancer [128] all these 
proteins are found to be regulated by SATB1. These markers were also regulated by SATB1 in liver 
cancer [145] and prostate cancer [146]. These are published reports which show direct alteration of EMT 
markers upon SATB1 depletion. However, this observation may well be extrapolated to other tumour 
entities where SATB1 has a pivotal role in controlling cell proliferation, migration, invasive potential and 










Rapidly proliferating cells have an excessively high demand of nutrients and oxygen. Hence, tumour cells 
develop capabilities to communicate with the endothelial cells of the nearby blood vessels via cytokines 
like Vascular Endothelial growth factor (VEGF) [147]. This causes endothelial cells to differentiate, 
migrate towards its source and develop blood vessels for developing constant blood supply to the new 
tissue (tumour angiogenesis). VEGF expression is influenced by SATB1 in three different cancers: breast 
cancer [148], colorectal carcinoma [128, 135] and in glioma [123, 149, 150]. They reported effects of 
SATB1 depletion on angiogenesis (by determining VEGF transcription rate or blood vessel stained by 
hematoxilin and eosin stain). Unpublished data from our group proved SATB1 regulatory effects on 
Hypoxia inducing factor 1 in colorectal carcinoma as well as glioma. Hence, we cannot ignore the process 
of angiogenesis when analysing SATB1-regulated, direct or indirect, cellular processes.  
 
2.5.2.5 Epigenetic regulation 
 
Epigenetic control of gene expression requires the interaction of a complex of several proteins with the 
DNA molecule and with the histone proteins used for packaging DNA as nucleosomes. In these 
processes, DNA as well as histone proteins receive chemical modifications which enhance or disrupt 
their interaction, resulting in switching on or off genes. SATB1 has been shown to interact with several 
epigenetic regulators to control gene expression both in normal as well as pathological state. In normal 
physiological condition, tumour suppressor genes are expressed. In this situation, SWI/SNF and p300 
complexes with the transcription factors at the promoter site which causes acetylation of the histones, 
releasing the DNA molecule from the nucleosomal complex and making it accessible for transcription. In 
a similar situation, oncogenes are suppressed by histone deacetylation (NuRD/HDAC1 complex), 
increasing the affinity of the histone molecules for DNA and packaging them tightly into nucleosomal 
complexes leading to inhibition of transcription. SATB1, in cancerous state, acts exactly opposite by 
interacting with both the SWI/SNF and p300 complex and the NuRD/HDAC1 complex. It directs a 
silencing complex (NuRD/HDAC1) to the promoter region of tumour suppressors and an activating 






2.5.3 SATB1 in lymphoma and leukaemia 
 
SATB1, unlike solid tumours, has not been studied so extensively in lymphomas and leukaemia. There 
are reports of its positive or negative association with disease progression but the precise role is yet to 
be elucidated. Costa Bachas et al performed a comprehensive analysis of the gene expression pattern 
between newly diagnosed and relapsed acute myeloid leukaemia (AML) in paediatric patients. SATB1 
was among the top five transcription factors which were found to be dysregulated in relapsed AML in all 
23 patients. It was not clarified by the authors whether SATB1 was found upregulated or downregulated 
in relapsed AML. The term dysregulation was used collectively to describe abnormal expression levels 
of 5 transcription factors (CEBPA, GHI1, SATB1, KLF2 and TBP) which have potential to control 
expression of several other genes. [152] 
A study by Yuxuan Liu et al reported the association of SATB1 and Human Leukocyte Antigen (HLA) 
expression in EBV positive Hodgkin lymphoma cells. Promyelocytic Leukaemia protein nuclear bodies 
(PML-NBs) and SATB1 were shown to regulate HLA class 1 expression. There was a direct correlation 
with the number of PML-NBs and HLA expression on EBV positive Hodgkin lymphomas. SATB1 was 
inversely correlated with HLA expression. Downregulation of SATB1 resulted in higher expression of HLA 
class 1. Moreover, in patient samples lower expression of SATB1 was associated with higher than normal 
HLA expression. Thus, SATB1 negatively, and PML-NBs positively regulate HLA expression in EBV 
positive Hodgkin lymphomas. [153]  
Another study by Ulrich Steidl et al reported SATB1 not in favour of disease progression. SATB1 regulates 
the expression of PU.1 gene. PU.1 is a transcription factor which binds to the purine rich sequences and 
acts as cofactor for transcription of several myeloid and B-lymphoid cell development associated genes. 
It is involved in generating splice variants of proteins. It is also required for differentiation or activation of 
macrophages. This protein is found to be repressed during AML. A Single nucleotide polymorphism 
(SNP) study revealed that mutations in the enhancer region upstream to the PU.1 gene are commonly 
found in AML patients. In addition to the SNP, this study also reported the involvement of SATB1 in AML 
and the regulation of PU.1. SNP disrupts the binding ability of SATB1 to the enhancer of PU.1 which 
results in reduced expression of PU.1 generating an aggressive disease phenotype. PU.1 expression 
was found to be in direct correlation with SATB1 levels. Hence, reduced SATB1 expression levels in AML 
leads to reduced PU.1 gene expression which resulted in progressive AML. [154] 
Luo et al reported SATB1 function in adult T cell leukaemia using Jurkat cells as model for their study. It 





expression of genes which are related to differentiation, proliferation and migration. SATB1 knockdown 
increased invasive the potential of the cells [155]. This result contrasts with the role of SATB1 in colorectal 
cancer published by Sanjeev Galande et al which showed Beta catenin as the direct mediator of SATB1 
in colorectal cancer. SATB1 in turn facilitated localization of beta catenin to the sites of its target gene, 
thus facilitating the process of EMT [156].  
The work of Aleksandra Grzanka et al on SATB1 in cutaneous T cell lymphomas showed a negative 
correlation of SATB1 expression and disease progression. Patient samples with very little or no SATB1 
expression had aggressive progression of the disease. They showed that SATB1 expression correlated 
significantly with better prognosis in patients with cutaneous T cell lymphomas, thus suggesting SATB1 
as a prognostic marker for the disease. [157] 
Work of Li et al also indicated a role of SATB1 against disease progression. SNF5 which is a core member 
of the SWI/SNF chromatin remodelling complex is an upstream regulator of SATB1. It not only regulates 
SATB1 expression but also utilizes it to control gene expression. SATB1, after being induced by SNF5, 
downregulates genes responsible for anti-apoptotic functions in Sezary syndrome (Leukemic variant of 
T cell lymphoma). It was suggested that SNF5 together with SATB1 is responsible for the expression of 
apoptosis related gene [158]. Another study in Sezary syndrome in the year 2011 also reported SATB1 
function in induction of apoptosis related genes [159]. Deficient expression of SATB1 in Sezary cells 
caused resistance to activation induced apoptosis. Restoration of SATB1 expression by lentiviral 
transformation of Hut78 Sezary cells sensitized them for activation induced cell death by regulating 
transcription of FasL/CD95L. Restoration of SATB1 expression was suggested as one of the possible 
cures for this disease.  
 
2.5.4 TNM, overall survival and prognosis 
 
Apart from the molecular analysis of SATB1 in different cancer moieties, the list of studies emphasizing 
the clinical significance of the protein is also extensive. High expression of SATB1 has been found to be 
tightly corelated with poor prognosis. SATB1 is also correlated with tumour differentiation and an 
aggressive tumour phenotype leading to higher TNM status. Aberrantly high expression of SATB1 is 
associated with metastatic prognosis. Its high expression has been linked with reduced overall survival. 






2.6 SATB proteins in HNSCCs 
 
Apart from the tumour entities mentioned above, correlation of clinical staging, metastasis, overall survival 
and drug sensitization with SATB1 and SATB2 proteins are proven also in HNSCC. Most of these studies 
were performed on tumour samples (immunohistochemical and/or western blot analysis).  
Xu-Dong Zhao et al showed a correlation of SATB1 with tumour differentiation grade. SATB1 stain 
intensity was inversely correlated with differentiation grade of the tumour cells. Poor differentiated 
tumours stained strongly for SATB1, while moderately differentiated tumour stained poorly for SATB1 
[160]. Yang-Fei Deng et al showed a correlation of SATB1 levels with overall survival rate. Higher 
expression of SATB1 was associated with poor survival rate. They also showed SATB1 was positively 
correlated with TNM classification (lymph node metastasis, distant metastasis, differentiation) [161] . The 
same conclusion was also drawn from the study of Y-C Li et al. This paper not only showed a positive 
correlation of SATB1 levels with TNM classification but also proved that SATB1 facilitates EMT. By 
knocking down SATB1 in established cell lines (SCC25 and Cal27), EMT markers like E- and N-cadherin, 
beta-Catenin, C4.4A and AGR2 protein levels were altered [162]. Effects of SATB1 on proliferation, 
migration and invasive capabilities as well as increased drug resistance (Docetexal) was shown by Chun-
Sheng Ye et al [163]. However, the model here was a single established cell line, CNE-2. The collective 
conclusion from these studies is that SATB1 is required for facilitating the process of differentiation for 
metastasizing and growth of the HNSCC tumour. 
SATB1 and its association with EBV positive tumours have been explored by Zhihua Shen et al [164] and 
Kazuhira Endo et al [138]. Latent membrane protein-1 (LMP-1) of EBV increases SATB1 expression. 
CTAR1 and CTAR2 domains of LMP-1 are required for transcriptional activation of SATB1. SATB1 and 
LMP-1 were positively correlated in tumour samples of 119 patients. Elevated levels of SATB1, due to 
LMP-1, facilitates differentiation, making the tumour aggressive and eventually leading to poor prognosis. 
An established cell line in this study (NP-69) exhibited no effect on proliferation upon SATB1 knockdown 
in absence of LMP-1. The knockdown was effective only when LMP-1 was ectopically expressed in the 
cells. They also showed that SATB1 directly or indirectly increases expression of Survivin, which is a 
survival protein preventing apoptosis.  
The Localization of SATB1 has been a matter of debate because of some contrasting results published 
until now. Zhihua Shen et al [164] and Y-C li et al [162] through immunohistochemical staining showed 
SATB1 to be present in both cytoplasm as well as nuclei. Although its primary site of action is nucleus. 





the protein was found to be associated with reduced overall survival and poor prognosis when compared 
with tumours with SATB1 localized in the cytoplasm.  
Jacky Chung et al reached a different conclusion. They showed SATB2, and not SATB1, as the real 
player in advancement of cancer. It was shown that SATB2 binds to the promotor of p53 family and 
activates the transcription of Delta-Np63-Alpha which is a survival protein. Np63 in its native form inhibits 
cell cycle. The splice variant (Delta-Np63-Alpha) works in the opposite direction by preventing apoptosis. 
Again, it was reported that SATB2 staining was visible in both the cytoplasm and the nucleus. Nuclear 
localization of SATB2 was positively correlated with poor survival. SATB2 was found to be at higher 
amounts in undifferentiated tumour cells than well differentiated tumour cells, indicating the importance 
of SATB2 for facilitating differentiation and hence advancement of the tumour. SATB1 was undetectable 
not only at protein level but also at mRNA level. Tumour samples showed only SATB2 staining, while the 
samples stained negative for SATB1. These conclusions were drawn from results from HNSCC cell lines 
(SCC9, SCC15, SCC17A and 17B) and 43 tumour specimens. [165] 
Work of Tian-Run Liu et al contradicted the conclusion of Jacky Chung et al. They showed reduced 
SATB2 protein levels in tumour samples. SATB2 was primarily found in normal surrounding mucosa from 
the patient samples. Also, the levels of SATB2 and SATB1 were antagonistic. Lower SATB2 protein 
correlated with poor prognosis. Higher SATB2 protein level were associated with better survival. They 
showed that, although protein levels (SATB1 and 2) were contrasting, overexpression of SATB2 in cell 
lines (Hep2 and Tca8113) did not affect the levels of SATB1. Hence, relative levels of SATB2 have no 
effect on expression levels of SATB1. SATB2 overexpression caused anti-proliferative effects not only in 
vitro but also in vivo. However, the contrary aspect of this axis was not reported: does overexpression of 
SATB1 or knockdown of SATB2 push proliferation forward? [166] 
 
2.7 Topics of this thesis 
 
It is clear from the above discussion that SATB1 has a wide variety of roles in different tissues and 
different stages of life (embryonic development, post-natal development and adult life span). The 
Cooperation of SATB1 with different proteins creates different cellular responses which is again tissue 
specific. The role of SATB1 in cancer progression has been proven in numerous studies covering most 
of the tumour entities. As discussed in previous section, even for HNSCC, its correlation with TNM 
classification and poor prognosis has been published. However, there has been no work published till 





cell lines. Because of its versatility, analysing the oncogenic relevance of this protein in HNSCCs is thus 
of major importance. The distinguishing factor of this study from already published work on SATB1 is the 
use of primary cell lines as a model. To the best of our knowledge, this is the first study of its kind which 
uses HNSCC primary cell lines as the model and show effects of SATB1 knockdown on molecular and 
cellular events in primary cancer cells. In vitro anti-proliferation in different culture settings, cellular and 
molecular analyses and in vivo anti-tumour effects upon SATB1 knockdown are presented here. Analyses 
of such a kind were lacking in the field of HNSCCs pertaining to SATB1.   
 
2.7.1 Primary cell lines 
 
Primary cell lines are cells isolated from tumour biopsies, in this case from HNSCC patients. These cells 
are cultured in vitro for several passages to create a continuous growing culture. In these settings, they 
adapt themselves to the favourable culture conditions (surface adherence and enriched media). These 
cells are neither chemically treated nor virally transformed to achieve unlimited proliferative capabilities. 
Hence, primary cell lines, despite their good replicative potential, have some limitations. The doubling 
time reduces after 15-20 passages. Above this, they are genetically instable. Thus, primary cell lines tend 
to change their growth behaviour, morphological appearance and gene expression pattern over several 
passages. Virally transformed cell lines (established cell lines) have a stable genome, making them ideal 
for studying molecular and cellular effects. Although ideal to study, they represent a biological model far 
from the actual in vivo condition. Primary cell lines used in this work were originally generated in the lab 
of Prof. Dr. Reidar Grenman from the University of Turku, Finland. They were cultured from the tumour 
biopsies of patient with head and neck squamous cell carcinoma. The detail of each cell culture used is 
described in the section of materials and methods (section 3.1.6 on page 56). 
 
2.7.2 siRNA mediated Knockdown 
 
The partial knockdown or a complete knockout of a gene of interest is a widely accepted method of 
studying its relevance in any physiological or cellular process. Prior to the discovery of RNA interference, 
the complete removal by knockout or the generation of mutant or truncated variants was mostly used. A 
more convenient method nowadays is the approach of knockdown. In RNAi-mediated knockdown, short 
interfering RNA (siRNAs) or small hairpin RNAs (shRNAs) are delivered inside the cell which bind to the 





cytoplasm, binds to the RNA induced silencing complex (RISC). shRNA needs to be processed by Dicer 
enzyme to generate siRNA ready to be incorporated in the RISC. RISC containing siRNA binds to the 
mRNA with sequence specificity. Target mRNA is then cleaved and further degraded by cytoplasmic 
Rnase. Thus, respective protein is not produced. Two approaches are possible for achieving the 
knockdown of a gene: delivering an shRNA construct in a plasmid or an siRNA. In case of a plasmid 
construct, the promoter of shRNA and the integration of the plasmid into the genome creates variations. 
The number of plasmid copies per cell, the site of integration inside the genome and cis-acting elements 
upstream of the shRNA construct have an impact on the knockdown efficiency and leads to variable 
results. These are often difficult to reproduce. Hence, the second approach of delivering siRNA for direct 
incorporation into RISC was preferred. Knockdown by delivering siRNA creates transient knockdown of 
SATB1. From previous work by Anja Frömberg [123, 128], siRNA si467, which worked better than the 
other tested siRNAs, was used for achieving transient SATB1 knockdown. Since this siRNA was already 
established and accepted, it was used solely. siRNA transfection always requires a negative control 
siRNA to be delivered parallel to the target gene siRNA.  Introducing huge amounts of siRNA into a cell 
tends to create unwanted cytotoxic effect, accompanied by non-specific effects on mRNA level and 
translation of other genes. Hence, in siRNA mediated knockdown experiments, inclusion of a negative 
control siRNA which does not target any gene in the model system has to be done. siLuc3 is an siRNA 
against Luciferase-3 gene which is absent in humans. Hence, siLuc3 was used as the negative control 
siRNA for this project.  
 
2.7.3 Effects of SATB1 knockdown analysed in this work 
 
Initially, SATB1 expression levels were analysed in 15 primary cell lines. siSATB1 transfections created 
knockdown at mRNA level in all the cell cultures tested. However, in only five primary cell lines SATB1 
knockdown had deleterious impact on proliferation. In addition to these five primary cell lines, two more 
which showed little anti-proliferative effects were also selected. In total, 7 primary cell lines were selected 
for further in-depth analysis. Post knockdown, anti-proliferation was measured by counting live cell 
population. Colony forming ability and growth in 3 dimensions (spheroid assay) were performed as well. 
Followed by growth inhibition studies was the assessment of processes causing cell death. For this, 
activation of Caspase-3/-7 was measured to mark the process of cell death by apoptosis. Along with 
apoptosis, the cell cycle progression rate was assayed. Results of apoptosis assays and cell cycle rate 





Effects of its knockdown on transcription rate of several oncogenes was an important outcome. 
Differences in the transcription rates of genes related to the process of EMT, HER family, Heregulin Alpha 
(A) and Beta (B) upon SATB1 knockdown were analysed. Lastly, siRNA mediated knockdown of SATB1 
created an anti-tumour effect in vivo, in subcutaneous xenograft tumours of UT-SCC-14 and 
UT-SCC-42B cells in immune-compromised mice.  
 
2.7.4 Additional experiments with primary cell lines of HNSCCs and 
FLAVINO assay 
 
Apart from studies related to primary cell lines, FLAVINO assays were performed on tumour samples of 
HNSCC patients in the department of Otolaryngology, Head and Neck surgery, University Clinic of Leipzig 
to check the effects of SATB1 knockdown on their colony forming ability. The technique involves 
immunocytochemical staining of keratinized tumour cells which helps to differentiate tumour cells from a 
mixture of different cell populations obtained by enzymatically digesting tumour biopsies.  
It has been previously shown that HER1 and HER3 transcription rate is influenced by SATB1 levels in 
glioblastoma [123] and colorectal carcinoma [128]. A similar effect, especially on HER3 and Heregulin A 
and B was also observed for the selected 7 primary cell lines. Thus, inhibition of HER1 and HER3 by 
monoclonal antibodies was performed to check its effect on transcription rate of SATB1. Along with this 
aim, anti-proliferative effects in adherent and non-adherent culture settings were analysed. HER1 was 
inhibited by commercially used Cetuximab, while HER3 was inhibited by Patritumab produced by Daiichi 




















1 25 kDa PEI Aldrich 9002-98-6  
2 3 Aminopthalhydrazide Sigma CDS019923  
3 Accutase Biowest S0950-100  
4 Acetic acid Roth A6283  
5 Acrylamide: Bisacrylamide Roth 3029.3 30% 
6 Ammonium Acetate Sigma A2706 
Molecular 
biology grade 
7 Ammonium peroxosulfate Roth 9592.2  
8 Beta mercaptoethanol Sigma M-6250  
9 Bovine serum albumin Sigma A2153-50G Fraction V 
10 Bromophenol blue Bio-Rad 127401A  
11 Calcein AM 
Thermo 
scientific 
C3099 1 ml 
12 Caspase glow assay Promega G8091 10 ml 
13 Cetuximab Merck Erbitux 5 mg/ml 
14 Chloroform J T Baker 7019 
Stabilized with 
0.75% ethanol 
15 Chloroform Roth  
Technical 
grade 
16 Citrate buffer Dako S-2369 pH 6.0 
17 DMSO Roth 4720.2  
18 dNTPs solution Fermantas R0192 10 mM each 
19 Dulbecco’s modified eagle’s medium Sigma D6546-500ML with pyruvte 
20 
Dulbecco’s modified Phosphate 
buffered saline 





22 Ethanol Roth 5045.2 99.8% pure 
23 Ethanol Roth  
Technical 
grade 
24 ethanol for disinfection Roth T171.2 96% pure 




26 Fetal calf serum Biochrom   





28 Glycine Roth 3908.3  
29 Glycoblue Invitrogen AM9515  
30 Goat Serum    
31 HEPES Roth 9105.4  
32 Hoechst 33342 Invitrogen H1399  
33 Hydrochloric acid Roth 4325.1  
34 Hydrogen peroxide Roth 9681.1  
35 Inteferin Polyplus   
36 Iscove’s modified Dulbecoo’s medium Sigma I3390-500ML  
37 Isofluran Baxter HDG9623  
38 Isopropanol Roth 6752.2 99.8% pure 
39 Isopropanol    
40 L Glutamine solution Sigma G7513-100ML 200 mM 
41 Methanol Roth AE71.2  
42 methylene blue Ferak 81047  
43 Milk Roth T145.2  
44 Nocodazole Calbiochem 487928  








47 p-courmaric acid Sigma C9008  
48 Penicillin and streptomycin solution Merck A2212  




50 Ponceau S Roth 5938.1  








53 propidium iodide Roth CN74.3  
54 Protease inhibitor cocktail Calbiochem 539134  
55 qPCR master mix Qaunta Bio 95056-500 
PerfeCTa 
Syber Mix with 
ROX 
56 Random hexamer primer 
Thermo 
Scientific 
S0142 0.2 ug/ul 
57 Reagent A (Dc kit protein estimation) Bio-Rad 500-0113  
58 Reagent B (Dc kit protein estimation) Bio-Rad 500-0114  
59 Reagent S (Dc kit protein estimation) Bio-Rad 500-0115  
60 Reverse transcriptase 
Thermo 
Scientific 
EP0441 200 U/ul 
61 Rnase A Sigma R6513-50MG  









64 Sodim azide Sigma S2002  
65 Sodium chloride Roth 3957.2  
66 Sodium deoxycholate Sigma 30970-25G  
67 Sodium flouride Sigma S7920-100G  
68 Sodium hydroxide Roth 6771.1  
69 TEMED Roth 2367.3  
70 TriFast VWR 30-2010  
71 Tris Roth AE15.2  
72 Triton X-100 Bio-Rad 161-0407  
73 Trizol Invitrogen 15596026  
74 Trypsin Biowest L0940-100  
75 Tween 20 Serva 37470.01  
76 Tween 80 Serva 37475  
77 WST-1 Roche 11644807001  
 
 FLAVINO assay reagents    
1 Collagenase IV 
Sigma 
Aldrich 
C5138-1G 125 CDU/mg 
2 Guava solution Millipore   
3 
ICF cleaning solution for Flow 
cytometer 
Millipore   
4 
RPMI 1640 (without riboflavin/phenol 
red/L-glutamate) 
Biochrom   
5 FCS (56 °C heat inactivated) Gibcco   





8 Glutamine    
9 Amikacin    
10 Human laminin Roche   
11 Collagen I (rat)    















3.1.2 List of Buffers and solutions 
 
• HN buffer 
o 10 mM HEPES 
o 150 mM NaCl 
o pH adjusted to 7.4 
• RIPA-SDS buffer 
o 50 mM Tris-HCl pH 7.4 
o 150 mM NaCl 
o 1% (v/v) Triton X-100 
o 0.5% (w/v) Sodium Deoxycholate 
o 0.1% (w/v) SDS 
o 1 mM EDTA 
o 10 mM NaF 
• Loading buffer (Western blot, 4x) 
o 0.25 M TrisHCl 
o 20 % Glycerin (v/v) 
o 10 % β-mercaptoethanol (v/v) 
o 8 % SDS (w/v) 
o 0.08 % Bromophenol blue (w/v) 
o pH 6.8 
• Running buffer (Western blot) 
o 1.92 M Glycin 
o 1 % SDS (w/v) 
o 250 mMTris 
• Transfer buffer (Western blot) 
o 1.92 M Glycin 
o 250 mMTris 
o 20 % methanol added when 1x prepared (v/v) 
• Stacking gel buffer (Western blot) 
o (4x) 0.5 M of Tris base 
o pH 6.8 (adjusted by HCl) 
• Seperating Gel buffer (Western blot) 
o (4x) 1.5 M of Tris base 
o pH 8.8 (adjusted by HCl)  
• TBST (Western blot) 
o 1 M Tris 
o 1.5 M NaCl 
o 10 ml Tween 20 





• Rnase A solution 
o Lyophilized Rnase A powder dissolved in PBS at 1 mg/ml concentration 
o Store at 4 °C 
• Propidium iodide 
o 1 µg/µl (1 mg/ml) in distilled water 
o Store at 4 °C (wrapped with aluminium foil) 
• ECL solution A (Western blot) 
o 89 ml distilled water 
o 10 ml Tris/HCl pH 8.5 
o 1 ml of 3-Aminophtalhydrazide (Sigma(#C9008)) 0.44 g/10 ml DMSO 
o 440 µl of P-courmaric acid (0.15 g/10 ml DMSO) 
• ECL solution B (Western blot) 
o 90 ml distilled water 
o 10 ml Tris/HCl pH 8.5 
o 60 µl 30% Hydrogen peroxide 
• Cryomix (Cell culture) 
o 20% (v/v) FCS 
o 10% (v/v) DMSO 
o In IMDM media 
• Colony staining solution 
o 1% (w/v) Methanol blue in 70% ethanol 
o Store at 4 °C 
• Wash buffer (ICC/fl) 
o 0.1% Tween 20 in 1x PBS 
• Blocking solution (ICC/fl) 
o 1% (w/v) BSA 
o 5% (v/v) goat serum 
o 0.1% (v/v) Tween 20 
o In PBS 
• Primary antibody dilution buffer (ICC/fl) 
o SATB1 (1:200), Beta Actin (1:500) 
o 1% (w/v) BSA 
o 0.1 % (v/v) Tween 20 
o In PBS 
• Secondary antibody dilution buffer (ICC/fl) 
o Anti rabbit (1:800 for SATB1), Anti mouse (1:200 for Beta Actin) 
o 1% (w/v) BSA  
o In PBS  
• Wash buffer (FLAVINO) 
o 0.05% (v/v) tween 20 in 1x PBS 
• Blocking buffer (FLAVINO) 






• Primary antibody solution (FLAVINO) 
o 1:400 
o 25 ml blocking buffer 
o 25 ml washing buffer 
o 125 µl primary antibody 
• Secondary antibody solution (FLAVINO) 
o 1:500  
o 25 ml blocking buffer 
o 25 ml washing buffer 
o 100 µl secondary antibody 
• Collagenase Type IV solution (FLAVINO) 
o 14 mg lyophilized powder in 30 ml complete tumour medium 
• Ponceau S 
o 1% (w/v) Ponceau S stain 
o 1% (v/v) acetic acid in distilled water 
• TAE buffer (10x) 
o 48.4 g Tris base 
o 11.4 ml glacial acetic acid 
o 20 ml 0.5 M EDTA (pH 8.0) 
 










1 0.2 micron filter Sarstedt 83.1826.001  
2 1.5 ml microfuge tubes Sarstedt 72.690.001  
3 12 well plate Sarstedt 83.3921  
4 2 ml microfuge tubes Sarstedt 72.691  
5 6 well plate Sarstedt 83.3924  
6 96 well plate Sarstedt 83.3920  
7 96 well round bottom plate Sarstedt 05-011-0100  
8 Beakers Schott duran  150 ml 
9 Cell scrapper Sarstedt 83.1832  
10 Chambers for ICC Sarstedt  
Flexiperm 8 
chambers 
11 Cryo vials Sarstedt 72.380  
12 Falcon tube Sarstedt 62.554.502 15 ml 
13 Falcon tube Sarstedt 62.547.254 50 ml 





15 Glass bottles Schott duran  250 ml 
16 Glass bottles Schott duran  100 ml 
17 Glass pipette Labsolute 7691061  
18 Loose pipette tips Sarstedt 70.762 1 ml 
19 Loose pipette tips Sarstedt 70.760.002 200 µl 
20 Loose pipette tips Sarstedt 70.1130 10 µl 
21 Multipipetter Eppendorf   
22 Multipipetter tips Eppendorf 30089642 10 ml 
23 Multipipetter tips Eppendorf 30089677 5 ml 
24 Multipipetter tips Eppendorf 30089669 1 ml 
25 Needle BD microlane 301300 20G 
26 Neubauer’s chamber Assistent   
27 Nitrocellulose membrane 
Amershem 
Bioscience 
RPN 303E 45 micron 
28 One step cooler VWR   
29 PAGE assembly Bio-Rad   




31 Petridish for ICC Sarstedt 821.473.001  
32 
Pipette for SDS-PAGE gel 
loading 
Sorenson 28480  
33 Pipette tips with filter Sarstedt 70.762.211 1 ml 
34 Pipette tips with filter Sarstedt 70.760.211 200 µl 
35 Pipette tips with filter Sarstedt 70.760.212 100 µl 
36 Pipette tips with filter Sarstedt 70.760.213 20 µl 
37 Pipette tips with filter Sarstedt 70.1130.210 10 µl 
38 Plate for luminescence    
39 Plate for spheroid formation    








42 Rnase free vials Eppendorf  1.5 ml 
43 Serological pipettes Sarstedt 86.1252.001 2 ml 
44 Serological pipettes Sarstedt 86.1253.001 5 ml 
45 Serological pipettes Sarstedt 86.1254.001 10 ml 
46 Serological pipettes Greiner Bio-one 760180 25 ml 
47 Slides for ICC 
Thermo 
Scientific 
J5800AMNZ Superfrost excel 
48 Spheroid plate for celigo Cenibra CELULA96U020  
49 Syringe BD Discardit 300296 20 ml 
50 Syringe B-Braun 9166017V 1 ml 
51 T flask Sarstedt 83.3910.002 25 cm2 
52 T flask Sarstedt 83.3911.002 75 cm2 





54 Wet transfer assembly Bio-Rad   
 FLAVINO assay hardware    
1 Scalpel    
2 Glass bottles (amber coloured) Schott duran 100 ml 
3 Forceps    
4 Tubes for Guava EasyCyte plus Greiner Bio-one  
5 96 well round bottom plate Sarstedt 05-011-0100  








1 Autoclave Sanoclav   
2 Camera for immunoblot QSI Model #540  
3 Camera for microscope Amscope MA500  
4 Celigo Nexcelom   
5 Centrifuge Heraeus Labofuge 400R 
15 ml/50 ml/ 96 well 
plate 
6 Centrifuge with cooling Thermo Scientific Fresco 17 1.5 ml/2 ml tubes 
7 Centrifuge without cooling Thermo Scientific Pico 17 1.5 ml/2 ml tubes 
8 Flow cytometer Applied Biosystem  
Attune Accoustic 
focus 
9 Gel documentation camera Sony Alpha 7  
10 Heater for water bath Julabo ED   





Heating block for microfuge 





13 Incubator Sanyo MCO-18AC  
14 
Inverted microscope for 
animal cell culture 
Hund (Wetzlar)   
15 Magnetic stirrer with heating Ika RH Basic 2  




17 pH meter Calimatic   
18 
Plate reader (Absorbance 
and Luminescence) 
BMG labtech  Polarstar Omega 
19 Power supply for wb MS major science MP-300V  
20 Power supply for wb Bio-Rad Power Pac 200  
21 q-PCR Applied Biosystem Step one plus  
22 Shaker for Antibodies in 4 °C CAT RM5-30V  
23 Shaker for western blot Grant Bio PMR30  
24 Shaker with incubator Heidolph Titramax 1000  
25 Short spin for PCR tubes Roth   
26 Sonicator Bandelin Sonorex TK52  





28 Tissue homogenizer Janke and Kunkel Ultra Turrax  
29 Vertical air flow Biomedis Esco Biosafety level 1 
30 Vortex Janke and Kunkel VF2  
31 Weight balance Kern 572 For gram 
32 Weight balance Mettler AT261 For milligram 
 FLAVINO assay instruments   
1 Big cell centrifuge Eppendorf  
2 Software cytosoft 5.3  
3 Cell incubator   
4 
Fluorescence microscope Carl 










3.1.4 List of Primers and siRNAs 
 
List of siRNAs 
siSATB1 
Sense: 5‘- GCU UCA AGA UGU GUA UCA UdTdT-3‘ 
Antisense: 5’- AUG AUA CAC AUC UUG AAG CdTdT-3’ 
siLuc3 (serving as negative control)  
Sense: 5′-CUU ACG CUG AGU ACU UCG AdTdT-3′  
Antisense: 5′-UCG AAG UAC UCA GCG UAA GdTdT-3′ 
q-RT-PCR primers 
cDNA Orientation Sequence (5’-3’) 
SATB1 
Forward CGA TGA ACT GAA ACG AGC AG 
Reverse CGG AGG ATT TCT GAA AGC AA 
E-Cadherin 
Forward GGC GGA GAA GAG GAC CAG GAC TT 
Reverse CAT CGG GAT TGG CAG GGC GG 
N-Cadherin 
Forward AAC TGG GCC AGG AGC TGA CCA 
Reverse GTG CCC TCA AAT GAA ACC GGG CT 
Beta catenin 
Forward TCG AGG ACG GTC GGA CTC CC 






Forward CAT GGT GCA CTT TCC TCC TT 
Reverse AGG TAA TGT TGT AGA GTT GGT GTC 
Cyclin D1 
Forward CCT CGG TGT CCT ACT TCA AA 
Reverse CAC TTC TGT TCC TCG CAG A 
MMP7 
Forward GGG GCA AAG AGA TCC CCC TGC AT 
Reverse CCC CAT GAG CTC CTC GCG CAA A 
Pim-1 
Forward ATC AGG GGC CAG GTT TTC T 





Forward TTC TTT TGA TTC CTC CGG TGA 
Reverse ACT CTG ATG GGC ATG TG CTG 
HER1 
Forward ACA CAG AAT CTA TAC CCA CCA GAG T 
Reverse ATC AAC TCC CAA ACG GTC AC 
HER2 
Forward TGG CTC AGT GAC CTG TTT TG  
Reverse GGT CCT TAT AGT GGG CAC AGG 
HER3 
Forward CTG ATC ACC GGC CTC AAT 
Reverse GGA AGA CAT TGA GCT TCT CTG G 
Heregulin A 
Forward CCC ATG AAA GTC CAA AAC CA 
Reverse CCG GTT ATG GTC AGC ACT CT 
Heregulin B 
Forward GAT CAG CAA ATT AGG AAA TGA CA 
Reverse GGC ATA CCA GTG ATG ATC TCG 
RPLP0 
Forward TCT ACA ACC CTG AAG TGC TTG AT 
Reverse CAA TCT GCA GAC AGA CAC TGG 
 
 




Method Protein Clone Diluent Company 
1 Western blot SATB1 14/SATB1 
1:1000 (5% BSA in 
TBST) 
BD bioscience 
2 Western blot GAPDH Ab 181602 1:10,000 (in Pierce) Abcam 
3 Western blot Anti-mouse 
Product 
number 31430 
1:2000 (3% milk in 
TBST) 
Thermo scientific 
4 Western blot Anti-rabbit Ab 6721 
1:5000 (3% milk in 
TBST) 
Abcam 
5 Western blot Anti-rabbit 7074 
1:2000 or 1:6000 in 
pierce 
Cell signalling 
6 Immunocytochemistry SATB1 EPR 3951 
1:200 (1% BSA in PBS-















H1399 1:100 (PBS-T) Invitrogen 




1:400 in 1:1 solution of 
wash buffer and 
blocking buffer 
Santa Cruz 




1:500 in 1:1 solution of 





















1 UT-SCC-5** M 58 Linguae T1N1M0 Tongue Primary G2 
2 UT-SCC-14** M 25 SCC linguae T3N1M0 Tongue Primary G2 
3 UT-SCC-15** M 51 SCC linguae T1N0M0 Tongue Recurrent G1 
4 UT-SCC-16A F 77 SCC linguae T3N0M0 Tongue Primary G3 
5 UT-SCC-16B** F 77 SCC linguae T3N0M0 Neck Metastatic G3 
6 UT-SCC-19A M 44 Glottic Larynx T4N0M0 Larynx Primary G2 
7 UT-SCC-24A M 41 SCC linguae T2N0M0 Tongue Primary G2 
8 UT-SCC-26A M 60 SCC hypopharyngis T1N2M0 Neck Metastatic G2 
9 UT-SCC-26B M 60 SCC hypopharyngis -- Neck Metastatic G2 
10 UT-SCC-31 M 58 Floor of the mouth T3N2BM0 
Floor of the 
mouth 
Primary G1(G2) 
11 UT-SCC-42A M 43 Supraglottic Larynx T4N3M0 Larynx Primary G3 
12 UT-SCC-42B** M 43 Supraglottic larynx T3N0M0 Neck Primary G3 
13 UT-SCC-60A** M 59 Left tonsilla T4N1M0 Tonsil (left) Primary G1 




15 UT-SCC-62 M 56 Hypopharynx T4N0M0 Neck Metastatic G2 
16 UT-SCC-74A M 31 SCC linguae T3N1M0 Tongue Primary G1-G2 
17 UT-SCC-74B M  SCC linguae met colli rN2 Neck Metastatic G2 
 








3.2.1 Primary cell line culture 
 
Primary cell lines (University of Turku-Squamous Cell Carcinoma-X, UT-SCC-x) were obtained from 
different labs (Table 1 on page number 57). Although the sources of the primary cell lines were different, 
they were all developed at Prof. Dr. Reidar Grenman’s lab at the University of Turku, Finland.  
All cell culture, treatment, transfection and other experiments were done in a standard animal cell culture 
lab and incubated in an animal cell culture incubator (37 °C, 5% CO2 and 95% relative humidity). Primary 
cell lines were cultured in DMEM with pyruvate, supplemented with 10% (v/v) Fetal Calf Serum, 1% (v/v) 
Glutamine and 1% (v/v) 100x antibiotic (Pen/Strep) solution. For splitting the cells or harvesting them for 
experiments, they were washed with 1x PBS, followed by trypsinization at 37 °C. Trypsinization was 
stopped by adding complete media, double the volume of trypsin, to the flask. Cell clumps were broken, 
and the suspension was homogenised by pipetting cells up and down using serological pipettes.  
Table 1 Sources of Primary cell lines used for this work; A and B next to the number of the cell lines indicate primary 
cells and their recurrent/metastasized counterparts, respectively, isolated from the same patient. 
Source Primary cell lines 
Prof. Dr. Robert Mandic (Marburg Universität, Marburg, 
Germany) 
UT-SCC-16A and SATB1 
 UT-SCC-19A 
 UT-SCC-26A 
 UT-SCC-42A and -42B 
 UT-SCC-60A and -60B 
 UT-SCC-74A and 74B 
  








The cells were always diluted at 1:10 or higher to prevent confluent culture. Primary cell lines were 





new vial from the cryopreserved stock was taken into culture. Cells were cultured for 2 weeks after 
thawing before performing experiments with them.  
They were checked for mycoplasm contamination by Venor ® GeM kit by Minerva BioLabs. It is a PCR 
based detection method. Primers for the 16s rRNA region of the mycoplasm genome is supplied with the 
kit. This set of primer exclusively amplifies 16s rRNA only from mycoplasm genome. It does not amplify 
other bacterial 16s rRNA region. The PCR conditions were as per the manufacturer. The amplicon was 
separated by gel electrophoresis (1% agarose gel in Tris-, acetic acid and EDTA (TAE) 1x buffer). 
Presence or absence of the amplicon from the sample confirms presence or absence of mycoplasm 
contamination. A positive control, provided with the kit, and a negative control (water for PCR) was also 
run to rule out false positive or negative results.   
Cryomix used for cryo-preservation consisted of 20% (v/v) Fetal Calf Serum and 10% (v/v) DMSO in 
IMDM media. The same cyromix was used for all the cell lines. For cryopreservation, cells were cultured 
in a 150 cm2 flask until 80% confluency was reached. Cells were washed once with PBS, and trypsinized. 
The cell suspension was transferred to a 50 ml falcon tube and were centrifuged at 1000 rpm for 10 min 
at 4 °C. The supernatant was aspirated, and the cell pellet was resuspended in the cryo-mix. After 
resuspending the cell pellet homogenously in cryo-mix, cell suspension was aliquoted (1.6 ml) in cryo-
tubes and stored in a one-step cooler at -80 °C. Cells were stored at -80 °C for 1-2 days before 
transferring them to liquid nitrogen storage. For thawing, the vials were directly thawed in a water bath at 




For introducing siRNA into cells (transfection), INTERFERin was used as transfecting reagent. Cells were 
easy to transfect and hence half of the recommended amount of INTERFERin was used. 0.5 µl instead 
of 1 µl of INTERFERin per pmole of siRNA was used.  
All primary cell lines were transfected with 5 nM of siRNA in 1100 µl of media. For most of the 
experiments, cells were seeded in 12 well plate format. Owing to different growth rates, cells were initially 
seeded at different densities to obtain nearly 80% confluency at the time of harvest (72/96 h); see Table 
2 on page number 59. For knockdown experiments, cells were allowed to grow for 96 h post transfection, 





Table 2 Growth rates and respective initial cell densities seeded for knockdown experiments in 12 well plate format 
Primary cell line Relative growth rate 
Cell density seeded in 12 well 
plate format 
UT-SCC-5 Moderate 25 k cells/well 
UT-SCC-14 Fast 15-20 k cells/well 
UT-SCC-15 Slow 40 k cells/well 
UT-SCC-16A and -16B Moderate 30 k cells/well 
UT-SCC-19A Moderate 30 k cells/well 
UT-SCC-24A Moderate 25-30 k cells/well 
UT-SCC-26A Slow 40 k cells/well 
UT-SCC-31 Moderate 25-30 k cells/well 
UT-SCC-42A Moderate 25-30 k cells/well 
UT-SCC-42B Fast 20 k cells/well 
UT-SCC-60A Moderate 30 k cells/well 
UT-SCC-60B Slow 40 k cells/well 
UT-SCC-62 Moderate 25-30 k cells/well 
UT-SCC-74A and 74B Fast 20 k cells/well 
 
Cells were seeded in 2 ml/well (12 well plate format) complete media. After 24 h, 1 ml of the media was 
removed from the wells. The reason for seeding the cells in 2 ml was to prevent major cell deposition at 
the edges of the wells due to the surface tension of the liquid generated in lower volumes. When seeded 
in 1 ml media, cell deposition would be more at the edges and only few cells in the centre of the well. 
Seeding them in 2 ml media, followed by forth and back shaking in 3 (↔ ↕ ∕ ) directions for 10 times 
helped in achieving uniform cell attachment.  
After removing 1 ml media, the transfection mix was prepared at a volume of 100 µl/well. Hence, 1000 µl 
of media + 100 µl of transfection mix makes a volume of 1100 µl which was calculated for the 
concentration of siRNAs; for example, 5 nM in 1100 µl of media. Serum free media was used for 
preparing the transfection mix. The protocol by the supplier of INTERFERin was used for preparing the 
transfection mix. siLuc3 was used for negative transfection. Every experiment consisted of three groups: 
Untreated, siLuc3 and siSATB1. 
 
3.2.3 Anti-Proliferation assay 
 
Cell death due to SATB1 knockdown was measured by quantitating the number of viable cells. For this, 





spheroid assay, PBS at 37 °C was used). Cells were trypsinized using 500 µl Trypsin-EDTA mix and 
incubated in shaker with incubator (37 °C). Cells that did not detach by trypsinization were detached by 
tapping the plate against the bench. Cell clumps were homogenized by pipetting (1000 µl pipette) and 
cells were transferred to a 1.5 ml vial. 500 µl complete media was added to the cell suspension to 
inactivate trypsin. The cell suspension was diluted 1:10 by PBS (100 µl cell suspension + 900 µl of PBS). 
From this, 500 µl was injected into the flow cytometer for counting the cells. The live cell population was 
counted based on the forward and sideward scatter of the entire population. The final live cell count 
(cells/ml) was obtained by multiplying the gated population with the dilution factor of 20 (10 (dilution factor) 
x 2 (volume used for counting the cells)). 
In flow cytometry, the Forward Scatter (FSC) and Sideward Scatter (SSC) help in scrutinizing the live cell 
population. Cell types can also be differentiated based on FSC and SSC in a mixture of different types of 
cell populations, like blood. In simple words, FSC is the shadow of the cell created on the sensor when it 
passes through the laser, while the sideward scatter is generated when the granular content of the cell 
deflects the laser which is recorded by sensors other than for forward scatter. Sensors for SSC are 
generally perpendicular to the forward scatter as well as the path of laser directed on the stream of cells. 
Live cells have higher FSC than cell debris owing to their size. They also have a higher SSC than cell 
debris owing to complex cytoplasm. The combination of the two parameters helps in determining the live 
cell population. However, in most cases there were several cells in the entire population which were not 
accounted for due to very high or very low FSC or SSC, but the gating of the population remained the 
same throughout the experiments, in all samples (untreated, siLuc3 and siSATB1). Hence a comparable 
number of live cell population was obtained which determines the degree of anti-proliferation. Figure 5 
on page 60 shows an example of the live cell population gated by the gate R1 (red area).    
Figure 5 The cell population in the gate R1 (red) is the live cell population. Cells outside R1 have extreme values of FSC and SSC 





The accuracy of live cell count could be increased by staining the cells with live cell stain (Calcein AM). 
However, live and dead cell populations where easily distinguishable without staining, hence staining 
was never performed for this assay. Primary cell lines like UT-SCC-5, UT-SCC-14 and UT-SCC-15 
showed very good anti-proliferative effects upon SATB1 knockdown 72 h post transfection, hence, cells 
were counted at 72 h post transfection. In other cases (UT-SCC-42B and UT-SCC-60B) and (UT-SCC-
16B and UT-SCC-60A), the cell count was performed at 96 h and 120 h, respectively.   
Before using flow cytometer for analysing anti-proliferative effects, WST-1 assay was used. The WST-1 
assay relies on a tetrazolium salt cleaved by a cellular enzyme, mitochondrial dehydrogenase. The 
amount of active enzyme present is directly proportional to the number of viable cells. For this, the cells 
were seeded in a 96 well plate at a density of 1000 cells/250 µl/well. The cells were transfected 24 h post 
seeding (5 nM in 260 µl media, transfection mix was 10 µl/well). For each time point and treatment 
(Untreated, siLuc3 and siSATB1), three wells were prepared.  
For the assay, the WST-1 reaction mix was prepared freshly, containing 1 part of WST-1 dye mixed with 
10 parts of serum free media. For example: For 500 µl of reaction mix, 50 µl WST-1 was mixed with 
500 µl serum free media. Media was aspirated from the wells and 50 µl/well of the reaction mix was 
added. The plate was incubated in the incubator for 1 h. After incubation, it was important to dry the lid, 
to remove any air bubbles if present in the well and to make sure that the bottom of the plate was clean 
(because these factors can contribute to the false reading). The plate was read at 450 nm with reference 
filter at 650 nm. Absorbance after subtracting from the blank reading (wells with only reaction mix) were 
directly plotted. 
WST-1 assay measures cell viability indirectly by measuring mitochondrial activity. In many of the cell 
lines, WST-1 assay readings did not represent the actual cell density. siSATB1 transfected cells even 
with lesser cell density as observed under the microscope had same readings as the control transfection 
(siLuc3). To avoid any doubts or problems and estimate the real degree of anti-proliferation, counting the 
live cell population by flow cytometry was preferred over the WST-1 assay.  
 
3.2.4 Colony formation assay (CFA) 
 
When metastasizing or migrating to different location, in vivo cancerous cells have the capability to 





additional readout to the anti-proliferation assay. CFA checks the colony forming ability of the cells post 
treatment (knockdown in this case) in monolayer.  
For CFA, cells were transfected in 12 well plate as described in section 3.2.2 on page 59. 72 h post 
transfection, cells were counted as described in section 3.2.3. 1000 cells for UT-SCC-42B & UT-SCC-14 
and 2000 cells for UT-SCC-5, UT-SCC-15, UT-SCC-60B, UT-SCC-16B and UT-SCC-60A were seeded 
in 4 ml/well of a 6 well plate format. Cells were allowed to grow for 7 to 12 days depending on the growth 
rate and till the point where colony size was distinguishable and visible to the naked eye. Immediately 
after aspirating the media, CFA staining solution (1 ml) was added to the wells. CFA staining solution 
was prepared in 70% (v/v) ethanol in distilled water. Hence, fixation of the cells and staining by Methylene 
blue was done in one step by colony staining solution.  
After incubation for 45 to 60 min at room temperature, the stain was drained off and colonies were gently 
washed using distilled water. Air dried plates were photographed and determination of the number of 
colonies was done using Image J software. Colony size bigger than 10 pixels was counted as a colony.  
 
3.2.5 Spheroid assay 
 
Primary cell lines grow at a much faster rate on plastic than in the actual in vivo situation. Hence, 
analysing how the cells behave under non-adherent condition was vital. In Spheroid assay, the cells are 
seeded in a special ‘U’ bottom plate which is coated with a substance that does not allow the cells to 
adhere to the surface. Hence, the cells adhere to each other and form a spheroid. Considering the cell-
cell contact in three dimensions, this assay is closer to the in vivo situation than the monolayer culture.  
Cells were harvested 72 h post transfection and counted as described in section 3.2.3 on page 59. 
5000 cells/250 µl/well were seeded in special ‘U’ bottom plate for the formation of a spheroid. In some 
cases, centrifugation at 800 rpm for 1 min was required to ensure the cells were settled at the lowest 
point, avoiding formation of several spheroids at different spots in the well. Usually spheroids were formed 
24 h after seeding the cells in the plate. However, they shrinked a bit and so the documentation always 
began at 48 h post seeding. From the final selection of 7 cell lines, UT-SCC-42B, UT-SCC-14, UT-SCC-5 
and UT-SCC-16B formed spheroids. Others did not form spheroids and the cells died because of absence 






3.2.5.1 Live/dead stain for the spheroid 
 
To estimate the viable fraction of the spheroids, a live/dead stain was performed. Initially, only the live 
stain, Calcein AM was used. 5 µM dye per 300 µl media was used for staining the spheroids. Spheroids 
were seeded in 250 µl of complete media. Fresh Live stain was prepared in 50 µl of serum free media. 
The total volume was 250 + 50 = 300 µl. After addition of the dye, spheroids were incubated in the 
incubator for 30 min before picturization. In case of UT-SCC-14 cells, Live stain was not sufficient. To 
rule out the possibility of improper penetration of the dye, a Live/dead stain was performed.  
For Live/dead stain, 5 µM/300 µl Calcein AM (Live cell stain), 1 µg/300 µl Propidium iodide (Dead cell 
stain) and 2 ng/300 µl of Hoechst 33342 (Nuclear stain) was used. Spheroids were incubated in the 
incubator for 20 min. Images were recorded using Celigo (Nexcelom Bioscience).  
 
3.2.6 Apoptosis Assay (Caspase 3/7 activation) 
 
Members of the Caspase family of proteases are activated when the cell is directed towards undergoing 
apoptosis. Apoptosis can be induced either by extrinsic or intrinsic signals. Different Caspases are 
activated in case of extrinsic and intrinsic pathways. However, Caspase 3 and 7 are downstream to both 
extrinsic and intrinsic pathways of apoptosis. Hence, estimating Caspase 3/7 activation indicates whether 
or not the cells are dying via apoptosis.  
The Caspase 3/7 Glow® assay by Promega was used for the quantification of Caspase 3/7 activation. 
Caspase 3/7 proteases target a particular amino acid sequence (DEVD: Asp-Glu-Val-Asp) for cleavage. 
The ready to use solution of the kit contains a pro-luminescent substrate, luciferase enzyme, cofactors 
as well as a detergent which aids cell lysis and release of the intracellular enzymes, Caspase 3/7 in this 
case. The ‘Quencher’ of the pro-luminescent substrate is coupled to the active substrate by the DEVD 
tetra peptide. The so-called Quencher prevents the binding of the substrate to the active site of the 
Luciferase enzyme. Active Caspase 3/7 released from lysed cells cleaves the tetrapeptide, allowing the 
substrate to bind to the active site of the luciferase enzyme, generating the luminescence which is 
measured. The intensity of the luminescence is directly proportional to the amount of active Caspase 3/7.  
For the Caspase 3/7 Glow® assay, 1000-2000 cells/250 µl media/well were seeded in a 96 well plate. 24 
h post seeding, cells were transfected with 5 µM siRNA in 260 µl volume (250 µl media + 10 µl 





Ready-to-use solution of the kit was diluted 1:10 or 1:4 with serum free media. Depending on the age of 
the solution, freshly made solution was diluted 10 times while 1-month-old was diluted 1:4 times with 
serum free media. The ready-to-use solution is active only for a few weeks after reconstitution. The 
company suggests to use of 1:1 dilution but this gives a very strong signal masking the difference between 
target and control treatment.  
The media was aspirated and 50 µl/well diluted Caspase 3/7 Glow® reagent was added. Plates were 
incubated at room temperature in the dark for 1 h. Luminescence was measured using a 96 well plate 
reader, Polar star.  
Parallel to the Caspase 3/7 glow® assay, a WST-1 assay was performed. For every well of Caspase 3/7 
glow® assay, a well for WST-1 assay was measured in parallel to normalise the Caspase 3/7 activity to 
the cell number. Although WST-1 was not the best choice for normalizing the cell number, the time point 
at which Caspase 3/7 activation was measured had more or less similar cell density. Although some cells 
started dying at 72 h in a 12 well plate, their response to the knockdown in 96 well plate was a bit slower. 
WST-1 assay was performed as described in section 3.2.3 on page 59. 
For the quantitation, each of the 3 wells of the Caspase 3/7 glow® assay was normalised to 3 wells of 
WST-1 of the same treatment group which generated 9 values for each group.   
 
3.2.7 Determination of Cell cycle rate 
 
In cancerous condition, not only the cell prevents apoptosis but also increases the rate of proliferation 
which are two separate phenomena.  
Two approaches are possible. First, the use of synchronous culture for transfection, and second, apply 
cell cycle block post transfection. The second approach of applying a block post knockdown was used. 
Transfecting cells after applying a block caused unwanted nonspecific cytotoxic effects. As opposed to 
that, applying a block post knockdown reduced nonspecific cytotoxic effects as well as magnified the 
difference of cell cycle rate upon SATB1 knockdown. Primary cell lines consist of a mixture of cell 
populations with different cell cycle rates. Hence analysing the cell cycle rate immediately after applying 
the block gives better and reproducible results.   
Cells were seeded in 12 well plate format. 72 h post transfection, Nocodazole which blocks dividing cell 





amounts of Nocodazole and time periods of nocodazole treatment were used. The details are given in 
Table 3 on page 65. 
Table 3 Amounts of Nocodazole and incubation times used for blocking the cells in G2/M phase for cell cycle rate 
estimation 
Primary cell line Amount of Nocodazole Time 
UT-SCC-5 24 ng/ml 12 h 
UT-SCC-14 24 ng/ml 18 h 
UT-SCC-15 24 ng/ml 18 h 
UT-SCC-42B 24 ng/ml 12 h 
UT-SCC-60B 24 ng/ml 12 h 
UT-SCC-16B 48 ng/ml 18 h 
UT-SCC-60A  72 ng/ml 18 h 
 
Cells, after applying the block, were gently washed with ice cold PBS. After aspirating the PBS, cells were 
trypsinized at room temperature with constant but gentle shaking. Cells were collected in a fresh 1.5 ml 
vial and trypsinization was stopped adding an equal amount of complete media. Cells were centrifuged 
at 1000 g for 10 min. The supernatant was discarded, and the pellet was washed with ice cold PBS. 
Again, the cells were centrifuged at 1000 g for 10 min. The pellet was resuspended in 50 µl PBS. Pre-
cooled (at -20 °C) 70% ethanol was used for fixing the cells. 1 ml Fixative was added to the 50 µl cell 
suspension with constant mixing by pipetting to avoid the formation of cell clumps. Cells were now stored 
at 4 °C overnight. Cells can be stored in this condition for a maximum period of one week. Fixation can 
also be done within 4 h but they were incubated at 4 °C overnight. The next day, cells were centrifuged 
at 1000 g for 15 min. The supernatant was aspirated by pipetting.  
25 µg of Dnase free Rnase H per 500 µl of PBS was used for resuspension of the cell pellet. The RNA 
content of the cells was digested for 1 h at 37 °C. To this, 25 µg of Propidium iodide was added and cells 
Figure 6 Nuclear content (DNA only) of the cells stained with propidium iodide: Cells in the gate R3 are the apoptotic bodies; cells 





were incubated for 10-15 min in dark at room temperature. Then, 500 µl of PBS was added for diluting. 
Propidium iodide and cell number. From 1 ml, 750 µl of the cell suspension was used for analysing. All 
events were recorded. To remove debris contributing to the main analysis, the intact cell population was 
selected using FSC and SSC. The BL2 Channel was used for propidium iodide stained nuclear content 
(DNA). Figure 6 on page 65 shows the stained nuclear content. G0/G1 indicates the 2n population. The 
G2/M phase consists of the 4n population. The S (Synthesis) phase is in between 2n and 4n.  
Nocodazole blocks cells in G2/M phase, so the cells get accumulated in the G2/M phase. If the cell cycle 
rate is altered, e.g. decreased upon treatment, the percentage of cells contributing to the peak of G2/M 
phase will be reduced compared to the negative control and untreated cells.  
 
3.2.8 RNA isolation 
 
RNA isolation was done from the cells in monolayer in 12 well plate format. The media was aspirated, 
and cells were washed with ice-cold PBS. After washing, plates were either stored at -20 °C or processed 
for RNA isolation. For RNA isolation, 500 µl of Extrazol reagent was added per well. Cells were agitated 
at room temperature for 10 min for efficient cell lysis and separation of proteins attached to the nucleic 
acid. The cell lysate in Extrazol was transferred to an Rnase free vial and stored on ice. 100 µl ice cold 
chloroform was added and vials were shaken vigorously. The emulsion was centrifuged at 13000 rpm 
(17000 g) for 15 min at 4 °C. The upper aqueous phase which contained total RNA was collected in a 
fresh Rnase free vial.  
An equal amount of isopropanol was added to the aqueous phase (250 µl). The mixture was mixed by 
shaking the tube vigorously and incubated on ice for 5-10 min before centrifugation (same as above). 
The supernatant was decanted, the pellet was washed with 80% ethanol by inverting the tube, prior to 
centrifugation (same as above) followed by the ethanol wash. The supernatant was decanted, and a short 
spin was given to bring down the remaining 80% ethanol of the tube, which was then removed by pipette. 
The pellet was stored on ice until dissolved in nuclease free water. After dissolving the pellet in 40 µl of 
water, the vial was put on a heat block at 75 °C for 10 min with lid closed and another 10 min with open 
lid. This heating steps ensured evaporation of the remaining ethanol which can otherwise interfere with 
downstream processes. RNA isolated using this technique was good for q-RT-PCR. The RNA amount 
was determined by nanodrop in µg/µl. The ratio of Absorbance at 260/Absorbance at 280 nm was 






3.2.9 Quantitative-Reverse Transcriptase-Polymerase Chain Reaction 
(q-RT-PCR) 
 
After determination of the amount, 1 μg of the total RNA was pipetted in a PCR vial for cDNA preparation. 
1 μl of Random primers (concentration 0.2 μg/μl) was added and the final volume was adjusted by PCR 
grade water to 11 μl. The mixture of RNA and primer was heated at 65 °C for 5 min to denature the 
secondary structures of RNA as well as primers. The master mix (9 μl) containing dNTPs, Reverse 
transcription buffer, Reverse transcriptase enzyme and water (details Table 4 on page 67) was added to 
the RNA and primer mix which finally constituted a 20 μl reaction. The reaction conditions were as 
described in Table 5 on page 67. 
For q-PCR, cDNA generated from the above-mentioned reaction was diluted 1:10 in PCR grade water. 
4 μl of the diluted cDNA was mixed with 6 μl of master mix for q-PCR. The composition of the q-PCR 
reaction is given in Table 6 on page 67. The primers were designed to span two consecutive exonic 
regions and hence only the cDNA was amplified, excluding any false positive results by genomic DNA 
contamination. The reaction conditions for q-PCR are given in Table 7 on page 68. 
 
Table 4 Master mix for cDNA preparation; the values are for one reaction. 
Master mix components Concentration Amount added (μl) 
Reverse transcription Buffer 5x 4 μl 
PCR-grade water -- 2.5 μl 
dNTPs 10 mM each 2.0 μl 
Reverse transcriptase enzyme 200 U/μl 0.5 μl 
 
Table 5 Reaction conditions for reverse transcription reaction 
Sequence Reaction steps Temperature (oC) Time (min:sec) 
1 Initialising 25 10:00 
2 Reverse transcription 42 60:00 
3 Denaturation 70 10:00 
4 Cooling 4 ∞ 
 
Table 6 Reaction mixture for q-PCR; the values are for one reaction. The final volume of the reaction mix was 10 μl. 
q-PCR Reaction mix Concentration Amount added (μl) 
Syber Green Master Mix 2x 5 μl 
Primers 5 μM Forward, 5 μM Reverse 0.5 μl of each primer 






Table 7 Reaction conditions for q-PCR 
Sequence Reaction steps Temperature (oC) Time (min:sec) Cycles 






40 - Annealing 55 00:10 
- Elongation 72 00:10 
3 Analysis mode (melting curve) 65 00:15 1 




3.2.10 Total cell protein preparation 
 
Total cell protein preparation was done by RIPA-SDS buffer. Two different approaches were tested. The 
first approach (section 3.2.10.1 on page 68) relied on preparing the cell lysate from the monolayer and 
the second (section 3.2.10.2 on page 69) on trypsinizing the cells and lysing them in suspension. The 
benefit of the latter were similar amounts of starting material, i.e., cells. However, a disadvantage was 
very low amounts of protein.  
 
3.2.10.1 Cells in Monolayer 
 
At the time of harvest cells, in a 12 well plate, were washed twice with ice cold PBS. It was made sure 
that every possible bit of PBS was aspirated. The plates were stored at -80 °C or directly processed for 
protein preparation. Protease inhibitor cocktail was added to the RIPA-SDS buffer at the ratio of 1:200 
before adding the buffer onto the cells. Cells with RIPA-SDS buffer were always kept on ice. To each well 
of a 12 well plate, 20 µl of the RIPA-SDS buffer was added. Cells were scrapped using a sterile 
disposable cell scraper. The scraped cell solution was collected in a sterile vial and stored on ice for 10-
15 min. Because of very low numbers of viable cells post SATB1 knockdown, the protein lysate of 3 wells 
of a 12 well plate format was pooled, making 50-60 µl of the protein solution. The cell clumps were broken 
and homogenised by pipetting (20 or 200 µl). After homogenising the solution, the cells were sonicated 
for 60 seconds, followed by centrifugation for 10 min at 5000 rpm (2400 g) at 4 °C. Sonication damages 





resuspended in the supernatant by pipetting. The sonication and centrifugation steps were repeated as 
described. The pellet was again resuspended in the supernatant. This time it was done carefully without 
generating any foam or bubble. 20 µl of the 4x loading buffer was added to the protein lysate. The mixture 
was denatured at 95 °C for 5 min. The vials were stored at -80 °C until resolved by denaturing PAGE. 
Before running through SDS-PAGE, the lysate was once again denatured at 95 °C for 5 min to ensure 
the precipitated SDS is dissolved back and no clumps of proteins are present before loading onto the gel. 
Equal volume of the protein lysate was loaded on to the gel. Protein levels were normalized by the loading 
control (GAPDH).  
 
3.2.10.2 Protein lysate after counting the cells 
 
To obtain equal amounts of protein in all samples, cells were harvested as described in section 3.2.3. on 
page 59. 100,000 cells or 200,000 cells, depending on the cell number of the treatment group (siSATB1), 
were pelleted from each group. The cell pellet was washed with PBS and centrifuged (3200 rpm (3000 g) 
for 10 min at room temperature). The washed cell pellet was resuspended in 10 µl of PBS. To this, 50 µl 
of RIPA buffer (supplemented with 1:200 protease inhibitors cocktail) was added. Cells were lysed by 
pipetting them up and down. In this approach, the step of sonication and centrifugation was done only 
once since the cells were lysed very efficiently when in suspension. Then, 20 µl of 4x loading buffer was 
added and the mixture was denatured at 95 °C for 5 min. Denatured samples were stored at -80 °C until 
resolved by SDS-PAGE. 
 
3.2.11 Western Blot 
 
Western blot is a technique used to separate proteins and identify a singular protein by tagging it with a 
specific antibody. There are different protocols for Western blot which vary from lab to lab and sometimes 
also because of the target protein of interest. The process begins with generating a protein lysate as 
described in section 3.2.10 on page 68. Denaturing PAGE (SDS-PAGE) was used in this project. 
Resolved proteins were blotted on to a nitrocellulose membrane (0.45 µm pore size) and tagged with 






3.2.11.1 SDS PAGE 
 
Polyacrylamide Gel Electrophoresis (PAGE) is used either in native or denaturing conditions. Here the 
proteins were already denatured during the process of generating total protein lysate. Denaturing 
conditions are conditions which do not allow the biomolecule to fold into its native secondary structure. 
The loading buffer contains SDS as a denaturing agent which is an ionic detergent. Moreover, reducing 
agents like Dithiothreitol (DTT) or β-mercaptoethanol (in this work) reduces the disulphide bridges 
preventing the protein to form inter- or intramolecular covalent bonds.  
SDS is also present in the gel and in the running buffer to maintain the denatured state of the protein. 
The advantage of the denaturing PAGE is that the proteins are separated based only on their molecular 
weight. Hydrophobicity, hydrophilicity, isoelectric pH, secondary structure, charge on the protein etc have 
a negligible effect on the mobility in SDS-PAGE. 
Glass plates used for preparing the gel were cleaned thoroughly with detergent and rinsed with distilled 
water. The plates and combs were dehydrated using isopropanol. An 8% acrylamide gel for SDS-PAGE 
was prepared. The sequence of the reagents added is given in Table 8 on page 70. At first, the running 
gel was made. After pouring the running gel between the glass plates, isopropanol was layered over it to 
get a straight edge. 
 
Table 8 Reagents in their order for running gel of the SDS-PAGE 
Reagents 
Volume for one 
gel 
Volume for two 
gels 
Acrylamide:Bisacrylamide (30 %) 3 ml 6 ml 
Distilled water 1.5 ml 3 ml 
Running gel buffer (pH) 1.5 ml 3 ml 
APS (10 %) 75 µl 150 µl 
TEMED 15 µl 30 µl 
 
After the running gel had polymerized, the isopropanol was decanted and wiped using a clean lint free 
paper towel. The stacking gel was prepared and layered over the polymerized running gel between the 
glass plates (Table 9 on page 71). Immediately, the comb was inserted between the glass plates and 







Table 9 Reagents in their respective order for stacking gel of the SDS-PAGE 
Reagents 
Volume for one 
gel 
Volume for two 
gels 
Distilled water 1.75 ml 3.5 ml 
Acrylamide:Bisacrylamide (30 %) 0.5 ml 1 ml 
Stacking gel buffer (pH) 0.75 ml 1.5 ml 
10 % SDS 25 µl 50 µl 
APS (10 %) 25 µl 50 µl 
TEMED 10 µl 20 µl 
  
The gel was run till the loading dye front left the gel. If low molecular weight proteins (30 kDa and lower) 
were to be blotted, the loading front was not allowed to run out of the gel.  
 
3.2.11.2  Development of the Immunoblot 
 
Transferring the protein from the gel to the membrane (Nitro-cellulose or PVDF or nylon) is referred to as 
generating the blot. Blotting is done by several ways: Dry transfer, semi wet transfer, standard wet 
transfer. For this project, standard wet transfer was done.  
After separating the proteins by denaturing PAGE, proteins were immediately transferred onto the 
nitro-cellulose membrane. The gel was incubated for few minutes in transfer buffer (running buffer without 
SDS and with 20% Methanol). The process of equilibration washes out excess of SDS bound to the 
protein, thus facilitating strong adsorption of the protein on to the nitro-cellulose membrane. The protein 
tends to precipitate (because of excess of methanol) or diffuse out of the gel if equilibrated in the transfer 
buffer for a long time. After 5-10 minutes of equilibration of the gel and the nitro-cellulose membrane, 
they were assembled in the transfer assembly for electroblot. The transfer was done for 1 h at 100 V.  
Now onwards, the membrane was never allowed to get dry. Staining the protein with a visible dye helps 
us to visualize if the transfer was alright. Air bubbles between gel and membrane or any deformities in 
the gel or membrane can result in improper transfer and eventually improper immunoblot. Proteins on 
the membrane were stained by Ponceau stain (red colour) to visualize the transfer. After staining, the 
membrane was cut into different parts for incubating them in different antibody solutions; usually it was 
cut into two pieces at 70 kDa. The membrane part with proteins above 70 kDa contained SATB1 while 





away by TBST. After washing the membrane with TBST, it was blocked by blocking agent (5% milk in 
TBST or 5% BSA in TBST or Pierce by Thermo Scientific) for at least one hour at room temperature. 
Then, the membrane was briefly washed by TBST to remove excess of blocking agent and to prevent 
contaminating the antibody solution. The membrane was incubated in the respective antibody solution 
overnight at 4 °C with gentle shaking.  
Next day, the membrane was washed thrice with TBST for 10 min. After the washing steps, the membrane 
was incubated with secondary antibody solution; Anti-mouse or anti-rabbit antibody if the primary 
antibody was generated in mouse or rabbit respectively. Incubation with secondary antibody was done 
for 1 h with gentle shaking at 4 °C. The secondary antibody incubation can be done even at room 
temperature, but at 4 °C the secondary antibody solution could be preserved for reuse without any 
microbial growth.  
After secondary antibody tagging, the membrane was again washed thrice with TBST for 10 min. The 
secondary antibodies used in the lab were mostly conjugated with Horse-raddish peroxidase (HRP). 
Hence, detection of the protein was done by the process of Chemiluminescence. For the loading control, 
homemade ECL was used for detection. For other proteins, Super signal West TM Femto ECL detection 
kit by Thermo Scientific was used. Equal volumes of Peroxide buffer and substrate solution were mixed 
and layered onto the membrane. Chemiluminescence was photographed.  
 
3.2.12 FLAVINO assay 
 
Background 
FLAVINO assay is an anti-proliferation assay performed to check the efficacy of the drug on tumour cells 
isolated from the HNSCC patient biopsies. The assay is named FLAVINO assay since the assay is 
performed in a Flavonoid free media and in a special light which has wavelength above 570 nm. Light 
rays with wavelength shorter than 570 nm can affect the efficacy of the drug. In human body, tissues 
other than skin are not exposed to any light rays. To bring the experimental condition closer to the in vivo 
situation, the assay is performed in this condition. Also, the media lack flavonoids which are affected by 
the light rays with wavelength lower than 570 nm. These flavonoids can increase the LD50 value of the 
drug in the assay which might be higher than the required amount for treatment regimen. 
Another feature of the FLAVINO assay is the outcome of the assay, which is selective for tumour cells 





Fluorescence). Hence contribution to live/dead cell count by cells other than tumour cells is eliminated, 
giving a precise read out. In this assay, colony forming ability of the tumour cells, post treatment, was 
accounted. Group of more than 4 tumour cells was counted as colony. Tumour cells colonies were 
counted manually as the outcome of the assay. The assay was performed at Dr. Gunnar Wichmann’s lab 
whenever a patient tumour sample was available for experimentation.  
Processing the tumour sample for the FLAVINO assay 
Tumour sample obtained from the operation theatre of the Head and Neck department of the 
UniversitätKlinikum Leipzig was minced into smallest possible pieces and digested with Collagenase 
Type IV over night at 37 °C. When tumour sample weighed less than 250 mg, 3 ml of Type IV collagenase 
was diluted using 17 ml complete media (media special for FLAVINO assay). For tumour samples more 
than 250 mg, 6 ml of Type IV collagenase enzyme in 14 ml complete media was used. The digestion was 
carried out in an amber coloured glass bottle in the incubator with aluminium foil covering the bottle to 
allow gas exchange.  
Counting of the cells 
Next day, the cells were singularized using pipette (5 ml). The enzyme was diluted by complete media, 
reducing further digestive effect on the cells. Live cell population was counted using live/dead cell stain 
by analysing it in a flow cytometer.  
Plating and treatment 
After counting, 30,000 live cells/250 µl media/well were seeded in a 96 well plate coated with 3 matrix 
proteins (Laminin, collagen and fibronectin) to facilitate cell attachment and growth. The cells were 
allowed to grow for 72 h. The reason for incubating them for a longer period was to check if there are any 
growing tumour cells in the wells. For treatment, transfection of siLuc3 and siSATB1 was done using 
INTERFERin; 5 nM of siRNA in 260 µl of media was used. After transfections, cells were allowed to grow 
for 96 h.  
96 h post transfection, the media was decanted, cells were fixed using ethanol (sequential incubation in 
40%, 65% and 90% ethanol). Pre-cooled (-20 °C) 150 µl/well of 40% ethanol was added and incubated 
for 10 min at room temperature. To this, pre-cooled (-20 °C) 150 µl/well of 90% ethanol was added and 
incubated for 10 min at room temperature. This solution was decanted off the plate and 150 µl of 
pre-cooled (-20 °C) 90% ethanol was added and incubated for another 10 min at room temperature. After 





as possible. The plates were air dried and stored at 4 °C until stained for immunocytochemistry 
(fluorescence). 
Immuno-cytochemistry (staining of the colonies) 
The staining began with the blocking step where the cells were blocked with blocking solution (2.5% (v/v) 
Fetal Calf Serum in PBS). 100 µl of the blocking solution per well was added and incubated for 30-45 min 
at room temperature. After blocking, the solution was decanted. 50 µl/well Primary antibody solution 
(1:400; 25 ml blocking buffer + 25 ml washing buffer (0.05% Tween-20 in PBS) + 125 µl primary antibody) 
was added. Cells were incubated with primary antibody at 4 °C overnight. 
Next day, primary antibody solution was decanted and washed 2 times with wash buffer (100 µl/well). 
50 µl/well Secondary antibody solution, Goat anti-mouse IgG tagged with Cy2 (1:500; 25 ml blocking 
buffer + 25 ml washing buffer + 100 µl secondary antibody) was added and plates were incubated 
overnight in dark at 4 °C.  
Next day, wells were washed 3 times with 100 µl/well wash buffer. At last, wells were washed with 
100 µl/well distilled water to wash off the excess of salt from PBS, washing & blocking buffers and media. 
Distilled water was decanted, and plates were tapped on clean paper towel to remove excess of liquid. 
Plates were air dried in dark and stored at 4 °C until the colonies were counted.  
Tumour cells appeared with sharp outline and unstained nucleus. Cells other than tumour cells also took 
up the stain, however, they could be differentiated based on their shape, growth pattern and association 
with other cells. Tumour cells tend to form a colony which was distinguishable from other non-tumour 
cells growing in the wells. Fortunately, though cancer associated fibroblast (CAF) grew faster than the 
tumour cells, they did not stain positive for CytoKeratin staining.  
 
3.2.13 Patritumab and Cetuximab treatment 
 
Use of Epithelial growth factor receptor (EGFR) inhibitor is accepted and widely used for treating HNSCC 
patients [53]. From the HER receptor family of four receptors, HER1 and HER3 were targeted by inhibitory 
antibodies, Cetuximab and Patritumab, respectively. For treatment, the cells were seeded in a 12 well 
plate format. Anti-proliferative effects of Cetuximab and Patritumab, alone and in combination were 
assayed. For this, 100 µg/ml of each of the antibody was used. Viable cells were counted by flow 





As described in the section 3.2.5 (Spheroid assay) on page 62, it was important to check the behaviour 
of the cells when growing in non-adherent conditions. Two approaches were explored for this treatment, 
which were informally named Treatment and Pre-treatment approach.  
 
3.2.13.1 Treatment and Pre-treatment approach 
 
In the treatment approach, a fixed dose of inhibitors was applied onto the pre-formed spheroids every 
other day for two weeks. In contrast, for the Pre-treatment approach, the cells were treated with the 
inhibitors while in monolayer. After 48 h of culturing with the inhibitors, cells were harvested and seeded 
for spheroid formation.  
10 µg/250 µl/well of a 96 well plate format was tested in the treatment approach. This created 4 groups 
per experiment: Untreated, Cetuximab 10 µg/well, Patritumab 10 µg/well, Cetuximab and Patritumab 
both 10 µg/well. Since only three of the primary cell lines, UT-SCC-5, UT-SCC-14 and UT-SCC-42B, 
formed active spheroids, only they were used in this experiment. In the pre-treatment approach, the flow 
of the experiment was same as with transfection of siRNAs: cells in monolayer were treated with 
100 µg/ml/well of a 12 well plate for 72 h and were seeded in the special ‘U’ bottom plate for spheroid 
formation. Spheroids were photographed at indicated time points.   
 
3.2.14 miRNA isolation 
 
During miRNA isolation, the possible occurrence of fragmented coding or noncoding RNA contaminating 
the preparation of miRNA is the major challenge. miRNAs itself are relatively small molecules which make 
them much more stable as compared to longer RNA molecules. Extra care was taken during miRNA 
isolation which are mentioned below: 
• Almost all steps should be on ice or at 4 °C, otherwise the temperature is mentioned.  
• Ensure that the microcentrifuge vials, pipettes, reagents, water and tips are Rnase free. Also 
wear gloves before touching anything on the work bench.  
• No harsh movements (like rigorous pipetting, vortex etc) are to be done at any point. This is to 
avoid breakage of long RNA molecules.  
• The volumes mentioned in this protocol are for 12 well plate format 
Cells were cultured in a 12 well plate. At the point of harvest, the media was aspirated and washed twice 





the plate was shaken at room temperature for 10 min. Trizol was aspirated into a fresh vial in one go with 
1000 µl tip. While dispensing the aspirated trizol into the microcentrifuge vial, care was taken that the 
dispensing step was done slowly. It is not recommended to freeze-thaw the samples at any step and all 
steps should be done on the same day without any interruption or break.  
To the Trizol solution, 100 µl Chloroform was added. Vials were shaken with hands for 10-15 seconds. 
Vials were incubated at room temperature for 5 min followed by centrifugation at 12000 rpm (13800 g) 
for 15 min. After centrifugation, the upper aqueous solution containing RNA was transferred to a fresh 
vial (~250 µl). 750 µl of absolute ethanol was added to the aqueous solution. It was mixed by inverting 
and incubated on ice for 10 min. After centrifugation, the supernatant was aspirated with pipette and the 
pellet was washed with 1 ml freshly made 70% ethanol. The pellet was resuspended by inverting (no 
tapping!) and centrifuged.  
As much as possible the supernatant was aspirated with a pipette and residual ethanol was evaporated 
at room temperature, while watching the pellet which should not dry out. The pellet was dissolved in 50 µl 
of Rnase free water by gentle tapping. To this, 1 µl of glycol blue (stain for RNA to visualize the pellet), 
(0.5 x 50 µl =) 25 µl of 7.5 M Ammonium Acetate, pH 5.2, and (2.5 x 50 µl =) 125 µl of absolute ethanol 
was added. The RNA was precipitated at -20 °C for one hour. The sequence of the reagents added is 
important at this step.  
(Ammonium Acetate is used for RNA precipitation and Sodium Acetate is used for DNA precipitation.) 
After the precipitation step, the vial was centrifuged for 30 min at 12000 rpm. The supernatant was 
aspirated, and the pellet was washed with 500 µl of 70% freshly made ethanol for three times. Finally, 
the air-dried pellet was dissolved in 50 µl of Rnase free water.  
The quality of the RNA isolated was analysed with 1% agarose gel to check for RNA degradation. 1 µg 
of total RNA was loaded on the gel for checking degradation.  
 
3.2.15 In vivo experiments 
 
To analyse the anti-tumour effect of the SATB1 knockdown, subcutaneously seeded xenograft tumours 
were generated in immunodeficient mice (NOD/SCID/IL2r gamma (null), Jackson Laboratory, Bar Habor, 
ME). UT-SCC-42B, UT-SCC-14, UT-SCC-5 and UT-SCC-16B formed subcutaneously seeded tumours. 
However, only UT-SCC-42B and UT-SCC-14 cells were found favourable with regards to growth kinetics 





mice were kept in cages with rodent chow (sniff, Soest, Germany) and water available ad libitum. Animal 
studies were performed according to the national regulations and approved by the local authorities 
(Landesdirektion Sachsen). For subcutaneous xenograft tumour generation, 5 million cells/150 µl PBS 
per flank of the animal were seeded.  25 mice with developed tumours were selected for experimentation; 
7 untreated, 9 injected with siLuc3/PEI-F25 particles and 9 with siSATB1/F25 particles. For UT-SCC-
42B, 10 µg F25 complexes/100 µl per animal were injected 3x/week for 3 weeks (3 + 3 + 3 + 1= 10 
injection). For UT-SCC-14, 15 µg F25 complexes/150 µl per animal was injected 3x/week for 3 weeks (3 
+ 3 + 3 + 1 = 10 injection).  
 
3.2.15.1 Protein isolation from tumour xenografts  
 
Tumours dissected from the mice were snap frozen and stored at -80 °C until processed for protein lysate 
preparation. Tumours were weighed before homogenizing. Tumour weighing more than 110 mg were cut 
and weight was adjusted to be below 110 mg. Tumours weighing less than 100 mg were completely used 
for protein lysate preparation. After weighing the tumours, they were transferred to a sterile round bottom 
tube. 1 ml RIPA-SDS buffer with protease inhibitory cocktail (1:200 dilution) was added to the tube. 
Tumours in lysis buffer were incubated on ice until mincing. Mincing of the tumours was done using a 
tissue homogenizer (Ultra Turrax, Ika). After lysing each tumour, the homogenizer was thoroughly 
washed with distilled water and isopropanol to wash away any protein stuck to the blades. Also, care was 
taken that no tissue debris were left in the blade before lysing the next sample.  
After homogenizing the tumours, they were incubated on ice till centrifuged. The lysate was centrifuged 
for 3000 rpm for 10 min. From 1 ml, 750 µl of the supernatant was collected in a fresh 1.5 ml vial. This 
supernatant was subjected to ultra-sonication for 60 seconds at room temperature to denature and 
degrade nucleic acids which can hinder the separation process. After sonication, the vial was centrifuged 
at 13,000 rpm for 10 min at 4 °C. From this, 600 µl of the supernatant was collected in a fresh vial and 
used for protein quantification and dilution for western blot as described in sections 3.2.10 and 3.2.11. 
The final volume of the lysate along with the loading buffer and distilled water was adjusted to give a 







3.2.16 Immunocytochemistry (fluorescence) 
 
For localization of SATB1 and additional proof of the knockdown, immunocytochemistry was performed 
on all seven primary cell lines. To begin with, all the slides (Superfrost Excel by Thermo Scientific) and 
Flexiperm (Sarstedt) were sterilized by autoclaving along with the forceps (for handling). Cells were 
seeded onto the slides. To create compartments on the slide for different cell lines, Flexiperm was used. 
Flexiperm adheres easily to the slide and helps in creating leak proof compartments enabling the seeding 
of different cell suspensions in adjacent compartments. Four slides, one for siLuc3, one for siSATB1 
transfected cells and one for untreated cells were created. The last slide with all the cells was to check if 
the secondary antibody binds non-specifically in absence of primary antibody in the samples. The entire 
setting was put in a sterile disposable petri-dish. The outer side of the flexiperm in the petri-dish was filled 
with complete media (~ 25 ml). This reduced the chances of leakage of the media and helped in 
maintaining the humidity of the chamber, for normal proliferation of the cells.  
Cells were seeded at a cell density of 5000 cells per 500 µl of complete media and transfected 24 h post 
seeding. For transfection, 5 nM siRNA in 600 µl of media was used (500 µl media + 100 µl transfection 
mix). The cells were allowed to grow for 96 h post transfection, to ensure distinguishable knockdown.  
Fixation 
At 96 h post transfection, the media was aspirated and flexiperms were removed carefully without eroding 
the monolayer of cells formed on the slide. Flexiperms were washed with distilled water and were 
autoclaved for sterilization. No soap or any organic solvent was used for washing which could reduce the 
adhesive capability of the flexiperms. The slides containing the cells in monolayer were washed twice 
with ice cold PBS. Immediately after the last wash, the slides were immersed in pre-cooled (-20 °C) 
absolute methanol and fixation was performed for 20 min at -20 °C. After fixation, the methanol was 
discarded, the slides were air dried and stored at 4 °C until processed for staining.  
Methanol fixation was recommended by the Abcam website (supplier of the SATB1 antibody) and hence 
their protocol was followed. However, air drying of the fixed cells reduced the volume of the cells which 
did not give optimal staining for beta actin. The aim of this experiment was SATB1 localization and proving 
the knockdown, hence, beta actin staining although not optimal was accepted. The purpose of staining 
the cytoplasm for beta actin was fulfilled. Nuclear staining (Hoechst) and SATB1 were not affected by 







Slides containing fixed and air-dried cells were subjected to the process of antigen retrieval. Two antigen 
retrieval buffers were tested. Urea buffer (100 mM Tris, 5% [w/v] urea, pH 9.5) which was recommended 
by the antibody supplier, and Citrate buffer, pH 6.0, by Dako. Slides were immersed in one of the buffers 
and boiled at 95 °C for 10 min (urea buffer) and 20 min (citrate buffer).  
Pilot experiments revealed that staining was more brilliant in slides which received citrate buffer treatment 
than the slides tested with Urea buffer. Thus, in contrast to the recommendation by Abcam, Citrate buffer 
was used for antigen retrieval for the experiments. Along with these two variables, a third slide which did 
not undergo the process of antigen retrieval was also tested. Results of this experiment revealed that the 
process of antigen retrieval was inevitable in this case. Without antigen retrieval the antibody bound to 
some other proteins in the cytoplasm and did not stain SATB1 which is in the nucleus.  
Primary antibody tagging 
After antigen retrieval, slides were washed with PBS three times for 5 min. Fresh PBS was layered over 
the slide and incubated for 5 min. At the end of each wash, PBS was decanted off and fresh PBS was 
layered. After three washes, the slides were incubated with blocking buffer which contained goat serum 
(1% BSA [w/v], 5% goat serum [v/v], 0.1% [v/v] Tween 20 in PBS). Goat serum was used for blocking 
since the secondary antibodies used in this experiment were generated in goat. Blocking was performed 
for 1 h at room temperature. Then, the blocking solution was aspirated and immediately replaced by 
freshly prepared primary antibody solution (200 µl per compartment). The SATB1 antibody was diluted 
1:200 while the beta actin antibody was diluted 1:500. Primary antibody incubation was done overnight 
at 4 °C. On the next day, the antibody solution was decanted, and slides were washed three times for 
5 min with PBS.  
Secondary antibody tagging and Nuclear staining 
The secondary antibody solution was prepared as follows:  for SATB1, anti-rabbit developed in goat, 
tagged with Cy3 (red) was diluted 1:800, while for Beta Actin, anti-mouse developed in goat, tagged with 
Cy2 (green) was diluted 1:200. After the last PBS wash, the secondary antibody mixture was pipetted 
onto the slides (150-200 µl per compartment). Slides were incubated with secondary antibody for 2-3 h 
at room temperature in the dark. After incubation, the secondary antibody solution was replaced by freshly 
prepared Hoechst solution in PBS, again 150-200 µl per compartment. Cells were incubated with 
Hoechst stain for 10 min at room temperature in dark. After that, the dye was decanted, and slides were 





The last wash was performed using distilled water to remove excess of salts deposited on the cells during 
the entire process. After the last wash, slides were allowed to air dry in dark at room temperature 
overnight. Before mounting, the slides were briefly dipped in a Butyl ester solution for enhancing the 
fluorescent signal. Immediately after dipping, the mounting media (Entellan, Sigma Aldrich) was pipetted 
onto the slide and coverslip was put carefully onto it, avoiding entrapping any bubble or exerting pressure 
on the cells. The mounting media was air dried at room temperature overnight in the dark. After this step, 
the slides were stored at 4 °C in the dark until picturized using a confocal microscope.  
 
3.2.17 Statistical analyses 
 
All experiments were performed in triplicates unless stated otherwise. Statistical analyses were 








4.1 SATB1 mRNA levels among different primary cell lines 
 
Primary cell lines were obtained from different sources as mentioned in the section 3.2.1 on page 57. 
The first step after obtaining them was to check for mycoplasm contamination. All primary cell lines were 
tested negative for mycoplasm contamination. Initially, cryopreservation was done at -80 °C. Later, it was 
realised that the stocks cryopreserved at -80 °C could not survive for a period of more than 6 to 8 months. 
Cryopreservation for longer period required storage in liquid nitrogen.  
The first experiment with all the primary cell lines was to determine their initial relative SATB1 mRNA 
levels. SATB1 mRNA levels were determined by relative quantification (ΔΔCt method) with respect to 
RPLP0 (Ribosomal protein lateral stalk subunit P0). Actin was initially included as a second reference 
gene for relative quantification. However, upon SATB1 knockdown, the shape of the cells changed which 
led us to exclude actin (member of the cytoskeleton group of biomolecules). Only RPLP0 was used for 
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Figure 7 SATB1 mRNA levels analysed in the primary cell lines of head and neck squamous cell carcinoma 
established in the University of Turku; RPLP0 was used as the reference gene for the relative quantification of the 
SATB1 mRNA. The colour code indicates the location from where the tumour cells were isolated. ‘#’ indicates patients 
with lymph node invasion. ‘A’ suffix indicates cells isolated from a primary tumour while ‘B’ indicates cells isolated 





Figure 7 on page 81 shows the relative SATB1 mRNA levels in all the primary cell lines. Tumour cells 
isolated from the primary tumours are suffixed with A. Metastatic or recurrent tumour cells isolated from 
the same patient are suffixed with B. Cell lines without any suffix did not have metastatic or recurrent 
tumour. As evident, primary cell lines with a wide range of SATB1 mRNA levels were used for initial 
screening. 
Figure 7 also shows different location (colour code) in the head and neck region from where the 
squamous cell carcinoma cells were isolated. In the same figure, bars marked with ‘#’ sign indicate lymph 
node invasion. Comparison of the location and lymph node metastasis with relative SATB1 mRNA levels 
revealed that SATB1 mRNA levels were independent from these factors. It varied amongst individuals.   
 
4.1.1 Comparison between primary cell lines isolated from the same patient 
 
Next, the trend of SATB1 mRNA levels between the primary (A) and the metastatic (B) cells isolated from 
the same patient was analysed. For this, A and B cells of four patients were procured, 
UT-SCC-16, -42, -60 and -74. SATB1 mRNA levels of these cell lines were compared with respect to 
RPLP0 and Actin. The trend of SATB1 mRNA levels with respect to both the reference genes was similar. 
Figure 8 on page 82 shows the comparison of SATB1 mRNA levels with respect to RPLP0 among tumour 
cells isolated from the same patients. The Comparison with respect to Actin is shown in the 





























































Figure 8 SATB1 mRNA levels in the primary and the metastatic tumour cells isolated from the same patient: RPLP0 was used as 





Studies on SATB1 reveal that the protein is expressed in lower amounts in moderately differentiated or 
primary tumour lesions than in poorly or un-differentiated tumours (metastatic, B counterpart). Its level 
increases as the tumour advances. Based on these findings, it was hypothesized that the A counterpart 
should have lower SATB1 mRNA levels compared to the B counterpart. In case of UT-SCC-16, SATB1 
mRNA levels of both A and B were almost similar. In case of UT-SCC-42, B had higher SATB1 mRNA 
levels as compared to A. Like UT-SCC-42, UT-SCC-74 also showed a similar trend of SATB1 mRNA 
levels but with a starker difference of ~58 times. In case of UT-SCC-60, it was the opposite. UT-SCC-60A 
showed higher SATB1 mRNA levels as compared to UT-SCC-60B. Thus, we did not find any strict 
association of SATB1 mRNA levels between primary and metastatic status of the tumour cells. It varied 
from amongst individuals.  
 
4.2 Screening of primary cell line candidates for further analysis by 
measuring anti-proliferation effects upon SATB1 knockdown 
 
Initially, the transfection protocol was optimized for each of the primary cell lines. It is important to note 
here that all the primary cell lines screened during this study were easy to transfect. 60 to 70% knockdown 
was achieved with 5 nM siRNA in 1100 µl media. Half amounts (0.5 µl/pmole of siRNA) of the transfecting 
reagent as opposed to the suggested quantity (1 µl/pmole of siRNA) was used to achieve the transient 
knockdown of SATB1. This was done in 12 well plate format and the knockdown was analysed by q-RT-
PCR at 96 h post transfection. In previous projects [123, 128], two siRNAs specific for SATB1 were 
compared (si467 and si989). From these two siRNAs, si467 yielded better knockdown in comparison to 
si989. Thus, a well-established siRNA (si467), which is referred to as siSATB1, was used for this project.  
 
4.2.1 Initial screening by visual confirmation and knockdown at mRNA and 
protein level 
 
For this, cell densities of untreated, control transfected (siLuc3) and siSATB1 transfected cells were 
compared to see if there is any effect of SATB1 knockdown. Initial screening showed specific anti-
proliferative effects in 5 primary cell lines (UT-SCC-5, UT-SCC-15, UT-SCC-14, UT-SCC-42B and UT-
SCC-60B). Along with these five, two other primary cell lines also showed mild effects on their proliferation 





transfection and siSATB1 transfected cells were nearly the same but the change in media colour indicated 
an effect of SATB1 knockdown on UT-SCC-16B and UT-SCC-60A. To analyse the downstream cellular 
and molecular effects upon SATB1 depletion in both strongly and weakly affected cell lines, UT-SCC-16B 
and UT-SCC-60A were also included in the final list. Knockdown at mRNA levels in all the seven short 
listed cell lines is shown in Figure 9 on page 84. When compared with siLuc3 transfected cells, 
knockdown of more than 70% was obtained in all 15 primary cell lines tested (data of the remaining 8 
primary cell lines is not shown). However, in the primary cell lines not short listed above, no changes in 
the morphology or reduced proliferation upon SATB1 knockdown was observed.  
Parallel to this, established cell lines (KB, FaDu and HN-5) from the American type culture collection 
(ATCC) were also tested for anti-proliferative effect post SATB1 knockdown. From these three cell lines, 
SATB1 knockdown inhibited proliferation only in KB. However, after 6 to 8 months, KB was tested positive 
for mycoplasm contamination. Though proliferation of KB was influenced upon SATB1 knockdown, it was 
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Figure 9 Transient knockdown of SATB1 in short listed primary cell line: RPLP0 was used as the reference gene. siLuc3 is the 





4.2.2 SATB1 knockdown and live cell count 
 
After visual confirmation of growth inhibition upon SATB1 knockdown, the quantification of anti-
proliferation was done. Initially, the widely accepted method of using the WST-1 reagent for proliferation 
assays was employed. The absorbance at 450 nm was higher than expected in siSATB1 transfected 
cells. (For troubleshooting, new vial of diluted siRNA, a new vial of INTERFERin and freshly thawed 
primary cell lines were used.) Visually, the cell density in siSATB1 transfected wells was lesser than 
siLuc3 transfected wells. But, the difference of same order was not obtained in the absorbance value 
determined by colorimetric estimation. After trying different incubation periods of cells with the WST-1 
reagent in the wells, different dilutions of the WST-1 reagent and also changing the plate reader it was 
concluded that WST-1 reagent does not reflect the actual cell density post SATB1 knockdown. Examples 
of the discrepancy between the visual cell density and the WST-1 absorbance obtained from the 
colourimeter are shown in Figure 10 on page 85 and Supplementary figure 2 on page 138. Though cell 
density was much lesser in siSATB1 transfected wells, the readings were closer to the siLuc3 and the 





























Figure 10 Example of WST-1 reading; photographs below the proliferation graph are representative images of the wells taken at 





To avoid any misinterpretation and technical errors, the method of directly counting the live cell population 
was performed. As described in section 3.2.3 on page 59, The live cell population was counted using 
flow cytometry. Based on the forward and sideward scatters, the live cell population was gated and actual 
event counts (cells) were plotted. Repetitions of this assay was converted to percentage values to be 
able to compile it into a single graph. Figure 11 on page 86 shows live cell counts normalised to the 
untreated cells in all seven primary cell lines.  
As evident from Figure 11, the degree of anti-proliferation varied among all the primary cell lines. SATB1 
knockdown exerted very strong effects on the proliferation rates of UT-SCC-14, UT-SCC-42B, 
UT-SCC-60B, UT-SCC-5 and UT-SCC-15 cells. In case of UT-SCC-16B and UT-SCC-60A cells, an effect 
on proliferation was visible only upon comparing it with negative control transfection (siLuc3). Next, initial 
SATB1 protein levels of these seven primary cell lines were analysed by western blot. To minimize 
experimental errors, 500,000 cells were resuspended in 50 µl 1x PBS and lysed with 150 µl 1x RIPA-



























































































































for loading precisely equal volumes and blots were reprobed for GAPDH as the loading control. Figure 
12 on page 87 shows the immunoblot of the cell lysate. The bar diagram shows the band intensities 
normalized to the loading control, GAPDH, as measured by Image J. SATB1 protein levels were not 
precisely correlating to the mRNA levels. However, the grouping of the primary cell lines into high, 
medium and low SATB1 expressing cells was similar, between mRNA and protein. Increasing SATB1 
mRNA levels were found in the order UT-SCC-60B < UT-SCC-15 < UT-SCC-16B < UT-SCC-60A < UT-
SCC-5 < UT-SCC-42B < UT-SCC-14. On the protein level, the order was UT-SCC-16B < UT-SCC-15 < 
UT-SCC-5 < UT-SCC-60B < UT-SCC-60A < UT-SCC-14 < UT-SCC-42B.  
Three time points were chosen for western blot, i.e. 72, 96 and 120 h post transfection. From this, 96 and 
120 h were preferred over 72 h because of higher cell densities. The cell density at 72 h was not sufficient 
in some cell lines to obtain detectable bands, like in case of UT-SCC-5, UT-SCC-15 and UT-SCC-16B. 
For successful detection of SATB1 protein bands, three wells of each treatment group were pooled in all 
seven primary cell lines. This was done mainly because siSATB1 transfected cell density was very low. 
Hence, to obtain reasonable amounts of protein, lysates of 3 wells of a 12 well plate were pooled. Equal 
amount and concentration of total protein was difficult to achieve in all experiments because of severe 
growth inhibition upon SATB1 knockdown. Hence, despite measurement of protein concentration and 
loading equal protein amounts (~ 30-40 µg) on to the gel, all the band intensities were measured and 
normalized to GAPDH bands by Image J. Figure 13 on page 88 shows immunoblots of UT-SCC-42B, 




































Figure 12 SATB1 protein levels in 7 short listed primary cell lines as detected by western blot using the Clone 14 monoclonal 





on page 139 for knockdown of SATB1 at protein levels in UT-SCC-5, UT-SCC-14, UT-SCC-15 and UT-
SCC-16B.  
Another method employed for detecting the SATB1 knockdown on the protein level was 
immunocytochemistry-fluorescence. For this, EPR 3951 antibody for SATB1 by Abcam was used. Hence, 
the knockdown of SATB1 in these primary cell lines was demonstrated by two different antibodies and 
by two different techniques. 96 h post transfection, cells on the slides were fixed by 100% ice cold 
methanol. There were some advantages of using the ICC/fluorescence technique; first, better 
visualization of SATB1 staining even in case of low expressers of SATB1 like UT-SCC-16B and UT-SCC-
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Figure 13 SATB1 knockdown on the protein level analysed by western blot in UT-SCC-42B, UT-SCC-60A and UT-SCC-60B cells at 
three time points (72, 96 and 120 h post transfection): bar diagram above the respective blot shows the quantitation by image J 





shows the SATB1 staining by ICC/fluorescence where the knockdown of SATB1 is clearly visible upon 


























Figure 14 Immunocytochemical (fluorescent) staining of SATB1 by EPR 3951 antibody by Abcam, for detecting SATB1 knockdown 
on the protein level: secondary antibody was tagged with Cy3 (red) which was picturized using confocal microscopy. The scale 





4.2.3 Relation of SATB1 and SATB2 mRNA levels 
Reports on the relevance of SATB1 and SATB2 for oncogenic progression in head and neck cancer [165, 
166] and the difference in the degree of anti-proliferation upon SATB1 knockdown found here led us to 
analyse the initial levels of SATB2 mRNA in the selected primary cell lines. SATB2 mRNA levels were 
compared with SATB1 mRNA levels. There was no correlation found among them (r2=0.0383). 
Respective levels of SATB1 and SATB2 mRNA levels are plotted in Figure 15 on page 90. The absence 
of a correlation between SATB1 and SATB2 mRNA levels (Figure 15 upper right) revealed that their 
levels were independent as far as these primary cell lines of HNSCCs are concerned. Moreover, initial 
SATB2 mRNA levels did not positively or negatively influence the growth inhibitory effects upon SATB1 











































































Figure 15 Comparison of SATB1 and SATB2 mRNA levels 
in selected 7 primary cell lines: mRNA levels were relatively 
quantified by using RPLP0 as the reference gene. No 





close to the negative control reaction (water), it was concluded that SATB2 mRNA was not present in 
UT-SCC-15.  
 
4.2.4 Nuclear localization of SATB1 
 
The literature suggests that SATB1, and SATB2 also, are localized in both the cytoplasm as well as the 
nucleus. Nuclear localization of SATB1 and SATB2 protein was found to be strictly correlated with poor 
prognosis and aggressive disease progression [162, 165, 167, 168]. As far as the biology is concerned, 
the main function of these two proteins is to organize genomic DNA, to act as a trans-acting element for 
regulating transcription and remodelling chromatins for switching on and off a variety of genes. No other 
function of SATB proteins has been reported, especially not in the cytoplasm. Here, with the help of 
immunocytochemistry-fluorescence, we proved the nuclear localization of SATB1 in all seven primary 
cell lines. SATB1 was distinctively found to be present only in the nucleus. Longer exposure did not detect 
any trace amounts of SATB1 in the cytoplasm. Figure 16 on page 92 shows nuclear localization of SATB1 





















































Figure 16 Nuclear localization of SATB1 protein, proven by immunocytochemical (fluorescence) staining: the nucleus was stained 





4.3 Colony formation assay and Spheroid assay 
 
The determination of the degree of growth inhibition upon SATB1 knockdown in 2D monolayer culture on 
plastic may be insufficient to adequately mimic the in vivo situation. Therefore, assays on colony forming 
ability or growth in three dimensions in non-adherent culture condition, was performed. Tumour cells 
possess a unique quality of establishing an entire tumour from a single cell. After epithelial to 
mesenchymal transition, cells possess structural and functional proteins that help them change shape, 
migrate, invade, proliferate when required and, at the same time, evade the process of apoptosis. Such 
colony forming abilities helps isolated tumour cells to metastasize and form distant tumours.  Hence, 
changes in the ability of these primary cell lines to develop colony and growth in 3 dimensions was 
examined post SATB1 knockdown.  
 
4.3.1 Colony Formation Assay 
 
After transfection, cells were harvested, counted and diluted at a very high ratio to obtain colonies 
developed from a single cell. In this case, approximately 300 to 500 thousand cells/ml were diluted to 
give 250 to 500 cells/ml. At such a dilution, single cells form distinct colonies which, after staining, can 
be counted with naked eyes. After formation of sizeable colonies (roughly 50-100 cells), colonies were 
stained, washed and dried, photographed and electronically counted using Image J.  
Colony count and representative images of the colonies are shown in Figure 17 on page 94 and in 
Supplementary figure 6 on page 140.  
Comparable to the proliferation assays, UT-SCC-16B and UT-SCC-60A did not show any effect of SATB1 
knockdown on their colony forming ability post siSATB1 transfection. In contrast, UT-SCC-60B and UT-
SCC-15 showed the strongest reduction in colony forming ability. In case of UT-SCC-14, a strong 
anti-proliferative effect 72 h post transfection was observed but colony forming ability was only mildly 
attenuated upon SATB1 knockdown. A similar behaviour was found in UT-SCC-42B. Effect of SATB1 

























































































4.3.2 Spheroid assay 
 
When testing all seven primary cell lines, only UT-SCC-5, UT-SCC-14, UT-SCC-42B and UT-SCC-16B 
cells were found to be able to form spheroids. It was observed that the cells formed spheroids 24 h after 
seeding them in those plates. Between 24 h and 48 h, some spheroid shrinkage was observed when 
5000 live cells per 250 µl were seeded at 72 h post siRNA transfection. After 48 h, the spheroid size 
increased, if they grew, like in case of UT-SCC-5, UT-SCC-14 and UT-SCC-42B. UT-SCC-16B formed 
spheroids which did not actively grow, not even in the untreated group.  
UT-SCC-42B spheroids showed a very strong and distinguishable effect on spheroid growth upon SATB1 
knockdown. Figure 18 on page 96 shows representative images of UT-SCC-42B and UT-SCC-16B 
spheroids. UT-SCC-16B did not show any positive or negative effect of SATB1 knockdown on spheroid 
growth.  
UT-SCC-5 spheroids did not grow substantially in size. However, a minor decrease in the spheroid size 
was seen in siSATB1 transfected cells. UT-SCC-14 cells on the other hand, showed no difference in the 
size of the spheroids of siSATB1 transfected cells. Light microscopy photos of UT-SCC-5 and UT-SCC-14 
spheroids are shown in Figure 19 on page 97. Upon increasing the brightness, UT-SCC-14 spheroids of 
siSATB1 transfected cells showed differences. Loosely attached cells surrounded a smaller spheroid in 
the core. This observation led to the live cell staining of the spheroids of UT-SCC-14. UT-SCC-5 was also 
included for live cell stain. Calcein AM (live cell stain) stained spheroids of UT-SCC-5 and UT-SCC-14 
are shown in Figure 19. Later, UT-SCC-16B spheroids were also stained with live cell stain which 
revealed that spheroids of UT-SCC-16B, even siSATB1 transfected cells, were alive but they did not grow 
(data not shown).  
Calcein AM staining of UT-SCC-14 spheroids revealed that more than 95% of the spheroids from 
siSATB1 transfected cells consisted of dead cells bound to each other, which appeared like a live 
spheroid in white light. Spheroids of siLuc3 and untreated cells stained positively, indicating the entire 
spheroid to be alive. To rule out the possibility of reduced penetration capabilities of the dye post SATB1 
knockdown, a live/dead staining of the spheroids was done. Since UT-SCC-5 and UT-SCC-42B showed 
differences in size which was easily distinguishable in bright field, live/dead stain was performed only for 





















Figure 18 Spheroid assay performed for UT-SCC-42B and UT-SCC-16B: representative images of the respective primary cell lines 
and treatment group at 10 days after cell seeding are shown. Each group consisted of 5 spheroids. scale bar indicates distance 






Calcein AM for staining live cells, propidium iodide for staining dead cells and Hoechst 33342 for staining 














































Figure 19 Spheroid assay for UT-SCC-5 and UT-SCC-14: (A) representative photos of spheroids of UT-SCC-5 and UT-SCC-14 in 
bright field microscopy; (B) representative mages of spheroids of UT-SCC-5 and UT-SCC-14 stained with Calcein AM for live cell 





in Figure 20 on page 98. The images reveal that penetration of the dyes was not an issue. The spheroids 
of siSATB1 transfected cells consisted of more than 95% dead cells. Photographs for documentation of 
the spheroid was done using Celigo (Nexcelom Bioscience). 
 
4.3.3 FLAVINO assay 
 
Tumour cells after processing (section 3.2.12 on page 72) were seeded in a 96 well plate at a cell density 
of 30,000 cells/well (live cell count) in 250 µl complete media. For this project, instead of treating with 
routinely tested chemotherapeutic drugs, cells were transfected with siRNA for transient knockdown of 
SATB1. Similar to the settings of primary cell lines, 5 nM siRNA in 300 µl volume (250 µl complete media 
+ 50 µl transfection mix) was used for transfection. 96 h post transfection, cells were fixed by ethanol 
and stored at 4 °C until stained (immunocytochemistry-fluorescence). Since the pan-Cyto keratin 
antibody stains keratinized tumour cells, positive staining was specific for tumour cells while excluding 









Figure 20 UT-SCC-14 stained spheroids imaged using Celigo Nexcelom Bioscience: spheroids of UT-SCC-14 stained with Calcein 
AM (live cell stain, green), propidium iodide (dead cell stain, red) and Hoechst 33342 (nuclear stain, blue). Merged representative 





From 22 tumour samples received for transfection treatment, 7 were positive for tumour cell colonies. 
Colonies for these 7 plates (3 groups per tumour sample: untreated, siLuc3 and siSATB1; 5 wells for 
each group) were counted. Before counting the colonies, a second confirmation of the plate being positive 
or negative was done by an experienced blind reader. The results of the colony counts are shown in the 
Figure 21 on page 99. As evident from the bar diagrams in Figure 21, there was no effect of siSATB1 
transfection on the colony forming ability of the tumour cells. Rather, a small increment in the number of 
colonies in siSATB1 transfected wells was observed.  
 
4.4 Cell death by apoptosis 
 
Cell death via apoptosis was analysed by using Caspase 3/7 glow assay from Promega. The readings 
are also influenced by the cell density. Hence, in addition to measuring Caspase 3/7 activation a WST-1 
assay was performed in parallel for each well of the three groups for normalizing for the cell density in 
the Caspase 3/7 glow assay. A single time point, that is 72 h post transfection, was analysed.  
Figure 22 on page 100 shows Caspase 3/7 activation upon SATB1 knockdown. In line with previous 
results, UT-SCC-16B and UT-SCC-60A cells did not show any Caspase 3/7 activation upon SATB1 
knockdown. The absence of growth inhibitory effect upon SATB1 knockdown is paralleled by negligible 
Caspase 3/7 activation in UT-SCC-16B and UT-SCC-60A. In contrast, UT-SCC-5, UT-SCC-14, 
UT-SCC-15, UT-SCC-42B and UT-SCC-60B showed increased activity of caspase 3/7 upon SATB1 















































































Figure 21 Colony count from FLAVINO assay performed on tumour samples received from the HNO division of the 







4.5 Effect of SATB1 knockdown on Cell cycle progression rate 
 
Beyond induction of apoptosis, the knockdown of SATB1 may also affect cell cycle. Thus, cell cycle 
progression rates were analysed by determining the number of cells reaching a nocodazole-induced 
G2/M block in a given time period. The first step was to determine the amount of nocodazole and the 
time needed to achieve sufficient number of cells into the G2/M block. As mentioned in the section 3.2.7 
on page 64, each primary cell line required different amount of nocodazole and different time points. To 
analyse the effects of SATB1 knockdown on cell cycle progression rate, the nocodazole block was 
































































Figure 22 Caspase 3/7 activation upon SATB1 knockdown: knockdown of SATB1 induces cell death via apoptosis which is 
indicated by increase of Caspase 3/7 activity. Measurements were done at 72 h post transfection and normalized for cell density 





Figure 23 on page 101 shows an example of a G2/M block achieved to analyse the effect of any treatment 
(SATB1 knockdown in this case) on cell cycle progression rate. The histogram on the left is of the cells 
without any block by nocodazole. The X axis indicates the stain intensity of propidium iodide (DNA only) 
while the Y axis indicates the number of cells. Sections in the histograms are defined as gates since they 
help in determining the percentage of the population in respective cell cycle phase. The population in 
gate R7 indicates apoptotic bodies. Gate R8 shows the population in G0 or G1 phase. Gate R9 indicates 
the population in Synthesis phase or S phase, while gate R10 highlights the population that is in G2/M 
phase. Cells in G0 or G1 phase are cells with 2n nucleus. Cells in G2/M are cells with 4n nucleus (double 
than G0/G1 phase). In between are the cells in S phase where the nuclear content is being replicated 
and hence it is between 2n and 4n. On careful examination of the numbers on X axis, the peak of R8 
(G0/G1 phase, 2n nuclear content) is somewhere between 3.5 and 4, while the peak of R10 (G2/M phase, 
4n nuclear content) is somewhere between 7.5 and 8. Thus, DNA content is adequately stained and the 
percentage of the population in each phase is reliable. Along with this, it also proves that the RNA 
digestion during the preparation of the cells for flow cytometric analysis was sufficient to stain only the 
DNA content of the cells. The histogram on the right side is of the same primary cell line but after 
introducing nocodazole block. The cell count on the Y axis indicates increase in percentage of cells 
blocked in G2/M phase (R10). 
Figure 24 on page 102 shows the percentages of cells in different stages of cell cycle post SATB1 
knockdown and introduction of the nocodazole block (please refer to the Supplementary figure 9 on 
page 142 for results of other primary cell lines). Cells whose growth was inhibited upon SATB1 
knockdown were expected to exhibit some effect on cell cycle progression rate, especially a reduced 
percentage of cells entering G2/M phase within a given time frame. Cell cycle progression was retarded 






Unblocked Untreated after nocodazole block
Figure 23 Example of the G2/M block introduced upon administration of nocodazole: the cell population was analysed by flow 
cytometry. The X axis indicates the staining intensity which is directly proportional to the nuclear content (2n or 4n), the Y axis 





reaching the G2/M phase upon SATB1 knockdown. The difference in UT-SCC-14 is noteworthy when 
compared with siLuc3 transfected cells instead of untreated cells.  
  
Table 10 Percentage of population in S phase post SATB1 knockdown: cells in different cell cycle phase were 
analysed by flow cytometer after staining the nuclear content (DNA only). 
Percentage of population in S-Phase 
Cell lines Untreated siSATB1 siLuc3 
UT-SCC-5 10.99 13.137 10.8 
UT-SCC-14 12.803 22.082 12.217 
UT-SCC-15 13.9 19.412 13.477 
UT-SCC-16B 8.631 8.935 9.188 
UT-SCC-42B 15.258 17.148 13.818 
UT-SCC-60A 14.661 17.617 16.426 
UT-SCC-60B 23.283 21.331 21.76 
 
Exceptions in this case were UT-SCC-5 and UT-SCC-60B cells. Both cell lines showed strong anti-
proliferative effect upon SATB1 knockdown. Activation of caspase 3/7 upon SATB1 knockdown was also 
found in these two primary cell lines, while negligible or no effects on cell cycle progression rate was 
determined.  
Table 10 on page 102 shows the percentage of population in Synthesis ‘S’ phase upon SATB1 


















































































was relatable to the decreased rate of transition into the G2/M phase in most of the primary cell lines. 
Exceptional increase of almost 10% of the population in S phase was unique to UT-SCC-14.  
 
4.6 Effect of SATB1 knockdown on the transcription rate of other 
oncogenes 
 
SATB1 is a genome organizer protein which also acts as a transcription factor and as a part of the 
chromatin remodelling complex by which it controls the expression of hundreds of genes. Thus, its 
knockdown might affect the expression of tumour relevant genes. As described in section 2.5.2.3 on page 
36, EMT markers like E- and N- cadherin and beta-catenin were selected. Matrix Metalloprotease 7 
(MMP7) which facilitates the invasive potential of the cells as well as cell cycle related genes, Cyclin B1 
and D1, were selected. Pim1, which is a survival kinase protein was also analysed. Based on previously 
published work from our group [123, 128], HER family receptors (EGFR, HER2 and HER3) and Heregulin 
Alpha (A) and Beta (B) were also chosen for analysis. Along with these genes, Metastasis associated in 
Colon cancer protein 1 (MACC1) was also analysed in a few selected primary cell lines. All effects on 
transcription rates of these genes were analysed 96 h post transfection.  
Initial studies were performed in UT-SCC-42B cells. Unexpectedly, an increase in the transcription rate 
of selected genes except beta catenin was found. A significant increase in the transcription rates of Cyclin 
B1 and D1 was particularly noteworthy since the results on cell cycle progression rates, it was expected 
that SATB1 knockdown would rather downregulate Cyclin B1 (S to G2/M phase). Figure 25 on page 104 
shows effect of SATB1 knockdown on transcription rates of selected genes in UT-SCC-42B and 
UT-SCC-60B cells. The results in UT-SCC-60B cells were comparable to UT-SCC-42B cells with respect 
to Cyclin B1 & D1, MMP7 and Pim1. However, reductions in the transcription rates of N-cadherin and 
beta catenin were an indication of a negative impact on the process of EMT. These genes were also 
analysed in UT-SCC-16B and UT-SCC-60A cells. Although, both the cell lines had not shown any cellular 
response upon SATB1 knockdown, there was reduction in the transcription rates of N-cadherin and Beta 
catenin. A reduction in the mRNA of MMP7 was also observed for these two primary cell lines. Results 





MACC1 gene was found unaffected by SATB1 knockdown in 5 selected cell lines (Supplementary figure 
12 on page 144).  
A profound impact of SATB1 knockdown on the transcription rates of HER3 and Heregulin A and B was 
observed in almost all primary cell lines. Figure 26 on page 105 shows effects in UT-SCC-42B, UT-SCC-
60B, UT-SCC-5 and UT-SCC-60A cells. Results of UT-SCC-16B, UT-SCC-14 and UT-SCC-15 regarding 
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Figure 25 Downstream effects of SATB1 knockdown on transcription rates of selected oncogenes: transcription rates of these 






The only exception was UT-SCC-42B cells which showed only HER3 downregulation upon SATB1 
knockdown while transcription rates of Heregulin A and B remained unchanged.  
Despite of lack of any cellular effect on UT-SCC-16B and UT-SCC-60A. transcription of HER3 and 
Heregulin A & B was downregulated upon SATB1 knockdown. Still effects were more or less consistent 
between all primary cell lines, indicating a direct or indirect involvement of SATB1 on the transcriptional 
regulation of HER3 and Heregulin A and B. HER1 and HER2 were also tested, with no effects on their 


























































































































































4.6.1 HER3 inhibition by Patritumab 
 
The attenuation in transcription rates of HER3 and Heregulin A and B upon SATB1 knockdown led us to 
check the effects of HER3 inhibition on transcription rate of SATB1. HER3 inhibition was achieved by a 
monoclonal antibody, Patritumab, developed by Daiichi, Japan. The aim was to see if HER3 receptor 
inhibition exerts growth inhibition and alters SATB1 expression. Cetuximab, for HER1 or EGFR, is a 
commercially available monoclonal antibody targeting EGFR and routinely prescribed by clinicians. 
Cetuximab was used as a positive control. Effects of HER1 and/or HER3 inhibition by Cetuximab and/or 
Patritumab, respectively, on cell growth were tested first. Growth inhibition was analysed by live cell count 
as described in the section 3.2.3 on page 59.  
Figure 27 on page 107 shows live cell counts 72 h post HER1 and/or HER3 inhibition. Cetuximab (Cetu) 
and Patritumab (patri) was used at a concentration of 100 µg per 1000 µl of complete media, alone and 
in combination. Growth inhibitory effects of cetuximab were observed in all seven primary cell lines, while 
patritumab was able to exert the effect in only two of the cell lines, UT-SCC-15 and UT-SCC-42B. A minor 
effect of patritumab was seen in UT-SCC-60A and UT-SCC-60B cells, while slightly increased 
proliferation was observed upon HER3 inhibition by Patritumab in UT-SCC-14 cells. The combination of 
cetuximab and patritumab exerted more profound anti-proliferative effects in all 7 primary cell lines.  
Like before, effects of HER1 and/or HER3 inhibition were also analysed in spheroid culture. As described 
in section 3.2.13.1 on page 75, two approaches were tested. In the pre-treatment approach, antibodies 
were administered to cells in monolayer prior to cultivation for 72 h and harvesting for spheroid formation. 
Figure 28 on page 109 shows the spheroid growth from pre-treated UT-SCC-42B in monolayer. Results 
of this assay for UT-SCC-5 are presented in the Supplementary figure 13 on page 145. The problem of 
dead but intact spheroids was encountered in UT-SCC-14, as before. Hence, live cell stain (calcein AM) 
was used. Supplementary figure 15 on page 147 shows merged images (fluorescent and bright field 
microscopy) of UT-SCC-14 cells for live cell stain 3 weeks after seeding them for spheroid formation. 
Severe growth inhibition in combination treatment, characterised by shrinking of the spheroids, in all the 





Another approach of using EGFR and/or HER3 inhibition after spheroid formation (treatment approach) 
was also tested for all the three primary cell lines (UT-SCC-5, UT-SCC-14 and UT-SCC-42B). For this, 
10 µg of each of the antibody, alone or in combination, was administered every second day for a period 
of 10 days, starting 48 h post seeding for spheroid formation. A minor reduction in the spheroid size of 
UT-SCC-5 for combination treatment (cetu 10 µg + patri 10 µg) was observed in 10 days.  Similar 
problem of dead but intact spheroid was encountered even for this assay for UT-SCC-14. Figure 29 on 
page 110 shows representative images of UT-SCC-42B with treatment approach.  
Combination of the inhibitory antibodies (cetu + patri) exerted strong growth inhibition in monolayer as 
well as in non-adherent culture setting. Interesting observations were made regarding spheroids of UT-
SCC-42B and UT-SCC-5 (Supplementary figure 14 on page 146). Few days after seeding them for 
spheroid formation, some cells got detached from the central spheroids. These detached cells started 
forming independent spheroids. This is clearly visible in the untreated group of both the cells. Formation 
of smaller spheroids is reduced in both treatment and pre-treated approach with single antibody (both 
cetuximab and patritumab). While in combination treatment, formation of additional spheroids is 










































































































































































































Figure 27 Live cell count 72 h after administration of cetuximab (EGFR) and/or patritumab (HER3): each antibody was administered 





observed in both treatment and pre-treated approach. This observation supports the inference of 
combination treatment being better than the use of single antibody.  
Effects of HER3 inhibition on transcription rates of SATB1 were analysed by q-RT-PCR. In this case, 
RPLP0, beta actin, glyceraldehyde 3 phosphate dehydrogenase (GAPDH) and succinate dehydrogenase 
(SHAD) were used as reference genes to relatively quantitate SATB1 transcription rate. mRNA levels, as 
reflected by the Ct values of each gene (reference genes and SATB1) analysed, were not altered upon 
HER3 inhibition. HER3 inhibition did not have any effect on the transcription rate of SATB1. The same 
was true for UT-SCC-42B and UT-SCC-15 cells which exhibited sensitivity towards HER3 inhibition by 
patritumab.  
However, combined treatment of HER1 and HER3 exerted an effect on the reference genes. The Ct 
values of SATB1 were relatively stable as compared to the Ct values of the reference genes. Unstable 
Ct values of the reference genes revealed increase in the transcription rate of SATB1 by the method of 
relative quantification (ΔΔCt). Since the final result contradicted the observation made during the analysis 
of the data, these set of results were not counted. The variation in the Ct values and relative levels of 
SATB1 mRNA levels are presented in the Supplementary figure 18, Supplementary figure 
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Figure 28 Representative images of spheroids (UT-SCC-42B) formed post HER1 and/or HER3 inhibition by Cetuximab and/or 
Patritumab, respectively: the same spheroid for each treatment group was photographed at the indicated time points. Scale bar 
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Figure 29 Treatment approach for spheroids of UT-SCC-42B cells for HER1 and/or HER3 inhibition by Cetuximab and/or 
Patritumab, respectively: 10 µg of antibody, alone or in combination, was administered a every second day. Spheroids were 
photographed before administering the antibodies. The same spheroid for each treatment group is photographed at the indicated 





4.7 In vivo anti-tumour effect of SATB1 knockdown  
 
Subcutaneously seeded xenograft tumours of UT-SCC-14 and UT-SCC-42B cells were selected for 
analysing in vivo anti-tumour effects of SATB1 knockdown. siSATB1 and siLuc3 (control) were delivered 
in vivo by complexing them with the polyethylenimine (PEI) F25-LMW at a mass ratio of 7.5:1 
(PEI : siRNA) [169].  
Mice with reasonably sized tumours (100-150 mm3) were selected for experimentation. Mice were 
randomly distributed in three groups. 7 mice were selected for the untreated group, 9 for siLuc3 and other 
9 for siSATB1 treatment. Nanocomplexes were prepared in advance, aliquoted and cryopreserved 
at -80 °C until use. Nanocomplexes were administered to the mice by intraperitoneal injection (ip) 
immediately after they were thawed at room temperature. Nanocomplexes once thawed were either used 
or discarded.  
Mice of the treatment group (siLuc3 and siSATB1) received nanoparticles every alternate day of the week 
for three weeks (total 10 doses). Each mouse of the respective group received 10 µg (UT-SCC-42B) and 
15 µg (UT-SCC-14) of siRNA in ~100 µl of the formulation for each dose. At the end of the treatment 
regimen, mice were anesthetized (isoflurane), killed by cervical dislocation and dissected for removing 
the tumours xenografts. Figure 30 on page 112 shows representative images of tumour bearing mice 
after cervical dislocation. Figure 30 also shows tumour growth kinetics of UT-SCC-14 and the end-point 
measurement of tumour volumes of UT-SCC-42B. As evident from Figure 30, anti-tumour effects were 
observed in both UT-SCC-14 and UT-SCC-42B xenografts in siSATB1 treated mice.  
To check for the knockdown at protein level, tumours were homogenized using an Ultra-Turrax 
homogenizer. The tumours were processed as described in section 3.2.15.1 on page 77. For western 
blot, two approaches were tried to see if siSATB1 treated mice had SATB1 knockdown. The first approach 
was to load each of the 25 samples of protein separately, to normalize for GAPDH as loading controls 
and quantitate the bands using image J. Second approach was to pool equal amounts of protein from 
each sample of a given group (9 for siLuc3/siSATB1 and 7 for untreated) into one sample and load the 
pooled sample onto SDS-PAGE. For pooled samples, normalization of the SATB1 bands was done for 





The results of the western blot with band quantification by image J are shown in the Figure 31 on page 
113. The results of the second approach of pooled sample is shown in Supplementary figure 22 on 
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Figure 30 Endpoint measurement of tumour volume (A) for UT-SCC-42B and growth kinetics of tumours of UT-SCC-14 (B): below 






In case of UT-SCC-14, bands of siLuc3 group and untreated were of same intensity. But in case of 
UT-SCC-42B, the band intensities of untreated were even lesser than siSATB1. Tumours of the untreated 
group of UT-SCC-42B grew very fast and were quite large. Upon dissection of the tumours, it was 
revealed that most of the tumours were necrotic from inside. This might be the reason for band intensity 
to be weaker in untreated group than in siSATB1 samples.  
 
 
Figure 31 Western blot to detect SATB1 protein levels from in vivo xenograft tumours of UT-SCC-42B and UT-SCC-14: all the 25 
samples of each of the experiment were loaded separately and blotted. One of the representative blots is shown here. 32 µg of 
each of the protein lysate was loaded onto the SDS-PAGE. Graph next to the blots are respective band intensity quantified for all 






























































































5.1 Variation in SATB1 mRNA levels 
 
SATB1 has been studied extensively for its role in cancer progression in various cancers. The molecular 
and the cellular effects analysed in this study are first of its kind with respect to HNSCC. Also, primary 
cell lines were used as models to study these effects. Primary cell lines, although having certain 
drawbacks, represent the in vivo situation better than established cell lines. A major drawback of primary 
cell lines is their unstable transcriptome and up to some extent also their unstable genome, which tends 
to change 1) after several (12 to 16) passages, 2) upon reaching confluency during culture and 3) when 
culture conditions change drastically. Thus, due care was taken throughout the project that the cells never 
became over-confluent and that new cells were thawed from cryopreserved stocks every 6 weeks.  
15 different primary cell lines were analysed for SATB1 mRNA levels. There were others (UT-SCC-26A, 
-26B and -24A) which were also procured but their inability to grow sufficiently led to their exclusion from 
the study. Relative quantification of the SATB1 mRNA levels was done using q-RT-PCR. RPLP0 and 
beta-actin were initially used as the reference genes. The trend of SATB1 mRNA levels among the 
primary cell lines was the same for both the reference genes. However, from the experience of other 
researchers, SATB1 knockdown changes the cell morphology from long spindle shaped cells to round 
button shaped cells. Since the shape of the cell was affected as reported by some studies [144, 148, 170] 
and also evident during our experiments, beta actin as one of the components of the cytoskeleton, was 
dropped from the list of reference genes. Transcription of RPLP0 was not affected upon SATB1 
knockdown or cell confluency. Hence, RPLP0 was selected for all relative quantifications of the mRNAs 
using quantitative PCR and the data were processed by the method of ΔΔCt. 
In HNSCC, SATB1 protein is reported to be completely absent in the normal mucosa adjacent to the 
tumour [160–162]. Its expression increases with tumour progression and de-differentiation of the tumour 
cells. SATB1 mRNA levels were found to be present in all the cell lines obtained for this work. This is in 
line with the published reports that SATB1 is abnormally expressed in tumour cells. 
Tumour cells isolated from tongue, larynx, pharynx, tonsils and floor of the mouth were included in the 
initial selection. As evident from Figure 7 on page 81, SATB1 mRNA levels varied. There was no 
association of SATB1 mRNA levels with the location from where the tumour cells were isolated. There 





(UT-SCC-14) expressing cell line in this study. Interestingly, both extremes were isolated from the 
squamous cell carcinoma developed on the tongue.   
TNM (Tumour nodules, lymph Node invasion and Metastasis) status of the tumour progression has been 
studied with respect to SATB1 expression levels along with other biological and non-biological factors. In 
2016, Huang et al reported a positive correlation of the SATB1 expression with TNM status in lung 
adenocarcinoma. They found an inverse correlation between SATB1 and the differentiation grade [171]. 
In 2008, Han et al showed a positive correlation of SATB1 expression levels with lymph node invasion 
and an inverse correlation with the differentiation grade with high significance in breast cancer biopsies 
[148]. In 2013, Zhang et al published a similar conclusion for the SATB1 correlation with TNM staging for 
colorectal carcinoma. Additionally, they also demonstrated by immunohistochemical staining of SATB1 
in tumour biopsies that SATB1 positives cells were concentrated more towards the core than in the 
periphery of the tumour [172]. Similar conclusions were reported for HNSCC by Zhao et al in 2010 
(laryngeal squamous cell carcinoma) [160], Deng et al in 2014 (nasopharyngeal carcinoma) [161] and 
Shen et al in 2013 (Nasopharyngeal carcinoma) [164].  
Establishing a correlation of SATB1 levels (mRNA or protein) with staging of the disease was not possible 
in this work because of the small number of samples for comparison. Still, a comparison of SATB1 mRNA 
levels with lymph node invasion and TNM status was attempted. Lymph node invasion was reported in 
the UT-SCC-74 and the UT-SCC-14 patient which had lowest and highest levels of SATB1 mRNA, 
respectively, in their tumour cells. When the list of 15 primary cell lines was divided into three groups as 
low, medium and high SATB1 mRNA levels, lymph node invasion was reported in all the three groups: 
low expressing cell lines UT-SCC-74A, -60B and -26A; medium expressing cell lines UT-SCC-60A, -42A, 
-74B, -5 and -31 as well as in high expressing cell line UT-SCC-14.  
Based on the published literature on the correlation of SATB1 with differentiation grade of tumour cells, 
it was hypothesized that the tumour cells isolated from primary tumours (moderately differentiated, A) 
should have lower SATB1 mRNA levels than the poorly differentiated or undifferentiated tumour cells 
from their B counterpart. As shown in Figure 8 on page 82, A and B pairs of four patients (UT-SCC-16, 
-42, -60 and -74) were included in this experiment. There was no strict pattern of relative SATB1 mRNA 
levels among these pairs. UT-SCC-42 and UT-SCC-74 were in line with the expectation of SATB1 mRNA 
levels being higher in B compared to SATB1 counterpart. In contrast, the other two, UT-SCC-16 and -60 






As explained above, we tried to find if SATB1 mRNA levels had any concurrence with the staging of the 
disease, primary tumour cells versus metastatic/recurrent tumour cells and location. In all the cases, the 
results on these primary cell lines revealed no association. It depended more on the individuals rather 
than these factors.  
The conventional approach of the selection of cell lines for deeper analysis has been comparing 
molecular and cellular effects amongst cell lines with highest and lowest levels of SATB1, respectively. 
Altering SATB1 mRNA levels, either by knockdown/knockout or by ectopic overexpression, was done to 
study the effect of the protein on cellular and molecular processes. Han et al for breast cancer [148], Tu 
et al for liver cancer [145] and Frömberg et al for colorectal carcinoma [128] employed this approach for 
analysing molecular and cellular processes being influenced by SATB1. The selection of primary cell 
lines for this study was independent on the initial SATB1 mRNA levels. The selection criteria relied mainly 
on the growth inhibitory effects observed upon transient knockdown of SATB1. Fortunately, the final list 
of the candidates consisted of 7 primary cell lines which had relatively low (UT-SCC-15, UT-SCC-60B 
and UT-SCC-16B), medium (UT-SCC-60A and UT-SCC-5) and high (UT-SCC-14 and UT-SCC-42B) 
levels of SATB1 mRNA, respectively.  
As explained in the Methods and the Results section, WST-1 assays failed to adequately show the actual 
degree of anti-proliferation upon SATB1 knockdown as seen under the microscope. One possible 
explanation could be that the WST-1 reagent indirectly estimates the cell density. It measures the 
metabolic rate of the cells. It is possible that upon SATB1 knockdown, the cell was under stress and by 
attempting to survive, metabolism of the cell was boosted to prevent cell death. High metabolic activities 
for survival might thus increase WST-1 absorbance, indicating false-high cell density.  
The degree of growth inhibition varied among the 7 primary cell lines. UT-SCC-60A and UT-SCC-16B 
showed weakest effects of SATB1 knockdown on its proliferation rate. UT-SCC-14 on the other side 
exhibited a very strong and instant effect, as early as 48 to 72 h. UT-SCC-5 and UT-SCC-15 showed 
reduced cell densities in siSATB1 transfected wells at 72 h while UT-SCC-42B and UT-SCC-60B showed 
an effect at 96 h. Apart from the time points, the severity of growth inhibition also varied. These variations 
led us to explore if the initial SATB2 mRNA levels were associated with the degree of anti-proliferation 
upon SATB1 knockdown. Initial SATB2 mRNA levels were analysed but there was no association with 
the magnitude of growth inhibition and SATB2 mRNA levels. This observation was in line with the 
published reports on the absence of a correlation of SATB1 and SATB2 mRNA/protein levels for breast 





Another important aspect that needs discussion is the precise location of SATB1 in the cell. There have 
been reports on the presence of SATB1, and also SATB2, in the cytoplasm. The location (cytoplasm or 
nucleus) of the protein correlates with prognosis in case of HNSCC. The exact words from these papers 
are quoted: 1) ‘As SATB1 translocates to the nuclei upon activation, we introduced a SATB1 
nuclear/cytoplasmic ratio of histoscore as a biomarker. This ratio significantly correlated with patients’ 
prognosis’ (oral squamous cell carcinoma, SATB1 antibody from Gentex, clone not specified) [162]; 2) 
‘In the majority of samples tested, SATB2 was detected in both nuclear and cytoplasmic compartments 
of the tumour cells’ (HNSCC, SATB2 by Abcam ab34735 and SATB1 by BD transduction laboratories 
NJ) [165]; 3) ‘Nuclear immunoreactivity of SATB1 was elevated in clear cell renal carcinoma while its 
cytoplasmic expression was decreased in normal cells’ ( SATB1 by GeneTex EPR 3951) [173]. The same 
group (Kowalczyk et al) also demonstrated cytoplasmic localization of SATB1 in colorectal carcinoma 
tumour samples by IHC [167]. All these was performed on paraffin embedded paraformaldehyde fixed 
tissue samples. 
Despite these reports, there has been no evidential report stating the reason for a cytoplasmic presence 
of SATB1 or SATB2. Nor is any post-translational modification proven which would prevent or cause the 
nuclear localization of SATB1.  
To clarify this issue of location, we performed immunocytochemical staining (fluorescence) in all 7 primary 
cell lines. Using confocal microscopy, SATB1 was found to be exclusively located in the nucleus. It was 
not detected in the cytoplasm in any of the primary cell lines analysed. An important aspect that requires 
attention is the protocol for the immunocytochemistry. Three variations were tested (with and without 
antigen retrieval step by two different antigen retrieval buffers: citrate buffer (pH 6.0) and urea buffer (pH 
9.5)). The staining of SATB1 was better with antigen retrieval step by citrate buffer as compared to urea 
buffer. In case of samples without antigen retrieval step, the staining was mostly in the cytoplasm instead 
of the nucleus. Thus, antigen retrieval with citrate buffer was performed in all preceding experiments. 
This variation might explain that if the process of antigen retrieval is not done at all or insufficiently to 
expose the epitope or increase the permeability of the nuclear membrane, the staining (IHC/ICC) of 
SATB1 might result in non-specific binding to some other protein in the cytoplasm. This is inferred 
because the protein will not localize into the nucleus because of antigen retrieval step. Thus, without 
antigen retrieval step if a positive stain is visible in the cytoplasm, it could be non-specific binding of the 
primary antibody. This might be one explanation for reports of cytoplasmic presence of SATB1 or SATB2 






5.2 Anti-proliferation effect 
 
Apart from growth inhibition studied in monolayer culture, there are other assays routinely tested for 
analysing the growth behaviour of primary and/or established cell lines in vitro. Soft-agar assay, colony 
assay, spheroid assay are some of these assays. The ability to form colonies in soft agar assay was 
tested for all 7 primary cell lines. However, none of them were able to form colonies and grow in soft agar 
assay. KB, an established cell line, was tested in parallel with the primary cell lines as a positive control. 
KB cells formed very nice colonies in the soft agar assay. This ruled out the possibility of any technical 
error in the protocol or sub-optimal access to the nutrition (growth media or serum amounts).  
Colony assay (anchorage dependent) and spheroid assay (anchorage independent) were tested for the 
seven primary cell lines. The colony assay analyses the ability of the cells to form colonies after the 
treatment (SATB1 knockdown in this case). Although the test conditions (monolayer on plastic and culture 
media) were very much like anti-proliferation assay, this assay tests the ability of the cell to establish a 
colony in isolation. The results were obtained 10 days post transfection (3 days post transfection + 5 to 
7 days for colony assay). A gap of 8 to 10 days is a huge gap for transient knockdown.  
Results of the colony assay indicated that colony forming capabilities of all five primary cell lines was 
hampered upon SATB1 knockdown. However, the aspect of recovery from the knockdown also gave 
astounding results. UT-SCC-42B and UT-SCC-14 which suffered heavily upon SATB1 knockdown were 
able to recover very well from the knockdown in the colony assay. For growth inhibition assay, only ~33% 
(UT-SCC-14) and ~53% (UT-SCC-42B) of the cells were alive post SATB1 knockdown (96 h). Whereas, 
the colony count of UT-SCC-14 and UT-SCC-42B of siSATB1 transfected cells was ~69% and ~66%, 
respectively, of the untreated cells. The effect of SATB1 knockdown was long lasting for other primary 
cell lines (UT-SCC-5, UT-SCC-15 and UT-SCC-60B). As expected, no effect on colony forming 
capabilities were reported in UT-SCC-16B and UT-SCC-60A.  
One possible explanation for better recovery of UT-SCC-14 and UT-SCC-42B from the knockdown is 
their fast growth rate. They were among the fast-growing cell lines (Table 2 on page 59). Faster cell cycle 
helped them to dilute the siRNA with each cell division. Thus, diluting the knockdown with steady rise in 
the SATB1 mRNA levels may have helped them to recover from the knockdown. Primary cell lines which 
showed a maximum effect of SATB1 knockdown on colony forming capabilities were UT-SCC-60B, UT-
SCC-5 and UT-SCC-15. All of them had moderate to slow growth rate which might be the reason for their 





5.2.1 FLAVINO assay 
 
The FLAVINO assay is simply a colony formation assay established for tumour samples obtained from 
the operation theatre of the Department of Otorhinolaryngology, Head and Neck Surgery, University Clinic 
Leipzig. This assay is designed for testing the effect of routinely used chemotherapeutic drugs on colony 
forming ability of cancerous cells from the tumour biopsies.  
There were some changes introduced to the original protocol to fit with the transfection protocol. The 
original protocol suggests the addition of the chemotherapeutic drugs immediately after seeding the cells 
into the plates. Instead, cells were allowed to grow for at least 72 h before transfecting them. The reason 
for waiting was that the transfection protocol, as given by the manufacturer (INTERFERin, Polyplus), is 
different for adherent cells and cells in suspension. Hence, time was given to the tumour cells to adhere 
onto the bottom of the plates and to start proliferation. The second reason for waiting at least 72 h after 
seeding was to see if there are distinguishable tumour cell colonies. This was done by carefully examining 
wells under the light microscope. Based on the growth characteristics (shape, nucleus size, growing in a 
bunch etc) it was decided whether to use the reagents (siRNAs and INTERFERin) for the plate or not. If 
the plate did not have any colony forming tumour cells, the assay for that patient sample was aborted. 
This was rarely the case. Even in case of slightest doubt, the assay was performed. A negative plate 
(plate without any tumour cells or a growing microbial contamination) was discarded when there were no 
live or colony forming cells found in at least 5 randomly chosen wells of the plate. A negative plate may 
have lots of non-proliferative live cells with different shapes and sizes but none of them would form a 
colony or a clump of cells. In such cases the cells do not adhere to the floor of the wells and stay as a 
single cell. To eradicate any experimental error and get hold of the technique, initially some tumour 
samples were tested for their sensitivity towards Simvastatin (data not shown) [174]. After practising the 
protocol on few samples with Simvastatin treatment, new samples received were tested for siSATB1 
transfection. 
Since the primary cell lines were easy to transfect, it was assumed that tumour cells from the biopsies 
would be easy to transfect. 96 h post transfection, the plate was processed for immunocytochemical 
staining (fluorescence). From 22 plates analysed for transfection, 7 plates were positive for colony 
forming tumour cells.  
In most of the cases, tumour cells did not grow, mainly because the patient had received chemotherapy 
which killed the majority of the dividing cells. Another explanation for the poor growth of the tumour cells 





cell death. Tumour micro-environment is hypoxic while tissue culture conditions were normoxic which 
created oxidative stress [175]. In most cases, when the total incubation period (prior to and during the 
treatment) lasted for more than a week, the wells often had elongated cells growing around the tumour 
cell colonies. These were presumably Cancer Associated Fibroblasts (CAF). Tumour cells which 
differentiate from epithelial to mesenchymal type, also exhibit a similar morphology [176]. However, it 
was not analysed by any means if they were CAF or tumour initiating cells with mesenchymal properties.  
As evident from the colony count, siSATB1 transfection did not exert any negative impact on the colony 
forming ability of the tumour cells. There could be several reasons for this result. Firstly, the wells were 
seeded with a mixture of cells obtained after enzymatic digestion of the tumour. This mixture contained 
tumour infiltrating lymphocytes, other immune cells, normal mucosa, fibroblast (CAF) along with the 
tumour cells. So far the observation was that the CAF were the fastest growing cells in many of the tumour 
samples. They grew faster than the tumour cells in most of the cases. These growing cells tend to absorb 
the nanoparticles of the transfecting reagent and thereby make the siRNA scarcely available for the 
tumour cells which began proliferation only after a lag phase of adaptation. The second reason could be 
insufficient knockdown. Before finalizing the transfection protocol for the FLAVINO assay, one tumour 
sample which had actively growing tumour cells was tested for knockdown efficiency. ~70% knockdown 
of SATB1 at mRNA level was detected 96 h post transfection. The knockdown of SATB1 did not exert 
any anti-proliferative effect on the cells of this tumour sample. After this experiment, the knockdown 
efficiency was never tested for any other samples to cross check if the decided concentration of siRNA 
and amounts of INTERFERin were sufficient to achieve a knockdown of SATB1. The third reason could 
be the relevance of SATB1 in tumour progression in these samples. If we compare the ratio with the 
primary cell lines tested, only 33% (5 of the 15) primary cell lines showed a negative impact of SATB1 
knockdown on their proliferation rate. The fourth reason could be proliferation of the tumour cells was too 
low to create an observable impact of the SATB1 knockdown. Lastly, whether SATB1 was expressed or 
not was unknown. If SATB1 was not expressed at all, introducing siSATB1 in the tumour cells will not 
make any difference on its colony forming capabilities.  
For the stated reasons, the FLAVINO assay, well established and successful for routinely used 
chemotherapeutic drugs [177, 178], might not be optimal for therapies which deal with the transcriptome 
of the cells. An additional step of analysing SATB1 mRNA/protein level in comparison with the adjacent 






5.2.2 Spheroid assay 
 
From 7 primary cell lines, only four of them were able to form spheroids, UT-SCC-5, UT-SCC-14, UT-
SCC-42B and UT-SCC-16B. In the spheroid assay, results were clearly visible and reproducible for UT-
SCC-42B, UT-SCC-14 and UT-SCC-5. The size of the spheroids of siSATB1 transfected cells shrinked 
drastically in UT-SCC-42B. In case of UT-SCC-5, the spheroids were smaller in size. The spheroids did 
not grow much but the effect on spheroids of cells transfected with siSATB1 was still noticeable. In case 
of UT-SCC-16B, the spheroids were formed and alive (confirmed by positive Calcein AM stain) but were 
dormant. The cells neither proliferated nor died. This was observed 3 weeks after seeding them for 
spheroid formation. Dormant spheroids of the untreated group ruled out the possibility of a negative 
impact of transfection on UT-SCC-16B cells.  
The story with the spheroids of UT-SCC-14 opened a new chapter of live and dead stain in spheroids. 
During the first spheroid assay experimenting of UT-SCC-14 cells, the spheroids of siSATB1 transfected 
cells did not show any difference in the size. However, specific knockdown group spheroids (siSATB1) 
had lot of dead cell debris around them. On increasing the brightness of the white light under the 
microscope, it looked like an intact and alive spheroid in the centre, surrounded by dead cells. The size 
of the core spheroid was considerably smaller. Live cell staining by Calcein AM revealed spheroids of the 
siSATB1 group consisted of more than 95% dead cells. Spheroids of negative control transfection and 
the untreated groups showed strong positive stain, indicating live spheroids. To clear the doubt if this was 
due to reduced penetration of the live cell stain, live and dead stain of the spheroids was performed. If 
propidium iodide and Hoechst 33342 can penetrate, Calcein AM should be able to penetrate deep inside 
the spheroids as well. Assuming this, it became clear that the siSATB1 group spheroids consisted of 
mostly dead cells which appeared dark red (propidium iodide stain) and some nuclei stained blue by 
Hoechst. Parallel to the live/dead stain, the spheroids were seeded in a fresh 96 well flat bottom plate. 
Tumour cells from the spheroids of untreated and control transfection started growing on the adherent 
surface within 2 days. The spheroids of siSATB1 did not yield any live cell that could grow on the adherent 
surface. This proved that the spheroids of siSATB1 transfected cells were completely dead and that there 
was no technical issue with the protocol or penetration of the dye.  
Important outcome of this observation was that the cells of UT-SCC-42B and UT-SCC-14 could recover 
from the knockdown when grown in monolayer (colony formation assay). But they were unable to dilute 
the knockdown in spheroid assay. Lack of adherent culture condition retarded the cell cycle progression 





about the anti-proliferation effect of any treatment. Tumour cells, when cultured on plastic adherent 
surface, grow very well. Certainly, their proliferation rate is much higher compared to the actual in vivo 
situation. This aberrantly high proliferation rate is reduced when cells are grown under non-adherent 
culture condition, like in spheroid assay. Thus, with the help of such assays (spheroid or soft agar assay) 
where cells are cultured in non-adherent conditions, the actual tumour cell sensitivity for the therapeutic 
agents should be tested more accurately.  
 
5.3 Apoptosis and Cell cycle progression rate 
 
Reports of SATB1 governing the expression of apoptosis related genes have been published in case of 
colorectal carcinoma (Bcl-xL), glioma (Bcl2, Bax, Caspase 9) and osteosarcoma (Bcl2 and Survivin) 
[121]. Thus, from the literature it was clear that by depleting SATB1, apoptosis should be induced. 
Caspase 3 and Caspase 7, which are downstream effector caspases of the apoptotic pathway, were 
chosen for the analysis. Triggering of intrinsic or extrinsic pathway later activates both caspase 3 and 7. 
Thus, selection of these two effector caspases would cover both, intrinsic and extrinsic pathways of 
apoptosis.  
As expected, Caspase 3/7 activation was profound in all 5 primary cell lines. Caspase 3/7 activation was 
strongest in case of UT-SCC-14 (4 to 5-fold of untreated). Notably, there was only very minor increment 
in caspase 3/7 activation in the cells of control transfection. These results indicate that the transfection 
conditions were optimum and cell death was induced purely by apoptosis upon SATB1 knockdown. There 
was no non-specific cytotoxicity experienced by the cells upon transfection. It was negligible in UT-SCC-
16B and UT-SCC-60A. 
If the cells are not proliferating or dying, there could be three possible reasons: 1) induction of apoptotic 
pathways; 2) absence of stimulation of cell cycle progression and 3) both, induction of apoptosis and 
halted cell cycle progression. Exploring if the cell cycle progression rate is affected by SATB1 knockdown 
was the next step. In the literature, SATB1 has been described to be able to govern directly or indirectly 
the expressions of cell cycle related genes, mainly Cyclin B1, Cyclin D1, Cyclin E1, Cyclin dependent 
kinase 4 (CDK4), cell division cycle 6 (CDC6), proliferating cell nuclear antigen (PCNA), budding 
uninhibited by benzimidazoles 1 homolog (BUB1) etc. Apart from this, SATB1 also regulates the 
expression of other signalling molecules (receptors, secondary messengers, transcription factors) which 





In UT-SCC-15 and UT-SCC-42B cells, SATB1 knockdown exhibited maximum effect on cell cycle 
progression rate. There was a difference of almost 24% (UT-SCC-15) and 20% (UT-SCC-42B) among 
siSATB1 and siLuc3 transfected cells. In contrast, SATB1 knockdown exerted the strongest effect on 
growth inhibition in UT-SCC-14 among these 7 primary cell lines and Caspase 3/7 activation was highest 
among all the primary cell lines. However, SATB1 knockdown did not exert effects of similar magnitude 
on the cell cycle progression rate. 15.4% lesser cells reached the G2/M phase upon SATB1 knockdown. 
Something interesting about UT-SCC-14 was distinct rise in the accumulation of cells in the S phase 
(~10%) (refer to the Table 10 on page 102). A possible explanation for this result could be that the 
transition from S phase to G2/M was hampered while the transition rate from G1 phase to S phase was 
lesser affected upon SATB1 knockdown. This resulted in increased accumulation of cells in S phase. In 
contrast, in case of UT-SCC-42B and UT-SCC-15, the transition of G1 to S phase might also be affected 
along with S to G2/M phase. Because of this, there was no noteworthy rise in the percentage of population 
in the S phase upon SATB1 knockdown. Although not confirmed by analysing the molecular markers, the 
conclusion that SATB1 depletion affects the rate of both G1 to S phase and S to G2/M phase transitions 
may hold true, at least for UT-SCC-42B and UT-SCC-15. UT-SCC-16B and UT-SCC-60A did not show 
any effect on their cell cycle rate, thus indicating major differences between the cell lines.  
Surprising was the absence of any effect on cell cycle progression rate in case of UT-SCC-5 and UT-
SCC-60B. These two primary cell lines exhibited good Caspase 3/7 activation upon SATB1 knockdown 
which also resulted in good growth inhibition both in monolayer and non-adherent culture condition. Upon 
repetition of the experiments, same results were reproduced to finally conclude absence of any effect of 
SATB1 knockdown on their cell cycle progression rate.   
Inference from these experiments was that reduced number of viable cells in UT-SCC-5 and 
UT-SCC-60B were primarily because of induction of apoptosis, while in case of UT-SCC-15, UT-SCC-
42B and UT-SCC-14, it was a combination of apoptosis and retardation of cell cycle progression.  
 
5.4 Effect on the transcription of oncogenes and HER3 inhibition by 
Patritumab 
 
The very first report of involvement of SATB1 in tumour progression demonstrated how its depletion and 
ectopic overexpression regulated transcription of hundreds of genes. These genes were mostly 
associated with the processes like cell cycle, EMT, cell-cell adhesion, receptors and mediators of 





reported similar findings. A molecular analysis of this kind was lacking in case of HNSCC, especially with 
the primary cell lines. For this project, the focus was on the transcriptional regulation of SATB1 on 
selected oncogenes.  
The most favoured primary cell line from this short list was UT-SCC-42B. UT-SCC-42B demonstrated 
good growth inhibition, both in adherent and non-adherent condition, activation of Caspase 3/7 and 
retardation of cell cycle progression upon SATB1 knockdown. Besides, by this time, it was also selected 
for the in vivo anti-tumour study as it formed good xenograft tumours with favourable growth kinetics. 
However, little effects were observed. In contrast, in UT-SCC-60B some differences were found. For 
example, effect on EMT markers was observed, although the data did not achieve significance. The 
reduction in the transcription rates of N-cadherin and Beta catenin was reproducible. Unaltered E-
cadherin transcription with minor de-escalation in the transcription rate of N-cadherin and beta catenin 
indicated that SATB1 knockdown negatively affects the process of epithelial to mesenchymal transition.  
Lesser effects were expected from UT-SCC-16B and UT-SCC-60A. But surprisingly, the transcription of 
the EMT markers was altered significantly upon SATB1 knockdown. A reduction in the transcription rate 
of N-cadherin and beta catenin was found also in these two cell lines. Additionally, a downregulation in 
the transcription rate of MMP7 was observed for these two primary cell lines.  
A lack of any effect on Cyclin D1 and Pim1 transcription was observed in all the primary cell lines. 
Cyclin B1 levels were rather increased. This does not fit to the cellular effects observed upon SATB1 
knockdown in UT-SCC-42B and draws attention to the process of post transcriptional regulation of protein 
expression. Although the mRNA is transcribed, it does not necessarily mean that the protein is expressed. 
At any given time point, there are several non-coding RNAs transcribed in the cell which have numerous 
functions. Some of such non-coding genes produce miRNAs, among other classes of non-coding RNAs, 
which can work on both transcriptional and translational level. They bind to the transcribing mRNA and 
stall the process of transcription [179]. Post transcriptionally, mature miRNA binds to the target mRNA 
either to stop the process of translation or degrade the mRNA with the help of RISC. The q-RT-PCR 
method used in this project detects the level of mRNA produced by the cell. In UT-SCC-42B, SATB1 
knockdown showed an effect on the cell cycle progression rate, particularly in the transition from S phase 
to the G2/M phase. Cyclin B1 is the responsible cyclin for this transition. Two possibilities could explain 
this result. First, certain miRNAs are transcribed upon SATB1 knockdown which halt the process of 
translation of Cyclin B1. Thus, mRNA levels in the cytoplasm increases but required protein is not 
produced which results in cellular effect of reduced progression into the G2/M phase. Second, even if 





consortium to carry out such complex processes. The absence or reduced amounts of these associated 
proteins (for example, Cyclin dependent kinase 1 (CDK1) or 13s Condensin) or increased amounts of 
inhibitors (like Cyclin B1 interacting protein 1) could regulate the transition of S to G2/M phase. 
mRNA/protein levels of these genes were not analysed in this work.   
The only gene whose transcription rate was attenuated significantly in all primary cell lines was HER3. 
Along with HER3, ligands like Heregulin alpha and beta also suffered downregulation in their transcription 
rate. Except UT-SCC-42B, all other primary cell lines showed an effect on these three mRNAs. An effect 
on transcription rate of HER3 and ligands like Heregulin A and B indicates the direct involvement of 
SATB1 in the regulation of the process of autocrine signalling. Autocrine signalling is one of the important 
characteristics of tumour cells which helps in sustaining proliferation of tumour cells in absence or scarcity 
of growth signals. Modern therapeutic strategies employ the idea of targeting such functions of tumour 
cells in combination with immunotherapy. These approaches are being tested at different phases which 
ultimately should help in reducing chemo- and radio-therapy intervention and improve progression free 
survival along with good quality of life for the patients [56].  
SATB1 knockdown reduced the transcription of HER3 receptor. Conversely, it was also of interest if 
inhibiting HER3 activation reduces SATB1 transcription. The main aim of including Patritumab in this 
study was to check the effect of HER3 inhibition on SATB1 transcription rates. HER3 inhibition alone did 
not produce any effect on the SATB1 transcription rate in any of the primary cell lines. No effect on the 
reference gene or SATB1 mRNA levels was observed upon HER3 inhibition. 
However, the combined inhibition by cetuximab and patritumab seemed to show a strong upregulation of 
SATB1 mRNA levels in all the primary cell lines except UT-SCC-5 and UT-SCC-15. Upon careful 
examination of the SATB1 Ct values, it was realised that the Ct values of SATB1 were almost same with 
a variation of ± 1 unit. It was the variation in the reference gene Ct values (RPLP0) which caused the 
seeming upregulation of SATB1 mRNA levels. Different reference genes like Glyceraldehyde 3 
phosphate dehydrogenase (GAPDH), succinate dehydrogenase (SHAD) and beta actin were tested to 
reveal instability in most of the reference genes. On the contrary, SATB1 Ct values were more stable 
than the reference genes. (Supplementary figure 19,Supplementary figure 20, and Supplementary 
figure 21 on page 151) 
This led us to conclude that it will not be possible to reliably determine the SATB1 mRNA levels using 
current methods of quantification. Perhaps testing the effect on SATB1 protein level would have given us 





An explanation for the increment in the Ct values of reference genes, which indicates decreased 
transcription, could be that HER1 and HER3 inhibition has pleotropic effects which might also affect cell 
metabolism. These pathways push the cell towards proliferation, a process that requires high metabolic 
activities.  Our selection of reference genes was quite wide (RPLP0 is for protein translation, GAPDH is 
for glycolysis, SHAD is for Krebs cycle and beta actin is one of the components of the cytoskeleton). The 
absence of signals that trigger the process of proliferation and growth might affect the transcriptional rate 
of these mRNAs.  
Downstream signalling pathways of EGFR and HER3 include the PI3K/AKT/mTOR pathway. This 
pathway is known for its effect on the process of glycolysis, cell growth, protein production, proliferation, 
differentiation etc [180, 181]. It is perhaps because of this effect that the transcription rates of the 
reference genes (RPLP0, GAPDH, SHAD or even Beta actin) are affected. mTOR phosphorylates 
p70S6k which will phosphorylate S6 which is a structural protein of the 40S subunit of the cytoplasmic 
ribosomes for protein translation [182]. RPLP0 is the component of the 60S subunit. The absence of a 
growth signal or mitogens will cause growth arrest and dephosphorylation of S6, thus, reducing protein 
translation and also curb its related machinery. This is one possible explanation how RPLP0 might be 
affected upon inhibition of both HER1 and HER3.  
 
5.5 In vivo anti-tumour effect 
 
The first step for investigating in vivo anti-tumour effects of SATB1 knockdown was to screen for suitable 
primary cell lines which could form subcutaneous xenograft tumours with favourable growth kinetics. Six 
primary cell lines were tested for this. UT-SCC-15 was not tested for its tumour forming capability since 
the growth rate of these primary cell line was very slow. If UT-SCC-15 did form xenograft tumours, then 
growth kinetics of the tumour as well as culturing enough cells to inject 25 mice with 10 million cells per 
mouse (5 million for each, right and left flank) would not be feasible. Except UT-SCC-60B & UT-SCC-
60A, all cell lines were able to form xenograft tumours. Coincidently or not, these were also the three 
primary cell lines which did not form spheroids. Molecular mechanisms for failure to form spheroids were 
not investigated. However, if there is correlation between spheroids and tumour forming capabilities, we 
could possibly have a protocol for screening cell lines for their potential to form xenograft tumours by 
checking their spheroid forming abilities and its molecular markers.  
UT-SCC-5 and UT-SCC-16B cells did form tumours, but the tumours took more than 3 to 4 weeks to 





did not grow for a very long period of time, spanning another 3 to 4 weeks. The growth kinetics was not 
favourable and hence they were dropped from the list.  
UT-SCC-42B and UT-SCC-14 formed xenograft tumours within a period of 7 to 10 days. Furthermore, 
the tumours also showed a favourable growth kinetics over a period of 2 to 3 weeks which fitted very well 
in the time frame of the in vivo anti-tumour experiments designed in our lab.  
As revealed by the tumour volume analysis of both UT-SCC-14 and UT-SCC-42B, there was a clear 
anti-tumour effect in the group of siSATB1 treated mice. During dissection, it was noticed (not 
documented) that most of the tumours were well vascularized, even in case of siSATB1 mice. Most of 
the tumours of the untreated group of UT-SCC-42B were necrotic from the inside. Very fast growth and 
scarcity of nutrition supply might have caused necrosis of the core which could provide nutrition to the 
cells growing on the periphery. In case of UT-SCC-14, all tumours from all groups were intact and formed 
solid tumours. Throughout the treatment of both UT-SCC-14 and UT-SCC-42B xenograft tumours (total 
36 mice in siLuc3/siSATB1 groups), none of the animal exhibited any signs of discomfort or illness.  
The literature review of studies which analysed in vivo anti-tumour effects of SATB1 in xenograft model 
reveals that most of the studies drew conclusions based on the tumour volume and tumour weight. 
Altering SATB1 protein level exerted respective effects on tumour growth as well as metastatic ability. 
The method of analysis in most of the studies on the role of SATB1 in tumour progression and metastatic 
ability was a) ectopic overexpression of SATB1 in cell lines with very low SATB1 expression and b) 
knockdown of SATB1 in cell lines with high expression of SATB1. This method was employed for 
evaluating SATB1 role in vivo for breast cancer [183–185], colorectal cancer [122, 128, 135], glioma 
[137], liver cancer [145], pancreatic cancer [186] and prostate cancer [187, 188]. Apart from these, only 
Peng et al (gastric cancer) [189], Frömberg et al (glioma) [123] and Chu et al (glioma) [188] reported anti-
tumour effect by creating SATB1 knockdown in vivo by delivering siRNA/shRNA via nanoparticles. From 
the extensive list of in vivo studies, only 6 of them reported alteration of SATB1 protein and/or mRNA 
levels. From these 6 studies, only Chu et al for glioma [188] demonstrated knockdown (protein and 
mRNA) achieved in vivo via plasmid delivery (shRNA). The other 5 studies proved that the cell lines 
transfected for SATB1 ectopic over-expression or knockdown prior to the subcutaneous implantation 
sustained the respective alteration at protein levels till the end of the experiment. Thus, it was clear that 
determining SATB1 knockdown in vivo was not a common practice. Most of the conclusions were drawn 
from determining the tumour volume, end-point tumour mass post explantation and metastatic potential 





of SATB1 protein/mRNA analysis from xenograft tumour models could be the inability of the 
antibodies/primers to differentiate between mouse and human SATB1 protein/mRNA. 
From the experiences in a variety of tumour entities and on different target genes analysed in PEI 
F25-LMW studies, knockdown was evident only at protein levels and not on mRNA levels. Perhaps siRNA 
in vivo manages to stop the process of translation but not degrade the mRNA. Moreover, if the primers 
do not have sequence specificity for human mRNA, it can also detect target gene expression in the blood 
cells and the connective tissues of the mice which contaminate the xenograft tumour during explantation. 
BLAST analysis of the SATB1 q-RT-PCR primers used in this study revealed that they could detect the 
mouse SATB1 transcript with 100% identity. 
For these reasons, only protein levels of SATB1 were determined. We wanted to see whether the anti-
tumour effect generated by delivering siSATB1 was reflected on SATB1 protein levels. The SATB1 
protein level determination was done by western blot. Antibody Clone 14 by BD bioscience, New Jersey, 
was used for detecting SATB1 protein. The manufacturer of the antibody did not specify on the species 
cross reactivity with mouse SATB1. A SATB1 specific band was obtained at a molecular weight slightly 
above 100 kDa as per the protein marker used for western blot (Thermo scientific, #26616).  
In case of UT-SCC-42B, there was a knockdown of SATB1 at protein level as compared to siLuc3 
samples. However, in untreated samples, SATB1 levels were even lesser than siSATB1. One possible 
explanation for this could be the necrotic tumours. Necrotic tissue contains protein but in its degraded 
form. Thus, even after loading equal amounts, normalization by the loading control (GAPDH in this case) 
yielded lesser protein levels than the target group. For UT-SCC-14, the knockdown was also analysed 
by determining the band intensity using Image J software.  
Knockdown of SATB1 as obtained by analysing the blots was weaker in comparison of the anti-tumour 
effects observed by analysing the tumour growth kinetics. A possible explanation for this could be 
detection of mouse SATB1 along with human SATB1 protein. As mentioned earlier, the tumours were 
well vascularised. That means there could be tumour infiltrating lymphocytes, or other activated cells of 
the immune system. Functions of SATB1 in development and healthy functioning of the immune system 
are described in section 2.5.1.4 on page 30. Thus, activated immune cells of the mice which might 
express SATB1 could have contaminated the tumour samples. This could mask the actual knockdown of 
SATB1. Argument for this explanation could be that the same extent of contamination of SATB1 protein 
from the mouse immune cells could also be there in siLuc3 and untreated mice. However, in case of 
siLuc3 and untreated groups, the relative abundance of the immune cells as compared to the tumour 





by mouse SATB1 in western blot. IHC staining would be a better technique to demonstrate transient 
knockdown, as shape and size of the cells and nucleus can help in distinguishing between mouse cell 
and human (tumour) cells.  
The first approach was to analyse SATB1 protein by loading individual samples separately onto the SDS-
PAGE. Second approach was to pool equal amounts of protein from each tumour of the group. Band 
intensity analysis of both the approaches demonstrated knockdown on protein levels. The conclusion 
was that although SATB1 knockdown at protein levels was weak, the deceleration in the growth kinetics 
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The functions of SATB1 as a genome organizer protein as well as a recruiter of chromatin remodelling 
complexes and enzymes are the basis for its ability to control expression of hundreds of genes. It is thus 
involved in several physiological processes, including the development and healthy functioning of the 
immune system, the prevention of the exhaustion of the hematopoietic stem cell population by preventing 
unwanted differentiation, the control of the expression of keratin associated proteins for skin 
development, as well as embryogenesis and pre- and post-natal brain development. Based on its 
overexpression in many tumors, SATB1 may also contribute to the process of tumour progression. 
Concomitantly, its oncogenic relevance in a variety of cancer entities has been demonstrated in several 
studies over the past decade. Beyond data on its functions on the cellular and molecular level, numerous 
publications have also proven strong correlations of SATB1 expression levels with prognosis, disease 





Some studies on the involvement of SATB1 in head and neck squamous cell carcinoma (HNSCC) have 
suggested its clinicopathological relevance. However, there are no comprehensive reports on cellular 
and molecular processes influenced by SATB1 in HNSCC, in particular using primary cell lines.  
This thesis provides a detailed analysis of molecular and cellular effects of siRNA-mediated transient 
knockdown of SATB1 in 7 primary cell lines. Cellular processes studied included proliferation in 
monolayer, colony forming ability, spheroid assay, induction of apoptosis and cell cycle progression rates. 
The molecular analysis covered effects of transient SATB1 knockdown on the transcription rates of 
selected oncogenes. For clinical relevance, FLAVINO assays were performed along with sensitivity of 
the primary cell lines towards HER1 and/or HER3 inhibition in monolayer and spheroid culture. The 
FLAVINO assay allows for the measurement of colony forming abilities of patient tumour cells, obtained 
by processing patient biopsies from the University Hospital Leipzig (Department of Otorhinolaryngology). 
Finally, in vivo anti-tumour effects of SATB1 knockdown were monitored in two xenograft models. To this 
end, polymeric nanoparticles based on polyethyleneimine (PEI) were used for delivering SATB1-specific 
siRNAs (siSATB1) in mice bearing established tumor xenografts.  
Prior to knockdown studies, SATB1 mRNA levels of 15 primary cell lines were determined. Different 
factors like location from where the tumour cells were isolated, staging of the disease (TNM status), lymph 
node invasion and SATB1 mRNA levels among primary and metastatic/recurrent tumour cells isolated 
from the same patients were compared to SATB1 expression and it was found that there was no 
association of SATB1 mRNA levels with any of these factors. There was a strong difference of ~300 fold 
between cells isolated from the patient with lowest and highest SATB1 mRNA. Co-incidentally, these 
cells were isolated from the same location, the tongue. Moreover, both patients showed lymph node 
invasion. Thus, it was concluded that SATB1 mRNA levels depended more on individual differences 
rather than the staging, location and lymph node invasion of the tumour. This was later on also supported 
by the cellular assays performed in the shortlisted primary cell lines.  
Since the SATB1 mRNA levels varied individually, primary cell lines for deeper analyses were selected 
based on the anti-proliferation effects observed upon SATB1 knockdown. These were found to be 
independent of the initial SATB1 mRNA levels, and the final selection of 7 primary cell lines consisted of 
cells with low (UT-SCC-15, UT-SCC-60B, UT-SCC-16B), medium (UT-SCC-5 and UT-SCC-60A) and 
high (UT-SCC-14 and UT-SCC-42B) SATB1 mRNA levels. Some of these 7 primary cell lines exhibited 
strong growth inhibition upon SATB1 knockdown (UT-SCC-5, UT-SCC-14, UT-SCC-15, UT-SCC-42B 
and UT-SCC-60B) while others did not show much growth inhibition (UT-SCC-16B and UT-SCC-60A). 





still analyze and compare effects on the molecular level. Growth inhibition in the shortlisted primary cell 
lines was proven by counting live cells using flow cytometry. Initial results of the knockdown analysis 
(mRNA and protein levels) and growth inhibition in monolayer indicated that the anti-proliferation effect 
was independent of initial SATB1 mRNA levels.  
The assessment of colony forming abilities and spheroid formation was performed next. Not all primary 
cell lines were able to form spheroids and grow in non-adherent culture condition. However, the others 
exhibited very strong anti-proliferation effects. The results of these two assays thus highlighted different 
aspects of anti-proliferation. Primary cell lines like UT-SCC-42B and UT-SCC-14, which were able to 
recover from the knockdown in the colony assay (monolayer) could not recover in spheroid assays, as 
indicated by the death of all cells within a period of two weeks. In the primary cell lines UT-SCC-5, UT-
SCC-15 and UT-SCC-60B, SATB1 knockdown showed very strong effects on the colony forming ability 
even after incubation for more than a week. Proliferation rates on plastic as monolayer are much faster 
than in non-adherent culture condition, with the latter thus being closer to the in vivo situation. It was 
concluded that the effects of any treatment is greatly governed by the culture conditions and proliferation 
rates. This also highlights that apart from proliferation assays (monolayer) the analysis the growth 
inhibitory effects in a single cell scenario (colony assay, monolayer) or under non-adherent culture 
conditions (spheroid or soft agar assay) is equally important.  
Tumor growth inhibition can be mediated by induction of apoptosis or retardation in cell cycle, or both. 
Indeed, the results of apoptosis assays revealed the induction of cell death upon SATB1 knockdown, 
caused by activation of Caspase 3/7. This was true for all cell lines showing inhibitory effects upon 
siSATB1 transfection, while there was no induction of Caspase 3/7 in primary cells with the absence of 
siRNA-mediated growth inhibition. Several studies have demonstrated direct or indirect involvement of 
SATB1 in cell cycle regulation. Hence, it was expected that the cell cycle progression rates could be 
retarded as well. Indeed, a retardation of cell cycle progression rates was observed upon SATB1 
knockdown in some cell lines. However, there were exceptions, with effects on cell cycle progression 
rates upon SATB1 knockdown being absent in UT-SCC-5 and UT-SCC-60B cells despite profound anti-
proliferation effects and induction of apoptosis. Thus, it was concluded that growth inhibition upon SATB1 
knockdown was mediated by activation of apoptotic pathways which was augmented in some cell lines 
by retardation in cell cycle progression rates.  
Another matter of discussion is the subcellular localization of the SATB1 protein. Several published 
studies have reported a cytoplasmic localization of SATB1 along with its nuclear presence in different 





associated with poor prognosis and reduced overall survival. The biology of SATB1 indicates the nucleus 
to be the preliminary site of its action. No post-translational modification that may cause or prevent the 
nuclear localization of the protein has been reported till date. Through immunocytochemical (ICC-fl) 
staining (immunofluorescence) it was demonstrated that in all 7 primary cell lines the protein is exclusively 
located in the nucleus. Using the same technique, the siRNA-mediated SATB1 knockdown was 
demonstrated on the protein level as well.  
The FLAVINO assay is a specially designed assay to analyze the effects of any treatment in question on 
the ability of the tumour cells to form colonies. Tumour cells for this assay were obtained by processing 
tumour biopsies of patients from the operation theatre. The assay is characterized by 
immunocytochemical staining of keratinized tumour cells, which helps in ruling out the false reading 
contributed by non-tumour cells to the final counting of the colonies. This assay was applied to 22 tumour 
biopsy samples, with 7 of those providing tumour cells that were able to form colonies. In this setting, 
however, SATB1 knockdown did not affect the colony forming ability of the tumour cells.  
For molecular analysis, effects of SATB1 knockdown on expression levels of selected oncogenes and 
other relevant proteins were tested. EMT markers (E- & N-cadherins and beta-catenin), MMP7 as a 
marker for invasive potential, Cyclin B1 and D1 for cell cycle progression, Pim1 as a survival kinase, 
members of the HER receptor family (HER1, HER2 and HER3) and the ligands Heregulin alpha (A) and 
beta (B) were selected. Comparably to the cellular assays, differences between the cell lines were seen. 
UT-SCC-42B cells, despite profound cellular inhibition, did not show any effect on the transcription rates. 
Instead, an even slight increase in the amount of Cyclin B1 and D1 transcript was observed, contradictory 
to the cell cycle assays. However, a more consistent reduction in the transcription rate of N-cadherin and 
beta-catenin was observed. The attenuation of transcription of HER3 and Heregulin A and B was 
observed in all seven primary cell lines, irrespective of growth inhibitory effects upon SATB1 knockdown. 
This indicated that SATB1 knockdown negatively affects the process of EMT and autocrine signaling, 
both of them being very critical for tumour progression.  
SATB1 knockdown reduced transcription rates of HER3 in all cell lines. Thus, it was interesting to see if 
a converse effect of HER3 inhibition on the SATB1 transcription rate was observed as well. For HER3 
inhibition, the novel monoclonal antibody Patritumab (Daiichi Sankyo, Japan) was used, but no effects of 
HER3 inhibition on the SATB1 transcription rate were found. However, the use of Patritumab along with 
Cetuximab, a routinely used HER1 inhibitory antibody for the treatment of HNSCC patients, revealed 
interesting results. Patritumab alone was not effective on most of the primary cell lines but the 





effects of these antibodies were tested in both monolayer as well as non-adherent culture conditions 
(spheroid assay). It was concluded from this set of experiments was that the combined use of HER1 and 
HER3 inhibitory antibodies provides better tumour cell inhibition over the single treatment.  
In vivo anti-tumour effects were analyzed in xenograft tumour models of two primary cell lines (UT-SCC-
14 and UT-SCC-42B). SATB1-speccific siRNAs were delivered in vivo using polyethyleneimine (PEI F25-
LMW)-based polyplexes. Group of animals receiving PEI/siSATB1 nanoparticles showed reduced tumor 
growth. The growth kinetics of the tumours as well as end volume measurements of the tumours thus 
revealed anti-tumour effects of SATB1 knockdown. Protein levels of SATB1 analyzed in the tumour 
lysates upon explantation showed a knockdown of SATB1 in tumours of the siSATB1 treatment group 
over the negative controls.  
Taken together, SATB1 was found to be involved in the inhibition of apoptosis and acceleration of cell 
cycle, thereby fueling aberrant proliferation which is required for tumour progression. Although the cellular 
analyses showed some differences between the cell lines with regard to the effects observed upon 
SATB1 knockdown, results of the molecular analysis emphasized the fact that irrespectively of the cellular 
effects, the transcription of genes contributing to tumorigenesis is under direct or indirect control of 
SATB1. This underlines the fact that SATB1 is of oncogenic relevance in HNSCC. While it is tempting to 
explore SATB1 as a therapeutic target, classifying it as a prognostic marker could be more practical 








SATB1 protein is of oncogenic relevance to head and neck squamous cell carcinoma. Based on the 
molecular and cellular processes analysed upon SATB1 transient knockdown, SATB1 influences 
epithelial to mesenchymal transition and autocrine signalling in these primary cell lines of HNSCC. Its 
knockdown resulted in cell death by apoptosis and retarded the cell cycle progression rate in some cell 
lines. These results emphasize that the protein is of pathological significance in HNSCC. Additionally, the 
combination of inhibitory antibodies targeting HER1 or HER3 receptors offers a better control over 
proliferating tumour cells as compared to single treatment. 
The lack of SATB1 expression analyses in tumour samples in comparison with normal mucosa from 
patient biopsies and the largely absence of clinicopathological correlation studies of SATB1 protein levels 
restricts us from conclusions with regard to its putative relevance as a prognostic marker in HNSCC. 
However, SATB1 could be assigned as a prognostic marker rather than representing a therapeutic target 
mainly because of a) its established prognostic significance in variety of tumour entities, b) variations 
observed in cellular assays of this study and c) its significance in various normal physiological processes 
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Supplementary figure 1 SATB1 mRNA levels with respect to beta actin from primary (A) and metastatic/recurrent (B) tumour cells 
isolated from the same patients. 
Supplementary figure 2 WST-1 assay for UT-SCC-60B cells: photographs below the proliferation curve are representative images 





































Supplementary figure 4 Western blot of UT-SCC-5, -15 and -16B cells to demonstrate SATB1 knockdown on protein level at 96 and 
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Supplementary figure 3 Western blot of UT-SCC-14 cells to demonstrate SATB1 knockdown on protein level at 72, 96 and 120 h 


































































































































































Supplementary figure 6 Colony formation assay: Bar diagram above are the colony count of respective cells obtained by counting 
the colony via Image J. Below are the representative photos of the colony assay of respective primary cell lines taken at 10 days 
post seeding for colony assay in a 6 well plate.  
Supplementary figure 5 Caspase 3/7 glow assay of respective cells: the apoptosis assay was performed 72 h post transfection. 

























Unblocked Untreated after nocodazole block
UT-SCC-42B UT-SCC-60B
Supplementary figure 7 Nocodazole block introduced in respective primary cell lines (right side histograms) 
Supplementary figure 8 siLuc3 and siSATB1 transfected cells histogram overlapped to illustrate presence and absence of effect 
of SATB1 knockdown on the cell cycle progression rate: SATB1 knockdown (green) brings down the percentage of cells entering 
G2/M block in UT-SCC-42B. Absence of any effect of SATB1 knockdown on cell cycle progression rate in UT-SCC-60B is clearly 




































































Supplementary figure 9 Cell cycle progression rate in UT-SCC-42B, UT-SCC-5 and UT-SCC-16B after SATB1 knockdown analysed 
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Supplementary figure 10 Effects of SATB1 knockdown on transcription rates of selected oncogenes: analysis of 






Supplementary figure 11 Effects of SATB1 knockdown on transcription rate of HER3, Heregulin Alpha (A) and Beta (B): analysis 
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Supplementary figure 13 Pre-treatment approach for UT-SCC-5: inhibitors were administered at a concentration of 100 µg/1000 
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Supplementary figure 14 Treatment approach for UT-SCC-5: 48 h after spheroid formation, 10 µg of each of the inhibitor, solely 















48 h 1 week
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Supplementary figure 15 Pre-treatment approach for UT-SCC-14: inhibitors were administered at a concentration of 100 µg/1000 














Supplementary figure 16 Spheroids of UT-SCC-14 stained for live cell stain: Cells in monolayer were administered   Cetuximab 
and patritumab at a concentration of 100 µg/1000 µl, solely and in combination. 72 h post administration of the inhibitors, cells 
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Supplementary figure 17 Treatment approach for UT-SCC-14: 48 h after spheroid formation, 10 µg of the inhibitors, solely and in 























































































































































Supplementary figure 18 SATB1 transcription rate upon HER1 and/or HER3 inhibition: RPLP0 was used as the reference gene. 









































Supplementary figure 19 Ct values of RPLP0 and SATB1 in UT-SCC-60B post HER1 and/or HER3 inhibition. Horizontal red lines 




































Supplementary figure 20 Ct values of RPLP0 and SATB1 in UT-SCC-14 analysed by q-RT-PCR 72 h post administration of HER1 























































Supplementary figure 21 Exemplary graph of Ct values of reference genes tested for analysing relative levels of SATB1 mRNA 








































































































Supplementary figure 22 Western blot of SATB1 in xenograft tumours of UT-SCC-14 and -42B cells: equal protein amounts of 
respective group were pooled as a single sample. 48 µg of protein from pooled sample was loaded per lane. Bar graph indicates 
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